

Cancer Incidence and Mortality in New Jersey, 2007-2011

Cancer Epidemiology Services
Public Health Services Branch
New Jersey Department of Health



Chris Christie, Governor
Kim Guadagno, Lt. Governor



Mary E. O'Dowd, MPH
Commissioner

Cancer Incidence and Mortality in New Jersey, 2007 - 2011

Prepared by:

Xiaoling Niu, MS

Karen Pawlish, ScD, MPH

Sumathy Vasanthan, MS

Stasia S. Burger, MS, CTR

Jie Li, MPH

Lisa Paddock, PhD, MPH

Pamela K. Agovino, MPH

Antoinette Stroup, PhD

Cancer Epidemiology Services
Public Health Services Branch
New Jersey Department of Health

Christina G. Tan, MD, MPH
State Epidemiologist/Assistant Commissioner

Mary O'Dowd
Commissioner

Chris Christie, Governor
Kim Guadagno, Lt. Governor

Cancer Epidemiology Services
New Jersey Department of Health
PO Box 369
Trenton, NJ 08625-0369
(609) 633-0500

<http://nj.gov/health/ces/index.shtml>

December 2014

ACKNOWLEDGMENTS

The following staff of the New Jersey State Cancer Registry and the Cancer Research Program of the Cancer Epidemiology Services, the Cancer Surveillance Unit of the Consumer, Environmental and Occupational Health Services and the Rutgers Cancer Institute of New Jersey were involved in the collection, quality assurance and preparation of the data on incident cases of cancer in New Jersey:

| | |
|-------------------------|---------------------------|
| Naila Ahmed, MA | Henry Lewis, MPH |
| Nicole Chiavarone | Helen Martin, CTR |
| Rudmila Chowdhury, CTR | Ilsia Martin, MS |
| Patricia Davis | Kevin Masterson, CTR |
| Thomas English, CTR | Nicole McAnaney |
| Ruthann Filipowicz | John Murphy, CTR |
| Raj Gona, MPH, MA | Manisha Narang, MPH |
| Maria Halama, MD, CTR | Cynthia Nunez |
| Essam Hanani, MD, CTR | Maithili Patnaik, CTR |
| Denise Hansen, CTR | Rhena Powell |
| Marilyn Hansen, CTR | Gladys Pyatt-Dickson, CTR |
| Natalia Herman, MPH | Karen Robinson, CTR |
| Donna Horn, CTR | Lisa M. Roche, MPH, PhD |
| Yvette Humphries | Katie Roman |
| Nicole Jackson | Antonio Savillo, MD, CTR |
| Jamal Johnson, CTR | Suzanne Schwartz, MS, CTR |
| Linda Johnson, CTR | Heather Stabinsky, CTR |
| Catherine Karnicky, CTR | Felicia Stewart |
| Harrine Katz, CTR | Neeru Suri |
| Joan Kay, CTR | Gabrielle Taylor |
| Jill Kelly, LPN | Renu Verma |
| Fran Krol, CTR | Annette Werts |
| Mireille Lemieux, CTR | |

We also acknowledge New Jersey hospitals, laboratories, physicians, dentists, and the states of Connecticut, Delaware, Florida, Maryland, New York, North Carolina, and Pennsylvania who reported cancer cases to the New Jersey State Cancer Registry.

Cancer Epidemiology Services, including the New Jersey State Cancer Registry, receives support from the Surveillance, Epidemiology, and End Results Program of the National Cancer Institute under contract HHSN 261201300021I and control No. N01PC-2013-00021, the National Program of Cancer Registries, Centers for Disease Control and Prevention under cooperative agreement 5U58DP003931-02, the State of New Jersey, and the Rutgers Cancer Institute of New Jersey.

TABLE OF CONTENTS

| | |
|---------------------------------------|----|
| Introduction | 1 |
| Summary..... | 3 |
| Technical Notes | 7 |
| New Jersey State Cancer Registry..... | 7 |
| Data Sources and Specifications | 9 |
| Data Presentation..... | 13 |
| References | 15 |

TABLES

| | |
|--|----|
| Table 1. Age-Adjusted Incidence Rates, Males all Races Combined..... | 18 |
| Table 2. Age-Adjusted Incidence Rates, Females all Races Combined | 20 |
| Table 3. Age-Adjusted Incidence Rates, White Males | 22 |
| Table 4. Age-Adjusted Incidence Rates, White Females..... | 24 |
| Table 5. Age-Adjusted Incidence Rates, Black Males..... | 26 |
| Table 6. Age-Adjusted Incidence Rates, Black Females | 28 |
| Table 7. Age-Adjusted Incidence Rates, Hispanic Males | 30 |
| Table 8. Age-Adjusted Incidence Rates, Hispanic Females..... | 32 |
| Table 9. Age-Adjusted Incidence Rates, Asian and Pacific Islander Males and Females | 34 |
| Table 10. Benign and Borderline Brain Tumor Incidence Rates, New Jersey, 2007-2011 | 36 |
| Table 11. Myelodysplastic Syndromes and Chronic Myeloproliferative Disorders Incidence Rates, New Jersey, 2007-2011..... | 37 |
| Table 12. Distribution of Stage at Diagnosis for Selected Cancer Sites in New Jersey | 38 |
| Table 13. Distribution Of Stage at Diagnosis for Selected Cancer Sites in New Jersey | 39 |
| Table 14. Comparative Incidence Rates, New Jersey and U.S., Males, 2007-2011 | 40 |
| Table 15. Comparative Incidence Rates, New Jersey and U.S., Females, 2007-2011 | 40 |
| Table 16. Age-Adjusted Mortality Rates, Males, all Races Combined | 42 |
| Table 17. Age-Adjusted Mortality Rates, Females, all Races Combined..... | 44 |
| Table 18. Age-Adjusted Mortality Rates, White Males..... | 46 |
| Table 19. Age-Adjusted Mortality Rates, White Females | 48 |
| Table 20. Age-Adjusted Mortality Rates, Black Males | 50 |
| Table 21. Age-Adjusted Mortality Rates, Black Females..... | 52 |
| Table 22. Age-Adjusted Mortality Rates, Hispanic Males and Females | 54 |
| Table 23. Age-Adjusted Mortality Rates, Asian and Pacific Islander, Males and Females, 2007-2011 Combined..... | 56 |
| Table 24. Comparative Mortality Rates, New Jersey and U.S., 2007-2011 | 58 |
| Table 25. Comparative Mortality Rates, New Jersey and U.S., 2007-2011 | 58 |
| Table 26. Population Denominators by Race, Age Group and Year | 59 |
| Table 27. Age Distribution (%) of Incidence Cases in New Jersey, 2007-2011 | 61 |
| Table 28. Median Age of Cancer Patients at Diagnosis, New Jersey 2007-2011 | 62 |

INTRODUCTION

This report presents statewide, age-adjusted incidence rates and counts for all cancers diagnosed among New Jersey residents during the period 2007-2011, age-adjusted mortality rates and counts for the period 2007-2011 and comparisons of state and national rates for 2007-2011.

The primary goal of this report is to provide 2007-2011 cancer statistics to healthcare planners, researchers and the public. Statistics are presented statewide for eight population subgroups: white men, white women, black men, black women, Hispanic men, Hispanic women, Asian and Pacific Islander men and Asian and Pacific Islander women. These statistics are also presented by gender for all races combined. Statistics are presented by stage at diagnosis for selected cancer sites by gender and race/ethnicity.

The age-adjusted incidence and mortality rates per 100,000 population are presented by major cancer sites and for all sites combined by year of diagnosis. Asian and Pacific Islander data are presented for the combined five-year period of 2007-2011. For the incidence counts and rates, *in situ* cancers are not included except for bladder cancer *in situ* cases, which are included with invasive urinary bladder, urinary system and all sites. Breast cancer *in situ* cases for women are shown but not included in the totals for all sites combined. Basal and squamous cell skin cancers are not collected and therefore not included in the tables. Benign and borderline brain tumor incidence data for 2007-2011 are presented separately. Myelodysplastic syndromes (MDS) and chronic myeloproliferative disorders (CMD) are defined as malignant starting in 2001 with ICD-O-3 and are included in “All Sites” and in the “Ill Defined” category in the rate tables. MDS and CMD incidence rates are presented separately. These conventions are standard practice for publication of cancer rates in the United States.

Additional New Jersey cancer incidence, mortality, survival, and prevalence data are available from the Cancer Epidemiology Services office or on our website, <http://nj.gov/health/ces/index.shtml>, including:

- *Cancer Survival in New Jersey 1979-2005;*
- *Cancer Prevalence in New Jersey, 1/1/2009;*
- *Cancers with Population-Based Screening Methods – Incidence, Stage at Diagnosis, and Screening Prevalence, New Jersey;*
- *Cancer Among Asians and Pacific Islanders in New Jersey, 1990-2007;*
- *Adolescent and Young Adult Cancer in New Jersey-1979-2006;*
- *Childhood Cancer in New Jersey, 1979-2005;* and
- *Area Socioeconomic Variations in Cancer Incidence and Stage at Diagnosis in New Jersey, 1996-2002.*

Our interactive cancer statistics mapping application provides incidence and mortality counts and rates statewide and at the county level by year, age, sex, race, and ethnicity for the years 1990 and later at <http://nj.gov/health/ces/cancer-rates.shtml>. Other New Jersey and U.S. cancer data can be found on the following websites:

- Cancer Control Planet, <http://cancercontrolplanet.cancer.gov/>
- North American Association of Central Cancer Registries' *Cancer in North America 2007—2011*, <http://www.naaccr.org/DataandPublications/CINAPubs.aspx>
- Surveillance, Epidemiology and End Results (SEER) Program's *Cancer Statistics Review*, <http://www.seer.cancer.gov/>
- Centers for Disease Control and Preventions, *United States Cancer Statistics*, <http://apps.nccd.cdc.gov/uscs/index.aspx>
- State Cancer Profiles, <http://statecancerprofiles.cancer.gov/>

SUMMARY

Cancer Incidence, New Jersey 2007-2011

A total of 48,953 cases of invasive cancer diagnosed in 2011 among New Jersey residents were reported to the New Jersey State Cancer Registry (NJSCR), which is slightly higher compared to 48,647 reported cases diagnosed in 2010. During the period 2007-2011, a total of 245,101 cases of invasive cancer were diagnosed among New Jersey residents, 50.7% among men and 49.3% among women, 84.2% among whites, 11.1% among blacks, and 3.4% among Asians and Pacific Islanders (API). Hispanics of any race accounted for 7.9% of the total cancer cases.

Primary cancers with the ten highest age-adjusted incidence rates during 2007-2011 in New Jersey were prostate, lung, colon and rectum, urinary bladder, melanoma of the skin, non-Hodgkin lymphoma, kidney and renal pelvis, leukemia, pancreas and oral cavity and pharynx for men; and breast, lung, colon and rectum, endometrial (corpus and uterus, NOS), thyroid, non-Hodgkin lymphoma, melanoma of the skin, ovary, pancreas, and urinary bladder for women. These accounted for 79% of all incident cancers (Tables 1 and 2).

In New Jersey, the average age-adjusted total cancer incidence rate for men was 581.3 per 100,000 for the years 2007-2011 combined, with decreasing rates since 2007 (Table 1). Lung, colorectal and bladder cancer incidence rates among all men continued to decrease during this time period (Table 1). Prostate cancer incidence rates decreased from 2007 to 2010, but increased slightly in 2011. Thyroid cancer incidence rates continued to increase for all men, especially among white men each year from 2007 to 2011. Thyroid cancer rates for white men were more than double the rates for black men, 9.8 per 100,000 versus 3.8, respectively (Tables 3 and 5). Total cancer incidence rates for black men decreased after 2009, becoming similar to white men in New Jersey. This convergence is fueled by decreasing trends in prostate, lung, colorectal, stomach and laryngeal cancer incidence rates (Tables 3 and 5). Black men still had higher prostate cancer, colorectal cancer, and multiple myeloma incidence rates and lower bladder cancer, melanoma, and non-Hodgkin lymphoma incidence rates compared to white men (Tables 3 and 5).

The age-adjusted total cancer incidence rates for all New Jersey women remained fairly stable, with a slight decrease after 2009. The average annual incidence rate for New Jersey women was 452.3 per 100,000 women during 2007-2011. Incidence rates for some of the most common cancers, including lung and endometrial, remained stable while decreasing rates were noted for colorectal and cervical cancers among women (Table 2). The total cancer incidence rate, as well as rates of lung, breast, and endometrial cancers and melanoma, for black women continued to be lower compared to white women (Tables 4 and 6). However, black women had higher incidence rates for most digestive system cancers, cervical cancer, and myelomas compared to white women. Thyroid cancer incidence rates increased for all women through 2009. The thyroid cancer rates for white women were more than double the rates for black women, 28.4 per 100,000 versus 12.1, respectively (Tables 4 and 6).

New Jersey Hispanics continued to have lower incidence rates for all cancers combined and for many of the most common types of cancer in the general population, including lung, colorectal, female breast, prostate, bladder, and melanoma of the skin (Tables 7 and 8). But Hispanics continued to have higher incidence rates for stomach, liver, and cervical cancers compared with

the general population in New Jersey. Among Hispanic men and women, thyroid cancer incidence rates followed an increasing trend similar to New Jersey as a whole (Tables 7 and 8).

New Jersey Asians and Pacific Islanders continue to have much lower cancer incidence rates compared to the general population for all cancers combined and most common types of cancer such as lung, colorectal, breast and prostate. Stomach, liver and nasopharyngeal cancer incidence rates were higher for Asians and Pacific Islanders than in the general population (Table 9).

A review of the incidence of benign and borderline brain and central nervous system tumors in New Jersey showed that these tumors occurred mostly in intracranial meninges and the sellar region, while invasive brain tumors occurred mostly in the brain proper. This pattern was similar to the results seen in U.S. SEER data (Howlader et al., 2014). New Jersey incidence data for 2007-2011 showed women had higher rates compared to men for these types of tumors and rates were fairly similar among whites and blacks. Women also had higher benign intracranial meningioma incidence rates compared to men during this same time period (Table 10).

A review of myelodysplastic syndromes (MDS) and chronic myeloproliferative disorders (CMD), which are precursors related to hematologic cancers, showed that they occurred more frequently among men than women in New Jersey. The age-adjusted incidence rate was 8.5 per 100,000 for MDS and CMD combined during 2007-2011. White men had higher incidence of MDS compared to any other racial group/ethnicity, while black and Hispanic men had higher incidence of CMD (Table 11).

Cancers diagnosed at an early stage (*in situ* and local) have better treatment outcomes and better survival. For screenable cancers among New Jersey men diagnosed during 2007-2011, 89% of melanomas of the skin, 83% of prostate cancers, 41% of colorectal cancers and 17% of lung cancers were diagnosed at an early stage (Table 12). Among New Jersey women during this same time period, 91% of melanomas of the skin, 70% of breast cancers, 43% of cervical cancers, 40% of colorectal cancers and 21% of lung cancers were diagnosed at an early stage (Table 13). Black men had lower percentages of early stage diagnoses compared to white men for all cancer sites presented. Black women had lower percentages of early stage diagnoses for breast, cervical, and lung cancers but a higher percentage of early stage diagnoses for colorectal cancer compared to white women. API women had a lower percentage of early stage diagnoses for colorectal cancer compared to the other groups. Hispanic men had lower percentages of early stage diagnoses for colorectal cancer and melanoma compared to the New Jersey male population and a higher percentage of early stage diagnoses for prostate cancer. Hispanic women had lower percentages of early stage diagnoses for breast cancer and melanoma but higher percentages of early stage diagnoses for cervical and colorectal cancers compared to the general female population (Tables 12 and 13).

Cancer Incidence in New Jersey and U.S. 2007-2011

Comparing New Jersey and U.S. age-adjusted incidence rates using data published in *Cancer in North America* by the North American Association of Central Cancer Registries (NAACCR) for 2007-2011, New Jersey incidence rates for all cancers combined continued to be higher

than the U.S. rates, except for rates among black and API men and women (Tables 14 and 15). Both New Jersey men and women had higher incidence rates compared to the U.S. for the most common cancers with some exceptions. New Jersey lung cancer incidence rates for all men combined, white, black and API men, and black and API women were lower than the corresponding U.S. rates. New Jersey colorectal cancer incidence rates for black and API men were lower than the U.S. rates, along with lower prostate, and bladder cancer incidence rates among API men. New Jersey female breast cancer incidence rates were lower than the U.S. rates for black women only and were similar to the U.S. rates for API women. New Jersey API women also had lower lung and colorectal cancer incidence rates compared to the U.S. (Table 14 and 15).

Cancer Mortality, New Jersey 2007-2011

Among New Jersey residents, a total of 16,708 deaths occurred in 2011 for which cancer was designated on the death certificate as the underlying cause, a slight decline compared to 16,815 reported cancer deaths in 2010. During the five-year time period 2007-2011, a total of 84,033 cancer deaths occurred among New Jersey residents, 49.1% among men and 50.9% among women. Primary cancers with the highest age-adjusted mortality rates for 2007-2011 in New Jersey were lung, prostate, and colon and rectum for men; and lung, breast, and colon and rectum for women. These cancers accounted for 46.3% and 49.8% of the total cancer deaths for men and women, respectively. Overall age-adjusted cancer mortality rates for men and women in New Jersey continued to decline (Table 16 and 17), reflecting the trends seen in U.S. mortality data (Howlander et al., 2014).

New Jersey cancer mortality rates continued to be higher for men than for women during 2007-2011 (203.7 per 100,000 versus 151.0 per 100,000). This pattern was observed among all races and ethnicity groups. Cancer mortality rates, including all sites, colorectal, prostate, and female breast for both black men and women continued to be higher compared to white men and women with a few exceptions. Black men also had higher lung cancer mortality rates but lower lymphoma, leukemia, melanoma, bladder and brain cancer mortality rates compared to white men. Black women had lower lymphoma, leukemia, lung, ovarian, and brain cancer, mortality rates than white women (Tables 18-21). Overall cancer mortality rates, as well as mortality rates for many common cancers, for New Jersey Hispanic men and women were lower than rates for all New Jersey men and women, except for slightly higher mortality rates for liver, stomach and cervical cancer (Table 22). New Jersey Asians and Pacific Islanders had much lower total cancer mortality rates than for the New Jersey total population. However, stomach cancer mortality rates for this group of men and women were higher than in the New Jersey general population (Table 23).

Cancer Mortality in New Jersey and U.S. 2007-2011

Comparing New Jersey and U.S. age-adjusted mortality rates using data published by the North American Association of Central Cancer Registries (NAACCR) for 2007-2011 (Copeland et al., 2014), New Jersey cancer mortality rates for all men for all cancers, lung, and prostate cancer, were lower than the corresponding rates for the U.S. for all men and in each racial/ethnic group. New Jersey colorectal cancer mortality rates for all men and white men

were slightly higher compared to the U.S. Among all New Jersey women during the same time period, the cancer mortality rates for all cancers, breast and colorectal cancers were higher compared to the U.S. mortality rates. New Jersey total cancer mortality rates were higher than the corresponding U.S. rates for white women, but lower for black, API, and Hispanic women. New Jersey women had lower lung cancer mortality rates than U.S. women, and this pattern was observed for women of all racial/ethnic groups. The breast cancer mortality rate for New Jersey white women was higher than the U.S. rate, while New Jersey API and Hispanic women had lower breast cancer mortality rates (Tables 24 and 25).

TECHNICAL NOTES

New Jersey State Cancer Registry (NJSCR)

NJSCR Overview

The objectives of the NJSCR are to:

- Monitor cancer trends in New Jersey
- Promote scientific research
- Educate the public
- Provide information for planning and evaluating cancer prevention and control activities
- Share and compare cancer data with other states and the nation
- Participate in population-based investigations of cancer etiology, prevention, treatment and outcomes

The NJSCR is a population-based cancer incidence registry that serves the entire state of New Jersey, which has a current estimated population of over 8.8 million people (U.S. Census Bureau). The NJSCR was established by legislation (N.J.S.A. 26:2-104 et seq.) and includes all cases of cancer diagnosed in New Jersey residents since October 1, 1978. New Jersey regulations (N.J.A.C. 8:57A) require the reporting of all newly diagnosed cancer cases to the NJSCR within three months of hospital discharge or six months of diagnosis, whichever is sooner. Reports are filed by hospitals, diagnosing physicians, dentists, and independent clinical laboratories. Every hospital in New Jersey reports cancer cases electronically. In addition, the NJSCR maintains reporting agreements with New York, Pennsylvania, and other surrounding states, as well as other state cancer registries that are enrolled in the NAACCR interstate data exchange program so that New Jersey residents diagnosed with cancer outside the state can be identified. Legislation passed in 1996 strengthened the NJSCR by requiring electronic reporting, requiring abstracting by certified tumor registrars, and establishing penalties for late or incomplete reporting.

All primary invasive and *in situ* neoplasms are reportable to the NJSCR, except cervical cancer *in situ* diagnosed after 1994 and certain carcinomas of the skin. Benign and borderline brain tumors diagnosed on or after January 1, 2004 are reportable according to Public Law 107-260, the Benign Brain Tumor Cancer Registries Act, which was signed in October 2002. The information collected by the NJSCR includes basic patient identifiers, demographic characteristics of the patient, medical information on each cancer diagnosis (such as the anatomic site, histologic type and stage of disease), first course of treatment and vital status (alive or deceased) annually. For deceased cases, the underlying cause of death is also included. The primary site, behavior, grade, and histology of each cancer are coded according to the *International Classification of Diseases for Oncology (ICD-O)*, 3rd edition for cancers diagnosed after 2000. The NJSCR follows the data standards promulgated by the North American Association of Central Cancer Registries (NAACCR), including the use of the Surveillance, Epidemiology, and End Results (SEER) multiple primary rules. An individual

may develop more than one cancer. Following the SEER multiple primary rules, patients could therefore be counted more than once if they were diagnosed with two or more primary cancers.

The NJSCR is a member of the NAACCR, an organization that sets standards for cancer registries, facilitates data exchange, and publishes cancer data. The NJSCR has been a participant of the National Program of Cancer Registries (NPCR) sponsored by the Centers for Disease Control and Prevention (CDC) since it began in 1994 and is a member of the National Cancer Institute's (NCI) SEER Program.

NJSCR Data Quality

NAACCR has awarded the Gold Standard, the highest standard possible, to the NJSCR for the quality of the data for each diagnosis year 1995 through 2010 and the Silver Standard for the 2011 diagnosis year. The NJSCR has consistently achieved the highest level of certification for its data since the inception of this award. The criteria used to judge the quality of the data are completeness of cancer case ascertainment, completeness of certain information on the cancer cases, percent of death certificate only cases, percent of duplicate cases, passing an editing program, and timeliness.

Completeness of reporting to the NJSCR was estimated by comparing New Jersey and U.S. incidence to mortality ratios for whites and blacks, standardized for age, gender, and cancer site. The data used to generate these ratios were the cancer incidence rates for all SEER registries combined. Using these standard formulas, it is possible for the estimation of completeness to be greater than 100 percent. For 2011 data, the completeness of case reporting was estimated as 103 percent at the time this report was prepared.

While our estimates of completeness are very high, some cases of cancer among New Jersey residents who were diagnosed and/or treated in out-of-state facilities may not yet have been reported to the NJSCR by other state registries. This should be considered in interpreting the data for the more recent years. However, these relatively few cases will not significantly affect the overall trends over the time period presented in this report. The most recent year of data, in this case 2011, may be considered preliminary.

Other 2011 cancer incidence data quality indicators measured as follows:

- percent death-certificate-only cases: 1.7 percent
- percent of unresolved duplicates: < 0.1 percent
- percent of cases with unknown race: 2.8 percent
- percent of cases with unknown county: 0.1 percent
- number of cases with unknown age: 17
- number of cases with unknown gender: 4

It should also be noted that there may be minor differences in the New Jersey incidence and mortality rates in this report compared to previous reports, due to delayed reporting, ongoing editing and reviewing of the data. We also included myelodysplastic syndrome (MDS) and chronic myeloproliferative disorder (CMD) malignancies in the "All Sites" and "Ill-Defined & Unspecified Sites" categories, which made these rates higher than in reports published in 2012

or earlier, which did not include cases of MDS or CMD. Changes in the estimated population denominators also affect the incidence rates in this report and on our cancer mapping website compared to the previous years' publication.

The NJSCR continues to work toward improving the timeliness, quality, and number of its reporting sources. The NJSCR offers electronic reporting options for ambulatory care providers, such as: physician offices, radiation therapy centers, and freestanding surgery centers. In the past few years, the NJSCR has participated in two quality improvement projects to increase provider reporting. A targeted outreach to dermatologists and dermatology groups enhanced reporting of melanoma and other skin cancers. Reporting by independent radiation therapy centers improved the number of prostate and urological malignancy reports from urology specialists and radiation oncologists.

NJSCR has also made significant headway in identifying incident cases in a timely manner by increasing the number of facilities that use electronic pathology laboratory case identification. Currently, several hospital-based laboratories use the Artificial Intelligence in Medicine (AIM) electronic reporting software (E-Path) to automate cancer case identification for hospital tumor registry programs. NJSCR also uses E-Path to identify cancer reports from national pathology laboratories. One significant use of E-Path by a national laboratory ultimately increased the identification of hematological malignancies for the reporting period. The ultimate goal is to enable electronic pathology laboratory reporting from every laboratory that serves New Jersey, because it is evident that electronic pathology cancer identification has improved the timeliness and completeness of cancer reporting, especially for non-hospitalized case reports. Trends in future reporting are driving the NJSCR to develop appropriate systems to identify and receive HL7 messages, as well as to accept Meaningful Use data upon the implementation phase for cancer reporting.

One limitation that could affect New Jersey cancer incidence data is the federal formal restrictions on the submission of cancer cases from Veterans Health Administration (VA) hospitals to cancer registries. NJSCR received 0.6% of the total cases exclusively from VA hospitals for the years 2004 and earlier. Since then, the NJSCR received only 0.3% of the total cases from VA hospitals for 2005 and no cases for 2006 through 2011. The impact of missing VA hospital cases in New Jersey could result in underestimates of cancer incidence rates for men in 2007 through 2011. NJSCR is exploring the possibility of receiving electronic VA cases through a secure file transfer source.

Data Sources and Specifications

Incidence Data

New Jersey cancer incidence data were taken from the September 2014 analytic file of the NJSCR. All the counts and rates were tabulated using SEER*Stat Version 8.1.5 (<http://www.seer.cancer.gov/seerstat/>), a statistical software package distributed by the NCI. U.S. cancer incidence data were obtained from NAACCR's publication, *Cancer in North America 2007-2011* (<http://www.naacr.org/DataandPublications/CINAPubs.aspx>).

The cancer categories in this report are based on the primary site and histology data fields as abstracted from the medical records. For detailed definitions of the cancer categories, please

visit the SEER program website (http://www.seer.cancer.gov/siterecode/icdo3_d01272003/). We used the cancer site recode with mesothelioma and Kaposi sarcoma in separate categories in all incidence tables except for the benign and borderline brain tumor table.

Benign and borderline brain tumors are classified into six groups by primary site: brain, intracranial meninges, cranial nerves and other central nervous system, tumor of the sellar region (pituitary gland, craniopharyngeal duct, and pineal gland), spinal cord, and spinal meninges.

The coding scheme for incident cancer cases in this report is derived from *International Classification of Diseases for Oncology, 3rd edition (ICD-O-3)*. Cases included in the rate tables are all invasive cancers in ICD-O-3 except the benign and borderline brain tumor table. There are some reportability changes from ICD-O-2 to ICD-O-3 beginning in 2001. Myelodysplastic syndrome (MDS) (9980, 9982-9987, 9989) and chronic myeloproliferative disorder (CMD) (9950, 9960-9962) were defined as malignant in ICD-O-3. In previous reports published before 2013, we had only included cases that were reportable in ICD-O-2 and ICD-O-3 to ensure the comparability of rates. Because these cancers were reportable for the entire time period covered by this report, MDS and CMD are included in the rate tables for “All Sites” and in “Ill-Defined & Unspecified Sites” categories. The “All Sites” rates are higher than in the previous report tables published before 2013 because of the inclusion of these additional types of cancer.

Caution must be used when looking at statistics over time for total cancers or categories that include tumors with revised behavior. In this report, data presented for the most recent five years, 2007-2011, include cancers classified as malignant based on ICD-O-3, which is the current standard. However, for any time trends where incidence rates are displayed by year from 1979 to 2011, the practice followed by the National Cancer Institute should be used, excluding most newly-reportable cancers as well as the tumors that are no longer classified as malignant, for consistency purposes. The SEER program provides more detailed explanations (see <http://www.seer.cancer.gov/behavrecode/>).

Exclusions

For this report, cases where the county of residence is unknown were excluded from the New Jersey rates and counts, in accordance with standard procedures used by SEER, and has been determined to have little effect on the incidence rates. For example, the total number of cases with unknown county for 2007-2011 is 250, representing 0.1% of the total cancer cases. The small numbers of cases with unknown age or gender were also excluded from the analyses. Since the number of records affected was very small, the rates were virtually unaffected by the exclusion of these records. Race-specific information is not shown separately for persons who are races other than white, black, or Asian and Pacific Islander, but these persons and persons of unknown race are included in the “all races” data.

Mortality Data

New Jersey cancer mortality data for 2007-2011 were obtained through the NCI SEER

Program from the National Center for Health Statistics (NCHS) and tabulated using SEER*Stat (<http://www.seer.cancer.gov/seerstat/>).

Mortality data were grouped by cancer site according to the revised SEER Cause of Death Recode 1969+ (9/17/2004). The detailed information can be found on the SEER website (<http://seer.cancer.gov/codrecode/>). U.S. cancer mortality data were obtained from NAACCR's publication, *Cancer in North America 2007-2011* (<http://www.naacr.org/DataandPublications/CINAPubs.aspx>).

Population Data

The 2007-2011 New Jersey population estimates for this report were provided by the NCI's SEER Program released in March 2014 and downloaded from the SEER website (<http://www.seer.cancer.gov/popdata/download.html>). The population estimates represent a modification of the intercensal and Vintage 2012 annual time series of July 1 county population estimates by age, sex, race, and Hispanic origin produced by the US Census Bureau's Population Estimates Program, in collaboration with the National Center for Health Statistics, and with support from the NCI through an interagency agreement. The bridged single-race estimates and a description of the methodology used to develop them are available on the National Center for Health Statistics (NCHS) website (http://www.cdc.gov/nchs/nvss/bridged_race.htm).

For New Jersey as a whole, the new population estimates for 2010 increased slightly for males and for females compared with the previous estimates that were obtained from the SEER Program in 2013 and published in last year's report. The new population estimates for 2010 also increased for white, black, and API males and females, but decreased slightly for Hispanic males and females compared with previous estimates.

Description of Algorithm for Designating Hispanic Ethnicity

In 2003, the NJSCR adopted the NAACCR Hispanic Identification Algorithm (NHIA) to assign Hispanic ethnicity to cases. This method uses data on birthplace, marital status, gender, race and surname match to the 1990 Hispanic surname list to augment the number of cases and decedents reported as Hispanic in the registry.

Since 2005, NAACCR made several revisions to the NHIA algorithm, now NHIA version 2. The most significant change in NHIA version 2 was the two additional options for registries to apply the algorithm to counties in which the Hispanic population is less than five percent. The NJSCR applied the algorithm to all records from patients residing in all New Jersey counties (option 0 of the NHIA algorithm) diagnosed during the years 1990-2011.

As a result of applying the NHIA algorithm, the number of cases who were coded as Hispanic increased by 23 percent for this time period, thereby correcting an under-identification of Hispanics. A more complete description of the NHIA version 2 is available at the following link to the NAACCR website:

<http://www.naacr.org/LinkClick.aspx?fileticket=6E200T41TcA%3d&tabid=118&mid=458>.

For a copy of the NHIA SAS program, please see the following link to the NAACCR website: <http://www.naacr.org/DataandPublications/CallforData.aspx>.

Caution should be used when comparing rates among Hispanics with the rates in the different race groups (e.g., black, white) because ethnicity and race are not mutually exclusive. In New Jersey, the majority of Hispanics identify themselves as white. The Hispanics who identify themselves as white, black, or API are included in the white, black, or API race category, as well as the 'all races' category.

Caution should also be used when comparing Hispanic mortality data to Hispanic incidence data in this report. Hispanic mortality data for this report were obtained from NCI's SEER Program and did not have the algorithm applied to them. In our detailed report, *Cancer Among Hispanics in New Jersey, 1990-1996*, our previous Hispanic algorithm was applied to mortality data from the New Jersey Center for Health Statistics, resulting in an increased mortality rate of 13% for men and 23% for women.

Race

Race information in the NJSCR database is collected from medical records and is not always complete and accurate. The impact of missing race for a relatively small proportion of cases results in slightly lower race-specific cancer incidence rates and counts. A small percentage of cases diagnosed in previous years were reported to the NJSCR with missing information on race at the time of the completion of last year's report, *Cancer Incidence and Mortality in New Jersey 2006-2010*, and later had their race updated after the publication of the report. This resulted in a slight increase in the race-specific cancer incidence rates and counts during 2007-2010 in the current report as compared to previous reports.

Asians and Pacific Islanders

Asians and Pacific Islanders account for only 3.4% of the total cancer cases in New Jersey, and missing race or misclassification of race may have a relatively greater effect on API cancer rates than rates for other racial groups. For total cancer cases diagnosed during 2007-2011, 2.8% were reported to be of other or unknown race. The NJSCR applied the NAACCR Asian Pacific Islander Identification Algorithm version 1 (NAPIIA v1.2.1) using the birthplace and name fields (first, last, and maiden names) to classify cases directly or indirectly as Asian/Pacific Islander for analytic purposes. The NAPIIA algorithm is focused on coding cases with a race code of other Asian or other Pacific Islander to a more specific Asian or Pacific Islander race category, and the total API case count did not change after applying the algorithm.

Data Presentation

Suppression of Rates and Counts under Five

It should also be noted that the annual rates for relatively uncommon cancers tend to fluctuate substantially from year to year because of small numbers of cases, particularly in minority populations. Rates generated from small numbers should be interpreted with caution. For this report, incidence rates and counts were suppressed where counts were fewer than five as a way to ensure statistical reliability and patient confidentiality. The mortality data were provided through NCI's SEER program in the SEER*Stat database and the data were suppressed by default where counts were fewer than ten.

Calculation of Rates

All the counts and rates were tabulated using SEER*Stat Version 8.1.5 (<http://www.seer.cancer.gov/seerstat/>), a statistical software package distributed by the National Cancer Institute. U.S. cancer incidence and mortality data were obtained from NAACCR's publication, *Cancer in North America 2007-2011* (<http://www.naaccr.org/DataandPublications/CINAPubs.aspx>). All rates are age adjusted to the 2000 U.S. Standard Population (19 age groups-Census P25-1130).

Rate Calculation Formulas

A cancer incidence rate is defined as the number of new cases of cancer detected during a specified time period in a specified population. Cancer rates are most commonly expressed as cases per 100,000 population. Cancer occurs at different rates in different age groups, and population subgroups defined by gender and race, have different age distributions. Therefore, before a valid comparison can be made between rates, it is necessary to standardize the rates to the age distribution of a standard population.

The first step in the age-standardization procedure is to determine the age-specific rates. For each age group for a given time interval (within each race-gender group, for the entire state), the following formula is applied:

$$r_a = \frac{n_a}{t \times P_a}$$

where

- r_a = the age-specific rate for age group a,
- n_a = the number of events (cancer diagnoses) in the age group during the time interval,
- t = the length of the time interval (in years), and
- P_a = average size of the population in the age group during the time interval (mid-year population or average of mid-year population sizes).

In order to determine the age-adjusted rate, a weighted average of the age-specific rates is calculated, using the age distribution of the standard population to derive the age-specific weighting factors (Rothman, 1986). This is the technique of direct standardization which uses the following formula:

$$R = \frac{\sum_{a=1}^n r_a \times Std.P_a}{\sum_{a=1}^n Std.P_a}$$

where

R = the age-adjusted rate,

r_a = the age-specific rate for age group a, and

Std.P_a = the size of the standard population in each age group a.

While age standardization facilitates the comparison of rates among different populations, there can be important age-specific differences in disease occurrence, which are not apparent in comparisons of the age-adjusted rates (Breslow and Day, 1987).

Analogous definitions and calculations apply for cancer mortality rates.

REFERENCES

Breslow NE, Day NE. *Statistical Methods in Cancer Research. Volume II – The Design and Analysis of Cohort Studies*. New York: Oxford University Press, 1987.

Centers for Disease Control and Prevention. *Data collection of primary central nervous system tumors. National Program of Cancer Registries Training Materials*. Atlanta, Georgia: Department of Health and Human Services, Centers for Disease Control and Prevention, 2004.

Chiang CL. "Standard error of the age-adjusted death rate." In *Vital Statistics Special Reports, Volume 47, Number 9*. USDHEW, PHS, Washington, D.C. U.S. Government Printing office, 1961.

Copeland G, Lake A, Firth R, et al. (eds). *Cancer in North America: 2007-2011*. Springfield, IL: North American Association of Central Cancer Registries, Inc. May 2014, <http://www.naacr.org/DataandPublications/CINAPubs.aspx>

Howlander N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). *SEER Cancer Statistics Review, 1975-2011*, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.

Ingram DD, Parker JD, Schenker N et al. United States Census 2000 population with bridged race categories. National Center for Health Statistics. *Vital Health Stat 2(135)*. 2003. [URL: http://www.cdc.gov/nchs/data/series/sr_02/sr02_135.pdf, accessed October 23, 2014]

Martin RM. "Age standardization of death rates in New Jersey: Implications of a change in the standard population." *Topics in Health Statistics*. Center for Health Statistics. 2000;01-02.

NAACCR Race and Ethnicity Work Group. *NAACCR Guideline for Enhancing Hispanic/Latino Identification: Revised NAACCR Hispanic/Latino Identification Algorithm [NHIA v2.2.1]*. Springfield (IL): North American Association of Central Cancer Registries. September 2011. [URL: <http://www.naacr.org/LinkClick.aspx?fileticket=6E200T41TcA%3d&tabid=118&mid=458>, accessed November 14, 2014]

NAACCR Race and Ethnicity Work Group. *NAACCR Asian Pacific Islander Identification Algorithm [NAPIIA v1.2.1]*. Springfield, IL: North American Association of Central Cancer Registries, August 2011. [URL: <http://www.naacr.org/LinkClick.aspx?fileticket=3HnBhlmhkBs%3d&tabid=92&mid=432>, accessed October 23, 2014].

National Center for Health Statistics. U.S. census population with bridged race categories, August 2008. [URL: http://www.cdc.gov/nchs/nvss/bridged_race.htm, accessed October 23, 2014]

Rothman K. *Modern Epidemiology*. U.S. Little, Brown, and Company. 1986.

Surveillance Research Program, National Cancer Institute SEER*Stat software (www.seer.cancer.gov/seerstat) version 8.1.15. March 31, 2014.

Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Mortality - All COD, Aggregated With State, Total U.S. (1969-2011) <Katrina/Rita Population Adjustment>, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released July 2014. Underlying mortality data provided by NCHS (www.cdc.gov/nchs).

Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Populations - Total U.S. (1969-2012) <Katrina/Rita Adjustment> - Linked To County Attributes - Total U.S., 1969-2012 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released March 2014 . [URL. <http://seer.cancer.gov/popdata/>, accessed August 2014]

U.S. Census Bureau. New Jersey QuickFacts from the U.S. Census Bureau. [URL: <http://quickfacts.census.gov/qfd/states/34000.html> , accessed 11/14/2014]

Weinstein R, Lee YS, Klotz J. *Cancer Among Hispanics in New Jersey 1990-1996*. New Jersey Department of Health and Senior Services, June 2000. [URL. <http://www.state.nj.us/health/cancer/hispanic/>, accessed October 23, 2014]

Incidence Tables

Table 1. Age-adjusted Incidence Rates, Males, All Races Combined

| Cancer Site | Rates | | | | | Cases | Rates |
|--|-------|-------|-------|-------|-----------------|-----------|-------|
| | 2007 | 2008 | 2009 | 2010 | 2011 Prelim. | 2007-2011 | |
| All Sites* | 616.0 | 590.6 | 583.3 | 561.4 | 558.4 | 124,173 | 581.3 |
| Oral Cavity and Pharynx | 15.3 | 14.4 | 15.8 | 15.3 | 14.6 | 3,410 | 15.1 |
| Lip | 0.7 | 0.5 | 0.8 | 0.5 | 0.6 | 128 | 0.6 |
| Tongue | 4.9 | 4.6 | 5.2 | 4.5 | 4.6 | 1,087 | 4.8 |
| Salivary Gland | 2.0 | 2.0 | 1.8 | 2.0 | 1.8 | 386 | 1.9 |
| Floor of Mouth | 1.0 | 0.6 | 0.6 | 0.8 | 0.4 | 164 | 0.7 |
| Gum and Other Mouth | 1.8 | 1.9 | 1.5 | 1.5 | 1.8 | 374 | 1.7 |
| Nasopharynx | 0.9 | 0.7 | 1.0 | 0.9 | 0.8 | 194 | 0.9 |
| Tonsil | 2.1 | 2.1 | 3.0 | 3.2 | 2.6 | 622 | 2.6 |
| Oropharynx | 0.5 | 0.7 | 0.6 | 0.9 | 0.7 | 153 | 0.7 |
| Hypopharynx | 1.2 | 1.1 | 1.1 | 0.9 | 1.0 | 235 | 1.1 |
| Digestive System | 112.4 | 111.0 | 109.4 | 104.3 | 101.3 | 22,795 | 107.6 |
| Esophagus | 8.8 | 8.1 | 7.9 | 8.8 | 7.8 | 1,782 | 8.3 |
| Stomach | 11.8 | 11.2 | 11.7 | 11.6 | 10.5 | 2,371 | 11.4 |
| Small Intestine | 2.4 | 2.8 | 2.9 | 1.7 | 2.6 | 533 | 2.5 |
| Colon and Rectum | 57.7 | 56.7 | 53.7 | 49.6 | 47.7 | 11,090 | 52.9 |
| Colon excluding Rectum | 40.1 | 39.4 | 37.1 | 33.7 | 32.4 | 7,528 | 36.4 |
| Rectum and Rectosigmoid Junction | 17.5 | 17.3 | 16.6 | 15.9 | 15.3 | 3,562 | 16.5 |
| Anus, Anal Canal and Anorectum | 1.1 | 1.7 | 1.4 | 1.6 | 1.3 | 316 | 1.4 |
| Liver and Intrahepatic Bile Duct | 10.1 | 10.4 | 11.3 | 10.7 | 11.6 | 2,452 | 10.8 |
| Liver | 9.3 | 9.9 | 10.6 | 9.6 | 10.4 | 2,264 | 10.0 |
| Intrahepatic Bile Duct | 0.8 | 0.5 | 0.7 | 1.1 | 1.2 | 188 | 0.9 |
| Gallbladder | 1.0 | 1.0 | 0.9 | 1.1 | 1.1 | 204 | 1.0 |
| Other Biliary | 2.3 | 2.5 | 2.8 | 2.4 | 2.7 | 523 | 2.5 |
| Pancreas | 15.9 | 15.5 | 15.6 | 15.7 | 14.9 | 3,279 | 15.5 |
| Respiratory System | 85.0 | 81.6 | 79.4 | 75.2 | 73.7 | 16,412 | 78.9 |
| Larynx | 6.3 | 5.9 | 6.5 | 6.0 | 5.7 | 1,321 | 6.1 |
| Lung and Bronchus | 77.4 | 74.1 | 71.7 | 68.2 | 66.9 | 14,830 | 71.6 |
| Bones and Joints | 1.4 | 1.0 | 1.2 | 1.3 | 1.2 | 262 | 1.2 |
| Soft Tissue (Including Heart) | 4.6 | 4.5 | 4.3 | 4.5 | 4.0 | 929 | 4.4 |
| Skin (Excluding Basal and Squamous) | 30.2 | 30.3 | 30.1 | 29.8 | 30.8 | 6,427 | 30.2 |
| Melanoma of the Skin | 27.9 | 28.3 | 27.2 | 27.8 | 28.5 | 5,965 | 27.9 |

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

*All ICD-O-3 invasive reportable cases are included.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 1 (continued). Age-adjusted Incidence Rates, Males, All Races Combined

| Cancer Site | Rates | | | | | Cases 2007-2011 | Rates |
|---|-------|-------|-------|-------|-----------------|--------------------|-------|
| | 2007 | 2008 | 2009 | 2010 | 2011 Prelim. | | |
| Breast | 2.1 | 1.6 | 1.2 | 1.7 | 1.4 | 332 | 1.6 |
| Male Genital System | 194.0 | 176.5 | 173.8 | 161.8 | 171.8 | 38,712 | 175.3 |
| Prostate | 187.2 | 170.2 | 166.9 | 155.1 | 164.5 | 37,287 | 168.5 |
| Testis | 5.7 | 5.3 | 6.0 | 5.8 | 6.1 | 1,210 | 5.8 |
| Penis | 0.8 | 0.8 | 0.7 | 0.5 | 1.0 | 163 | 0.8 |
| Urinary System | 71.7 | 68.3 | 66.2 | 64.2 | 63.2 | 13,832 | 66.6 |
| Urinary Bladder (Including <i>in situ</i>) | 46.7 | 44.1 | 42.1 | 41.5 | 40.5 | 8,677 | 42.9 |
| Kidney and Renal Pelvis | 23.3 | 22.3 | 22.7 | 20.9 | 21.3 | 4,832 | 22.1 |
| Ureter | 1.1 | 1.0 | 0.7 | 1.2 | 1.0 | 202 | 1.0 |
| Eye and Orbit | 1.0 | 1.0 | 0.7 | 0.4 | 0.7 | 164 | 0.8 |
| Brain and Other Nervous System | 8.3 | 8.8 | 8.6 | 8.7 | 7.8 | 1,805 | 8.4 |
| Brain | 7.7 | 8.1 | 8.1 | 8.0 | 7.2 | 1,672 | 7.8 |
| Endocrine System | 8.6 | 9.6 | 10.1 | 10.2 | 10.9 | 2,191 | 9.9 |
| Thyroid | 7.6 | 8.3 | 9.1 | 9.2 | 10.1 | 1,966 | 8.8 |
| Lymphomas | 28.8 | 29.7 | 29.4 | 28.7 | 27.8 | 6,104 | 28.8 |
| Hodgkin Lymphoma | 3.3 | 3.6 | 4.1 | 3.8 | 3.3 | 770 | 3.6 |
| Non-Hodgkin Lymphoma | 25.5 | 26.1 | 25.4 | 24.8 | 24.5 | 5,334 | 25.2 |
| Myelomas | 8.8 | 8.3 | 9.0 | 8.4 | 7.8 | 1,775 | 8.4 |
| Leukemias | 18.2 | 17.3 | 17.2 | 20.2 | 18.5 | 3,834 | 18.3 |
| Lymphocytic Leukemia | 9.5 | 9.3 | 9.0 | 10.9 | 9.7 | 2,047 | 9.7 |
| Acute Lymphocytic Leukemia | 2.0 | 1.7 | 1.9 | 2.3 | 1.7 | 403 | 1.9 |
| Chronic Lymphocytic Leukemia | 6.9 | 6.8 | 6.6 | 7.8 | 7.2 | 1,484 | 7.0 |
| Myeloid and Monocytic Leukemia | 7.7 | 7.1 | 7.2 | 8.2 | 8.0 | 1,594 | 7.7 |
| Acute Myeloid Leukemia | 4.7 | 4.2 | 4.1 | 5.5 | 5.2 | 978 | 4.7 |
| Acute Monocytic Leukemia | 0.5 | 0.4 | 0.4 | 0.3 | 0.3 | 84 | 0.4 |
| Chronic Myeloid Leukemia | 2.2 | 2.3 | 2.4 | 2.1 | 2.0 | 469 | 2.2 |
| Other Leukemia | 1.0 | 0.9 | 1.0 | 1.1 | 0.8 | 193 | 0.9 |
| Mesothelioma | 2.8 | 2.8 | 3.0 | 2.9 | 2.4 | 541 | 2.8 |
| Kaposi Sarcoma | 0.9 | 0.7 | 0.9 | 0.7 | 0.6 | 159 | 0.8 |
| Ill-Defined & Unspecified Sites* | 21.9 | 23.2 | 22.8 | 23.1 | 20.0 | 4,489 | 22.2 |

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

*All ICD-O-3 invasive reportable cases are included.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 2. Age-adjusted Incidence Rates, Females, All Races Combined

| Cancer Site | Rates | | | | | Cases 2007-2011 | Rates |
|--|-------|-------|-------|-------|-----------------|--------------------|-------|
| | 2007 | 2008 | 2009 | 2010 | 2011 Prelim. | | |
| All Sites* | 456.9 | 457.9 | 458.1 | 446.7 | 442.2 | 120,928 | 452.3 |
| Oral Cavity and Pharynx | 5.6 | 6.2 | 6.6 | 5.6 | 6.3 | 1,619 | 6.0 |
| Lip | 0.2 | 0.3 | 0.3 | 0.2 | 0.3 | 77 | 0.3 |
| Tongue | 1.6 | 1.8 | 1.8 | 1.5 | 1.7 | 457 | 1.7 |
| Salivary Gland | 1.1 | 1.2 | 1.1 | 1.0 | 1.1 | 294 | 1.1 |
| Floor of Mouth | 0.2 | 0.3 | 0.4 | 0.4 | 0.4 | 97 | 0.4 |
| Gum and Other Mouth | 1.1 | 1.2 | 1.4 | 1.1 | 1.3 | 329 | 1.2 |
| Nasopharynx | 0.3 | 0.3 | 0.3 | 0.4 | 0.4 | 88 | 0.4 |
| Tonsil | 0.4 | 0.5 | 0.6 | 0.4 | 0.6 | 134 | 0.5 |
| Oropharynx | 0.2 | 0.3 | 0.2 | 0.2 | 0.2 | 59 | 0.2 |
| Hypopharynx | 0.2 | 0.1 | 0.2 | 0.3 | 0.3 | 61 | 0.2 |
| Digestive System | 74.4 | 72.8 | 72.2 | 70.1 | 70.8 | 20,145 | 72.1 |
| Esophagus | 2.0 | 2.1 | 2.0 | 2.0 | 1.7 | 556 | 2.0 |
| Stomach | 6.3 | 5.9 | 5.6 | 5.9 | 5.6 | 1,630 | 5.8 |
| Small Intestine | 1.4 | 2.1 | 2.0 | 1.7 | 1.9 | 497 | 1.8 |
| Colon and Rectum | 42.6 | 40.8 | 39.8 | 39.0 | 38.7 | 11,254 | 40.1 |
| Colon excluding Rectum | 31.5 | 30.7 | 28.9 | 29.4 | 29.0 | 8,441 | 29.9 |
| Rectum and Rectosigmoid Junction | 11.1 | 10.1 | 10.8 | 9.7 | 9.7 | 2,813 | 10.3 |
| Anus, Anal Canal and Anorectum | 1.7 | 2.1 | 2.1 | 1.8 | 2.0 | 523 | 1.9 |
| Liver and Intrahepatic Bile Duct | 3.8 | 3.3 | 3.7 | 3.6 | 3.2 | 973 | 3.5 |
| Liver | 3.1 | 2.9 | 3.1 | 2.7 | 2.4 | 782 | 2.8 |
| Intrahepatic Bile Duct | 0.7 | 0.4 | 0.6 | 0.9 | 0.8 | 191 | 0.7 |
| Gallbladder | 1.9 | 1.7 | 1.8 | 1.8 | 1.6 | 493 | 1.8 |
| Other Biliary | 1.7 | 1.2 | 1.4 | 1.3 | 1.5 | 407 | 1.4 |
| Pancreas | 11.1 | 11.8 | 12.2 | 11.4 | 12.8 | 3,339 | 11.9 |
| Respiratory System | 60.0 | 60.3 | 57.5 | 53.7 | 55.8 | 15,663 | 57.4 |
| Larynx | 1.7 | 1.5 | 1.4 | 1.4 | 1.3 | 388 | 1.4 |
| Lung and Bronchus | 57.6 | 58.1 | 55.3 | 51.8 | 53.7 | 15,088 | 55.3 |
| Bones and Joints | 0.7 | 1.0 | 1.0 | 1.0 | 0.9 | 215 | 0.9 |
| Soft Tissue (Including Heart) | 2.8 | 2.8 | 3.2 | 3.0 | 2.9 | 744 | 2.9 |
| Skin (Excluding Basal and Squamous) | 20.3 | 18.0 | 17.9 | 19.0 | 17.0 | 4,760 | 18.5 |
| Melanoma of the Skin | 19.1 | 16.8 | 16.7 | 18.0 | 15.6 | 4,428 | 17.2 |
| Breast (Invasive) | 130.5 | 131.6 | 133.2 | 129.0 | 127.1 | 34,427 | 130.3 |
| <i>In situ</i> (not included in All Sites) | 38.9 | 41.8 | 41.3 | 41.6 | 40.5 | 10,605 | 40.8 |

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

*All ICD-O-3 invasive reportable cases are included.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 2 (continued). Age-adjusted Incidence Rates, Females, All Races Combined

| Cancer Site | Rates | | | | | Cases 2007-2011 | Rates |
|---|-------|------|------|------|-----------------|--------------------|-------|
| | 2007 | 2008 | 2009 | 2010 | 2011 Prelim. | | |
| Female Genital System | 57.2 | 55.7 | 56.4 | 56.4 | 53.7 | 14,897 | 55.9 |
| Cervix Uteri | 9.3 | 8.1 | 8.7 | 8.2 | 7.7 | 2,046 | 8.4 |
| Corpus and Uterus, NOS | 30.2 | 29.6 | 30.7 | 30.2 | 29.5 | 8,166 | 30.0 |
| Corpus Uteri | 29.5 | 28.7 | 29.7 | 29.4 | 28.5 | 7,921 | 29.1 |
| Uterus, NOS | 0.6 | 0.9 | 1.0 | 0.9 | 1.0 | 245 | 0.9 |
| Ovary | 13.6 | 13.7 | 12.9 | 13.7 | 12.8 | 3,551 | 13.3 |
| Vagina | 0.7 | 0.7 | 0.5 | 0.7 | 0.7 | 182 | 0.7 |
| Vulva | 2.4 | 2.5 | 2.6 | 2.6 | 2.2 | 690 | 2.5 |
| Urinary System | 23.1 | 24.0 | 22.9 | 21.0 | 20.6 | 6,105 | 22.3 |
| Urinary Bladder (Including <i>in situ</i>) | 11.7 | 12.1 | 11.7 | 11.0 | 10.3 | 3,180 | 11.4 |
| Kidney and Renal Pelvis | 10.6 | 11.3 | 10.7 | 9.3 | 9.5 | 2,738 | 10.3 |
| Ureter | 0.6 | 0.4 | 0.5 | 0.4 | 0.5 | 132 | 0.5 |
| Eye and Orbit | 0.7 | 0.4 | 0.5 | 0.4 | 0.4 | 119 | 0.5 |
| Brain and Other Nervous System | 6.3 | 5.8 | 5.6 | 6.1 | 5.4 | 1,461 | 5.8 |
| Brain | 5.5 | 5.2 | 5.0 | 5.5 | 5.0 | 1,321 | 5.3 |
| Endocrine System | 22.7 | 25.2 | 29.2 | 28.2 | 27.6 | 6,367 | 26.6 |
| Thyroid | 21.9 | 24.5 | 28.2 | 27.3 | 27.0 | 6,177 | 25.8 |
| Lymphomas | 20.6 | 21.7 | 20.8 | 20.5 | 21.5 | 5,530 | 21.0 |
| Hodgkin Lymphoma | 3.0 | 3.5 | 2.9 | 2.7 | 3.3 | 684 | 3.1 |
| Non-Hodgkin Lymphoma | 17.6 | 18.2 | 17.9 | 17.8 | 18.2 | 4,846 | 18.0 |
| Myelomas | 5.3 | 5.4 | 5.4 | 5.8 | 5.4 | 1,506 | 5.4 |
| Leukemias | 11.0 | 10.5 | 10.4 | 10.9 | 11.9 | 2,885 | 10.9 |
| Lymphocytic Leukemia | 5.4 | 4.3 | 5.1 | 5.6 | 5.6 | 1,378 | 5.2 |
| Acute Lymphocytic Leukemia | 1.8 | 1.3 | 1.3 | 1.3 | 1.6 | 311 | 1.4 |
| Chronic Lymphocytic Leukemia | 3.4 | 2.8 | 3.6 | 4.1 | 3.7 | 999 | 3.5 |
| Myeloid and Monocytic Leukemia | 5.1 | 5.5 | 4.7 | 4.8 | 5.4 | 1,332 | 5.1 |
| Acute Myeloid Leukemia | 3.2 | 3.7 | 3.0 | 3.1 | 3.9 | 891 | 3.4 |
| Acute Monocytic Leukemia | 0.3 | 0.2 | 0.2 | 0.2 | 0.2 | 54 | 0.2 |
| Chronic Myeloid Leukemia | 1.4 | 1.4 | 1.3 | 1.5 | 1.1 | 343 | 1.3 |
| Other Leukemia | 0.5 | 0.7 | 0.6 | 0.4 | 0.8 | 175 | 0.6 |
| Mesothelioma | 0.6 | 0.8 | 0.4 | 0.5 | 0.6 | 165 | 0.6 |
| Kaposi Sarcoma | 0.2 | 0.1 | 0.2 | 0.1 | 0.2 | 51 | 0.2 |
| Ill-Defined & Unspecified Sites* | 15.0 | 15.7 | 14.8 | 15.5 | 14.1 | 4,269 | 15.0 |

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

*All ICD-O-3 invasive reportable cases are included.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 3. Age-adjusted Incidence Rates, White Males

| Cancer Site | Rates | | | | | Cases 2007-2011 | Rates |
|--|-------|-------|-------|-------|-----------------|--------------------|-------|
| | 2007 | 2008 | 2009 | 2010 | 2011 Prelim. | | |
| All Sites* | 630.8 | 606.5 | 593.3 | 568.9 | 560.2 | 104,421 | 591.3 |
| Oral Cavity and Pharynx | 15.5 | 14.8 | 16.4 | 15.9 | 15.1 | 2,876 | 15.5 |
| Lip | 0.8 | 0.5 | 0.8 | 0.6 | 0.6 | 120 | 0.7 |
| Tongue | 5.3 | 4.9 | 5.7 | 4.9 | 4.8 | 956 | 5.1 |
| Salivary Gland | 2.1 | 2.0 | 1.9 | 2.1 | 1.9 | 340 | 2.0 |
| Floor of Mouth | 0.9 | 0.7 | 0.6 | 0.8 | 0.5 | 132 | 0.7 |
| Gum and Other Mouth | 1.7 | 1.7 | 1.3 | 1.3 | 1.6 | 283 | 1.5 |
| Nasopharynx | 0.7 | 0.6 | 0.7 | 0.7 | 0.6 | 118 | 0.7 |
| Tonsil | 2.1 | 2.3 | 3.3 | 3.5 | 3.0 | 555 | 2.9 |
| Oropharynx | 0.5 | 0.7 | 0.6 | 0.8 | 0.8 | 124 | 0.7 |
| Hypopharynx | 1.0 | 1.1 | 1.2 | 0.9 | 1.0 | 189 | 1.0 |
| Digestive System | 111.5 | 110.6 | 107.7 | 102.0 | 100.5 | 18,738 | 106.4 |
| Esophagus | 9.1 | 8.3 | 8.2 | 8.7 | 8.3 | 1,524 | 8.5 |
| Stomach | 10.8 | 10.7 | 11.3 | 11.1 | 10.3 | 1,895 | 10.9 |
| Small Intestine | 2.2 | 2.9 | 2.6 | 1.8 | 2.5 | 427 | 2.4 |
| Colon and Rectum | 58.1 | 57.4 | 53.0 | 49.2 | 47.0 | 9,226 | 52.9 |
| Colon excluding Rectum | 40.7 | 39.9 | 36.5 | 33.5 | 31.5 | 6,285 | 36.3 |
| Rectum and Rectosigmoid Junction | 17.4 | 17.5 | 16.5 | 15.7 | 15.5 | 2,941 | 16.5 |
| Anus, Anal Canal and Anorectum | 1.0 | 1.7 | 1.4 | 1.4 | 1.3 | 250 | 1.4 |
| Liver and Intrahepatic Bile Duct | 9.7 | 9.3 | 10.8 | 9.6 | 10.7 | 1,851 | 10.0 |
| Liver | 8.9 | 8.8 | 10.0 | 8.4 | 9.5 | 1,693 | 9.1 |
| Intrahepatic Bile Duct | 0.8 | 0.5 | 0.8 | 1.2 | 1.2 | 158 | 0.9 |
| Gallbladder | 0.9 | 0.9 | 0.9 | 1.1 | 1.1 | 165 | 1.0 |
| Other Biliary | 2.2 | 2.7 | 2.8 | 2.4 | 2.8 | 447 | 2.6 |
| Pancreas | 16.0 | 15.6 | 15.7 | 15.6 | 15.1 | 2,753 | 15.6 |
| Respiratory System | 85.2 | 82.9 | 80.4 | 76.1 | 75.4 | 13,930 | 79.9 |
| Larynx | 6.1 | 5.8 | 6.5 | 5.8 | 5.9 | 1,083 | 6.0 |
| Lung and Bronchus | 77.8 | 75.4 | 72.6 | 69.3 | 68.5 | 12,634 | 72.7 |
| Bones and Joints | 1.6 | 1.1 | 1.4 | 1.5 | 1.4 | 224 | 1.4 |
| Soft Tissue (Including Heart) | 5.0 | 4.8 | 4.5 | 4.7 | 4.3 | 796 | 4.7 |
| Skin (Excluding Basal and Squamous) | 35.1 | 35.7 | 35.1 | 34.5 | 35.3 | 6,173 | 35.1 |
| Melanoma of the Skin | 32.8 | 33.5 | 32.2 | 32.3 | 33.0 | 5,766 | 32.7 |

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

*All ICD-O-3 invasive reportable cases are included.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 3 (continued). Age-adjusted Incidence Rates, White Males

| Cancer Site | Rates | | | | | Cases 2007-2011 | Rates |
|---|-------|-------|-------|-------|-----------------|--------------------|-------|
| | 2007 | 2008 | 2009 | 2010 | 2011 Prelim. | | |
| Breast | 2.0 | 1.5 | 1.1 | 1.7 | 1.4 | 273 | 1.6 |
| Male Genital System | 192.6 | 175.5 | 170.0 | 156.1 | 160.7 | 31,000 | 170.7 |
| Prostate | 184.1 | 167.8 | 161.5 | 148.4 | 152.1 | 29,708 | 162.5 |
| Testis | 7.4 | 6.7 | 7.5 | 6.9 | 7.4 | 1,113 | 7.2 |
| Penis | 0.9 | 0.9 | 0.7 | 0.4 | 1.0 | 134 | 0.8 |
| Urinary System | 77.3 | 73.2 | 71.3 | 68.9 | 66.5 | 12,411 | 71.4 |
| Urinary Bladder (Including <i>in situ</i>) | 51.1 | 47.9 | 46.0 | 45.1 | 43.9 | 8,012 | 46.7 |
| Kidney and Renal Pelvis | 24.4 | 23.3 | 23.8 | 21.7 | 21.1 | 4,101 | 22.9 |
| Ureter | 1.2 | 1.1 | 0.8 | 1.5 | 1.1 | 193 | 1.1 |
| Eye and Orbit | 1.1 | 1.2 | 0.8 | 0.5 | 0.8 | 152 | 0.9 |
| Brain and Other Nervous System | 9.0 | 9.8 | 9.4 | 9.5 | 8.3 | 1,566 | 9.2 |
| Brain | 8.4 | 9.0 | 8.9 | 8.7 | 7.7 | 1,461 | 8.6 |
| Endocrine System | 9.6 | 10.4 | 10.9 | 11.2 | 12.0 | 1,897 | 10.8 |
| Thyroid | 8.5 | 9.1 | 9.9 | 10.2 | 11.2 | 1,718 | 9.8 |
| Lymphomas | 30.9 | 31.3 | 31.1 | 30.0 | 29.6 | 5,267 | 30.5 |
| Hodgkin Lymphoma | 3.5 | 3.7 | 4.4 | 3.9 | 3.6 | 626 | 3.8 |
| Non-Hodgkin Lymphoma | 27.4 | 27.6 | 26.7 | 26.1 | 25.9 | 4,641 | 26.7 |
| Myelomas | 8.0 | 7.7 | 8.6 | 7.8 | 7.2 | 1,372 | 7.8 |
| Leukemias | 19.6 | 18.4 | 17.9 | 21.2 | 18.3 | 3,278 | 19.1 |
| Lymphocytic Leukemia | 10.3 | 10.2 | 9.7 | 11.4 | 9.3 | 1,750 | 10.2 |
| Acute Lymphocytic Leukemia | 2.2 | 1.8 | 2.1 | 2.5 | 1.7 | 324 | 2.1 |
| Chronic Lymphocytic Leukemia | 7.3 | 7.4 | 7.0 | 8.1 | 6.9 | 1,291 | 7.3 |
| Myeloid and Monocytic Leukemia | 8.3 | 7.3 | 7.2 | 8.7 | 8.3 | 1,370 | 8.0 |
| Acute Myeloid Leukemia | 5.0 | 4.5 | 4.1 | 6.0 | 5.4 | 851 | 5.0 |
| Acute Monocytic Leukemia | 0.6 | 0.4 | 0.5 | 0.4 | 0.4 | 80 | 0.5 |
| Chronic Myeloid Leukemia | 2.4 | 2.3 | 2.4 | 2.1 | 2.0 | 386 | 2.2 |
| Other Leukemia | 1.0 | 0.9 | 1.0 | 1.0 | 0.8 | 158 | 0.9 |
| Mesothelioma | 3.1 | 3.2 | 3.3 | 3.1 | 2.6 | 512 | 3.1 |
| Kaposi Sarcoma | 0.9 | 0.7 | 0.7 | 0.6 | 0.4 | 109 | 0.7 |
| Ill-Defined & Unspecified Sites* | 22.7 | 23.7 | 22.7 | 23.5 | 20.3 | 3,847 | 22.6 |

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

*All ICD-O-3 invasive reportable cases are included.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 4. Age-adjusted Incidence Rates, White Females

| Cancer Site | Rates | | | | | Cases 2007-2011 | Rates |
|--|-------|-------|-------|-------|-----------------|--------------------|-------|
| | 2007 | 2008 | 2009 | 2010 | 2011 Prelim. | | |
| All Sites* | 476.8 | 477.9 | 480.2 | 462.0 | 456.9 | 101,845 | 470.7 |
| Oral Cavity and Pharynx | 5.7 | 6.7 | 6.8 | 5.9 | 6.8 | 1,389 | 6.4 |
| Lip | 0.2 | 0.4 | 0.3 | 0.3 | 0.3 | 73 | 0.3 |
| Tongue | 1.7 | 2.1 | 2.0 | 1.6 | 2.0 | 407 | 1.9 |
| Salivary Gland | 1.1 | 1.2 | 1.2 | 1.2 | 1.1 | 245 | 1.2 |
| Floor of Mouth | 0.2 | 0.4 | 0.5 | 0.5 | 0.4 | 89 | 0.4 |
| Gum and Other Mouth | 1.1 | 1.3 | 1.4 | 1.2 | 1.4 | 280 | 1.3 |
| Nasopharynx | 0.3 | 0.3 | 0.3 | 0.2 | 0.3 | 57 | 0.3 |
| Tonsil | 0.5 | 0.5 | 0.6 | 0.5 | 0.6 | 120 | 0.6 |
| Oropharynx | 0.2 | 0.3 | 0.2 | 0.1 | 0.2 | 48 | 0.2 |
| Hypopharynx | 0.2 | 0.1 | 0.2 | 0.3 | 0.3 | 49 | 0.2 |
| Digestive System | 72.9 | 71.5 | 72.4 | 68.7 | 68.5 | 16,507 | 70.8 |
| Esophagus | 2.0 | 1.9 | 2.0 | 2.0 | 1.6 | 454 | 1.9 |
| Stomach | 5.6 | 5.4 | 5.0 | 5.3 | 4.8 | 1,215 | 5.2 |
| Small Intestine | 1.3 | 2.0 | 2.0 | 1.5 | 2.1 | 398 | 1.8 |
| Colon and Rectum | 42.1 | 40.6 | 40.6 | 38.7 | 37.5 | 9,335 | 39.9 |
| Colon excluding Rectum | 30.7 | 30.6 | 29.6 | 29.1 | 28.1 | 7,033 | 29.6 |
| Rectum and Rectosigmoid Junction | 11.4 | 10.0 | 10.9 | 9.6 | 9.5 | 2,302 | 10.3 |
| Anus, Anal Canal and Anorectum | 1.9 | 2.3 | 2.3 | 2.0 | 2.1 | 457 | 2.1 |
| Liver and Intrahepatic Bile Duct | 3.3 | 3.1 | 3.6 | 3.4 | 3.1 | 745 | 3.3 |
| Liver | 2.6 | 2.7 | 2.9 | 2.5 | 2.2 | 587 | 2.6 |
| Intrahepatic Bile Duct | 0.7 | 0.3 | 0.7 | 0.9 | 0.9 | 158 | 0.7 |
| Gallbladder | 1.8 | 1.6 | 1.8 | 1.7 | 1.4 | 389 | 1.7 |
| Other Biliary | 1.7 | 1.3 | 1.3 | 1.3 | 1.3 | 336 | 1.4 |
| Pancreas | 11.1 | 11.6 | 11.9 | 11.4 | 12.8 | 2,786 | 11.8 |
| Respiratory System | 63.0 | 63.1 | 60.5 | 56.0 | 59.6 | 13,616 | 60.4 |
| Larynx | 1.6 | 1.5 | 1.4 | 1.5 | 1.4 | 321 | 1.4 |
| Lung and Bronchus | 60.7 | 60.9 | 58.4 | 54.1 | 57.4 | 13,142 | 58.3 |
| Bones and Joints | 0.9 | 1.1 | 0.9 | 1.2 | 1.0 | 183 | 1.0 |
| Soft Tissue (Including Heart) | 2.8 | 2.8 | 3.3 | 3.1 | 2.8 | 592 | 2.9 |
| Skin (Excluding Basal and Squamous) | 24.5 | 21.9 | 21.7 | 22.9 | 20.1 | 4,531 | 22.2 |
| Melanoma of the Skin | 23.1 | 20.7 | 20.4 | 21.8 | 18.6 | 4,241 | 20.9 |
| Breast (Invasive) | 135.6 | 135.9 | 138.3 | 132.4 | 130.8 | 28,490 | 134.6 |
| <i>In situ</i> (not included in All Sites) | 41.1 | 44.2 | 44.5 | 43.4 | 41.0 | 8,759 | 42.8 |

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

*All ICD-O-3 invasive reportable cases are included.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 4 (continued). Age-adjusted Incidence Rates, White Females

| Cancer Site | Rates | | | | | Cases 2007-2011 | Rates |
|---|-------|------|------|------|-----------------|--------------------|-------|
| | 2007 | 2008 | 2009 | 2010 | 2011 Prelim. | | |
| Female Genital System | 59.3 | 57.7 | 59.4 | 57.9 | 56.1 | 12,417 | 58.1 |
| Cervix Uteri | 8.9 | 8.0 | 8.8 | 7.7 | 7.6 | 1,520 | 8.2 |
| Corpus and Uterus, NOS | 31.6 | 31.2 | 32.5 | 31.3 | 31.0 | 6,907 | 31.5 |
| Corpus Uteri | 31.1 | 30.4 | 31.6 | 30.6 | 30.2 | 6,744 | 30.8 |
| Uterus, NOS | 0.5 | 0.8 | 0.9 | 0.6 | 0.7 | 163 | 0.7 |
| Ovary | 14.4 | 14.2 | 13.9 | 14.3 | 13.6 | 3,018 | 14.1 |
| Vagina | 0.7 | 0.6 | 0.4 | 0.7 | 0.7 | 138 | 0.6 |
| Vulva | 2.7 | 2.7 | 2.8 | 2.8 | 2.4 | 616 | 2.7 |
| Urinary System | 24.8 | 25.6 | 24.7 | 21.8 | 21.5 | 5,334 | 23.7 |
| Urinary Bladder (Including <i>in situ</i>) | 12.8 | 13.2 | 12.9 | 11.8 | 11.2 | 2,874 | 12.3 |
| Kidney and Renal Pelvis | 11.2 | 11.8 | 11.2 | 9.4 | 9.6 | 2,297 | 10.6 |
| Ureter | 0.6 | 0.5 | 0.5 | 0.5 | 0.5 | 122 | 0.5 |
| Eye and Orbit | 0.9 | 0.5 | 0.5 | 0.5 | 0.4 | 112 | 0.6 |
| Brain and Other Nervous System | 7.0 | 6.6 | 5.9 | 6.6 | 6.0 | 1,272 | 6.4 |
| Brain | 6.2 | 6.0 | 5.3 | 6.1 | 5.5 | 1,159 | 5.8 |
| Endocrine System | 25.0 | 27.8 | 32.7 | 30.1 | 29.6 | 5,281 | 29.1 |
| Thyroid | 24.3 | 27.2 | 31.8 | 29.4 | 29.0 | 5,146 | 28.4 |
| Lymphomas | 22.2 | 23.7 | 21.9 | 22.3 | 22.6 | 4,790 | 22.5 |
| Hodgkin Lymphoma | 3.4 | 4.1 | 3.1 | 3.2 | 3.4 | 576 | 3.4 |
| Non-Hodgkin Lymphoma | 18.8 | 19.6 | 18.8 | 19.1 | 19.1 | 4,214 | 19.1 |
| Myelomas | 4.8 | 4.9 | 4.6 | 5.2 | 4.6 | 1,101 | 4.8 |
| Leukemias | 11.8 | 11.3 | 11.0 | 11.5 | 11.8 | 2,459 | 11.4 |
| Lymphocytic Leukemia | 6.1 | 4.9 | 5.5 | 5.9 | 5.4 | 1,190 | 5.6 |
| Acute Lymphocytic Leukemia | 2.0 | 1.5 | 1.5 | 1.4 | 1.6 | 258 | 1.6 |
| Chronic Lymphocytic Leukemia | 3.8 | 3.1 | 3.8 | 4.3 | 3.4 | 874 | 3.7 |
| Myeloid and Monocytic Leukemia | 5.2 | 5.6 | 4.9 | 5.1 | 5.6 | 1,122 | 5.3 |
| Acute Myeloid Leukemia | 3.4 | 3.8 | 3.3 | 3.2 | 4.2 | 764 | 3.6 |
| Acute Monocytic Leukemia | 0.3 | 0.3 | 0.2 | 0.3 | 0.2 | 50 | 0.3 |
| Chronic Myeloid Leukemia | 1.3 | 1.3 | 1.1 | 1.6 | 1.1 | 270 | 1.3 |
| Other Leukemia | 0.5 | 0.8 | 0.6 | 0.5 | 0.8 | 147 | 0.6 |
| Mesothelioma | 0.6 | 1.0 | 0.5 | 0.6 | 0.6 | 154 | 0.7 |
| Kaposi Sarcoma | 0.2 | 0.1 | 0.1 | 0.1 | 0.2 | 36 | 0.1 |
| Ill-Defined & Unspecified Sites* | 14.7 | 15.9 | 15.1 | 15.2 | 13.9 | 3,581 | 14.9 |

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

*All ICD-O-3 invasive reportable cases are included.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 5. Age-adjusted Incidence Rates, Black Males

| Cancer Site | Rates | | | | | Cases 2007-2011 | Rates 2007-2011 |
|--|-------|-------|-------|-------|-----------------|--------------------|--------------------|
| | 2007 | 2008 | 2009 | 2010 | 2011 Prelim. | | |
| All Sites* | 632.3 | 612.1 | 642.9 | 583.8 | 544.4 | 13,878 | 601.6 |
| Oral Cavity and Pharynx | 14.7 | 12.5 | 12.5 | 12.6 | 10.2 | 321 | 12.5 |
| Lip | - | - | - | - | - | - | - |
| Tongue | 3.2 | 3.7 | 3.1 | 2.2 | 3.5 | 80 | 3.1 |
| Salivary Gland | - | 1.2 | 1.6 | 1.7 | - | 28 | 1.1 |
| Floor of Mouth | 1.6 | - | 0.9 | 1.0 | - | 21 | 0.8 |
| Gum and Other Mouth | 1.6 | 1.9 | 1.2 | 1.1 | 1.3 | 35 | 1.4 |
| Nasopharynx | 0.9 | 1.6 | 1.6 | 1.2 | - | 33 | 1.1 |
| Tonsil | 2.5 | 1.6 | 1.8 | 2.8 | 1.7 | 56 | 2.1 |
| Oropharynx | - | 0.9 | - | 1.3 | - | 25 | 0.9 |
| Hypopharynx | 3.1 | 1.2 | 1.5 | - | 1.4 | 36 | 1.6 |
| Digestive System | 131.5 | 129.8 | 137.8 | 131.0 | 101.1 | 2,823 | 125.9 |
| Esophagus | 9.9 | 9.5 | 8.6 | 11.3 | 6.1 | 200 | 9.0 |
| Stomach | 18.7 | 16.1 | 15.4 | 13.1 | 9.2 | 296 | 14.4 |
| Small Intestine | 4.7 | 3.1 | 6.2 | 2.2 | 4.5 | 89 | 4.1 |
| Colon and Rectum | 61.1 | 59.9 | 65.7 | 60.0 | 49.6 | 1,294 | 59.1 |
| Colon excluding Rectum | 43.7 | 45.1 | 45.6 | 42.8 | 36.1 | 901 | 42.6 |
| Rectum and Rectosigmoid Junction | 17.3 | 14.8 | 20.0 | 17.2 | 13.5 | 393 | 16.5 |
| Anus, Anal Canal and Anorectum | 2.1 | 2.3 | 2.0 | 3.0 | 2.0 | 64 | 2.3 |
| Liver and Intrahepatic Bile Duct | 10.6 | 17.2 | 14.3 | 17.7 | 13.3 | 391 | 14.7 |
| Liver | 9.4 | 16.2 | 14.2 | 16.6 | 12.7 | 373 | 13.9 |
| Intrahepatic Bile Duct | 1.2 | - | - | 1.1 | - | 18 | 0.8 |
| Gallbladder | - | 1.5 | 1.9 | 1.4 | - | 26 | 1.3 |
| Other Biliary | 3.7 | 1.4 | 2.9 | 1.8 | 1.5 | 44 | 2.2 |
| Pancreas | 18.2 | 17.7 | 19.7 | 18.1 | 13.1 | 388 | 17.3 |
| Respiratory System | 103.9 | 89.6 | 95.5 | 83.3 | 77.9 | 1,944 | 89.7 |
| Larynx | 9.7 | 8.7 | 8.5 | 8.1 | 5.9 | 194 | 8.1 |
| Lung and Bronchus | 92.9 | 79.9 | 86.2 | 73.8 | 70.3 | 1,718 | 80.3 |
| Bones and Joints | 1.3 | 0.9 | 0.9 | 0.7 | - | 27 | 0.9 |
| Soft Tissue (Including Heart) | 3.4 | 2.8 | 4.6 | 3.6 | 2.9 | 94 | 3.5 |
| Skin (Excluding Basal and Squamous) | 2.3 | 2.0 | 1.7 | 2.0 | 2.1 | 53 | 2.0 |
| Melanoma of the Skin | - | - | - | 1.1 | - | 19 | 0.8 |

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

*All ICD-O-3 invasive reportable cases are included.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 5 (continued). Age-adjusted Incidence Rates, Black Males

| Cancer Site | Rates | | | | | Cases 2007-2011 | Rates 2007-2011 |
|---|-------|-------|-------|-------|-----------------|--------------------|--------------------|
| | 2007 | 2008 | 2009 | 2010 | 2011 Prelim. | | |
| Breast | 2.9 | 1.9 | 1.7 | 2.2 | 1.5 | 44 | 2.0 |
| Male Genital System | 255.3 | 240.6 | 249.2 | 229.0 | 229.1 | 5,665 | 240.1 |
| Prostate | 254.4 | 238.6 | 247.7 | 226.0 | 226.7 | 5,609 | 238.2 |
| Testis | - | 1.0 | 1.1 | 1.9 | 1.6 | 37 | 1.2 |
| Penis | - | 1.0 | - | - | - | 15 | 0.6 |
| Urinary System | 44.8 | 47.0 | 47.3 | 41.5 | 47.5 | 1,004 | 45.6 |
| Urinary Bladder (Including <i>in situ</i>) | 22.8 | 24.7 | 23.8 | 20.6 | 22.3 | 443 | 22.8 |
| Kidney and Renal Pelvis | 21.5 | 21.3 | 22.4 | 20.6 | 24.7 | 546 | 22.1 |
| Ureter | - | - | - | - | - | - | - |
| Eye and Orbit | - | - | - | - | - | 5 | 0.2 |
| Brain and Other Nervous System | 4.5 | 5.7 | 4.9 | 5.6 | 4.4 | 131 | 5.0 |
| Brain | 3.9 | 5.1 | 4.4 | 5.0 | 4.0 | 116 | 4.5 |
| Endocrine System | 3.7 | 5.6 | 5.4 | 4.0 | 4.9 | 124 | 4.7 |
| Thyroid | 3.1 | 4.5 | 4.1 | 3.2 | 4.1 | 97 | 3.8 |
| Lymphomas | 16.8 | 23.0 | 22.5 | 20.1 | 18.0 | 527 | 20.1 |
| Hodgkin Lymphoma | 2.5 | 4.2 | 3.6 | 3.7 | 2.0 | 95 | 3.2 |
| Non-Hodgkin Lymphoma | 14.3 | 18.8 | 18.9 | 16.4 | 16.0 | 432 | 16.9 |
| Myelomas | 16.3 | 14.3 | 15.1 | 13.3 | 13.4 | 321 | 14.4 |
| Leukemias | 11.2 | 12.4 | 13.1 | 12.5 | 11.5 | 287 | 12.1 |
| Lymphocytic Leukemia | 5.9 | 5.4 | 4.7 | 5.4 | 5.1 | 127 | 5.3 |
| Acute Lymphocytic Leukemia | 0.8 | 0.8 | 1.5 | 1.5 | 0.7 | 36 | 1.1 |
| Chronic Lymphocytic Leukemia | 4.5 | 3.9 | 2.9 | 3.9 | 3.4 | 78 | 3.7 |
| Myeloid and Monocytic Leukemia | 4.4 | 6.4 | 6.3 | 6.0 | 5.5 | 136 | 5.8 |
| Acute Myeloid Leukemia | 2.5 | 2.9 | 3.9 | 3.9 | 4.2 | 82 | 3.5 |
| Acute Monocytic Leukemia | - | - | - | - | - | - | - |
| Chronic Myeloid Leukemia | 1.8 | 2.5 | 2.1 | 1.8 | 1.2 | 45 | 1.9 |
| Other Leukemia | - | - | 2.0 | - | 0.9 | 24 | 1.1 |
| Mesothelioma | - | - | 2.4 | 1.4 | - | 25 | 1.4 |
| Kaposi Sarcoma | 1.4 | 1.2 | 1.7 | 1.1 | 1.5 | 40 | 1.4 |
| Ill-Defined & Unspecified Sites* | 17.0 | 22.0 | 26.6 | 19.9 | 16.6 | 443 | 20.4 |

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

*All ICD-O-3 invasive reportable cases are included.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 6. Age-adjusted Incidence Rates, Black Females

| Cancer Site | Rates | | | | | Cases | Rates |
|--|-------|-------|-------|-------|-----------------|-----------|-------|
| | 2007 | 2008 | 2009 | 2010 | 2011 Prelim. | 2007-2011 | |
| All Sites* | 410.6 | 408.2 | 407.2 | 411.9 | 384.4 | 13,293 | 404.2 |
| Oral Cavity and Pharynx | 5.8 | 4.4 | 4.9 | 4.2 | 4.3 | 163 | 4.7 |
| Lip | - | - | - | - | - | - | - |
| Tongue | 1.2 | 1.3 | 0.7 | 1.2 | - | 34 | 1.0 |
| Salivary Gland | 1.4 | 1.3 | 0.9 | - | 1.4 | 38 | 1.1 |
| Floor of Mouth | - | - | - | - | - | 7 | 0.2 |
| Gum and Other Mouth | 1.6 | - | 1.1 | 0.8 | 0.7 | 30 | 0.9 |
| Nasopharynx | 0.7 | - | - | 0.8 | - | 16 | 0.4 |
| Tonsil | - | - | 0.8 | - | - | 13 | 0.4 |
| Oropharynx | - | - | - | - | - | 10 | 0.3 |
| Hypopharynx | - | - | - | - | - | 11 | 0.3 |
| Digestive System | 94.6 | 88.2 | 79.7 | 83.0 | 83.9 | 2,719 | 85.8 |
| Esophagus | 2.5 | 3.5 | 2.2 | 2.3 | 2.6 | 84 | 2.6 |
| Stomach | 9.0 | 8.7 | 8.8 | 9.2 | 8.7 | 278 | 8.9 |
| Small Intestine | 2.5 | 3.5 | 2.9 | 3.0 | 1.4 | 86 | 2.6 |
| Colon and Rectum | 51.9 | 46.1 | 40.0 | 44.4 | 44.1 | 1,436 | 45.2 |
| Colon excluding Rectum | 40.4 | 34.5 | 28.6 | 34.7 | 33.8 | 1,086 | 34.3 |
| Rectum and Rectosigmoid Junction | 11.6 | 11.6 | 11.4 | 9.8 | 10.3 | 350 | 10.9 |
| Anus, Anal Canal and Anorectum | 1.5 | 1.5 | 1.8 | 1.5 | 2.1 | 55 | 1.7 |
| Liver and Intrahepatic Bile Duct | 6.7 | 4.5 | 3.8 | 3.9 | 3.6 | 148 | 4.5 |
| Liver | 5.7 | 3.2 | 3.7 | 3.3 | 3.4 | 127 | 3.8 |
| Intrahepatic Bile Duct | 0.9 | 1.3 | - | - | - | 21 | 0.6 |
| Gallbladder | 3.5 | 2.2 | 1.7 | 2.3 | 2.2 | 76 | 2.4 |
| Other Biliary | 1.4 | 1.3 | 1.6 | 1.5 | 1.6 | 47 | 1.5 |
| Pancreas | 14.0 | 14.9 | 15.0 | 13.5 | 15.6 | 454 | 14.6 |
| Respiratory System | 51.9 | 56.2 | 50.5 | 53.6 | 46.7 | 1,648 | 51.7 |
| Larynx | 2.5 | 2.1 | 1.9 | 1.3 | 0.7 | 57 | 1.7 |
| Lung and Bronchus | 49.0 | 53.7 | 47.4 | 51.7 | 45.5 | 1,570 | 49.4 |
| Bones and Joints | - | - | 0.9 | - | - | 18 | 0.5 |
| Soft Tissue (Including Heart) | 2.9 | 3.2 | 3.4 | 2.9 | 4.0 | 111 | 3.3 |
| Skin (Excluding Basal and Squamous) | 1.6 | 1.7 | 2.1 | 1.8 | 1.6 | 61 | 1.8 |
| Melanoma of the Skin | 0.9 | 0.8 | 1.3 | 1.0 | 0.9 | 35 | 1.0 |
| Breast (Invasive) | 119.5 | 120.9 | 124.1 | 119.5 | 113.9 | 4,053 | 119.6 |
| <i>In situ</i> (not included in All Sites) | 29.9 | 29.7 | 29.0 | 32.2 | 33.8 | 1,078 | 30.9 |

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

*All ICD-O-3 invasive reportable cases are included.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 6 (continued). Age-adjusted Incidence Rates, Black Females

| Cancer Site | Rates | | | | | Cases 2007-2011 | Rates |
|---|-------|------|------|------|-----------------|--------------------|-------|
| | 2007 | 2008 | 2009 | 2010 | 2011 Prelim. | | |
| Female Genital System | 51.2 | 50.9 | 52.8 | 55.3 | 45.9 | 1,722 | 51.2 |
| Cervix Uteri | 13.6 | 10.3 | 11.5 | 11.8 | 9.8 | 395 | 11.4 |
| Corpus and Uterus, NOS | 24.7 | 24.7 | 27.3 | 29.5 | 24.7 | 880 | 26.2 |
| Corpus Uteri | 23.4 | 23.4 | 24.9 | 27.4 | 21.9 | 813 | 24.2 |
| Uterus, NOS | 1.2 | 1.3 | 2.4 | 2.1 | 2.8 | 67 | 2.0 |
| Ovary | 9.6 | 11.8 | 10.0 | 10.4 | 9.0 | 329 | 10.1 |
| Vagina | - | 1.7 | 0.8 | 0.8 | - | 31 | 0.9 |
| Vulva | 1.9 | 1.5 | 2.0 | 1.9 | 1.1 | 57 | 1.7 |
| Urinary System | 16.3 | 19.0 | 19.6 | 20.3 | 18.5 | 592 | 18.8 |
| Urinary Bladder (Including <i>in situ</i>) | 6.8 | 7.6 | 7.8 | 8.8 | 7.0 | 227 | 7.6 |
| Kidney and Renal Pelvis | 9.0 | 10.7 | 11.5 | 10.8 | 11.0 | 349 | 10.6 |
| Ureter | - | - | - | - | - | 7 | 0.3 |
| Eye and Orbit | - | - | - | - | - | 5 | 0.2 |
| Brain and Other Nervous System | 3.4 | 2.4 | 4.5 | 4.3 | 3.0 | 120 | 3.5 |
| Brain | 2.5 | 1.8 | 4.0 | 3.6 | 2.7 | 101 | 3.0 |
| Endocrine System | 12.3 | 13.3 | 12.6 | 14.8 | 13.2 | 465 | 13.3 |
| Thyroid | 11.2 | 12.0 | 11.6 | 13.0 | 12.6 | 425 | 12.1 |
| Lymphomas | 14.1 | 13.6 | 16.7 | 12.7 | 15.1 | 481 | 14.4 |
| Hodgkin Lymphoma | 1.7 | 2.4 | 2.5 | 1.6 | 3.3 | 80 | 2.3 |
| Non-Hodgkin Lymphoma | 12.4 | 11.2 | 14.2 | 11.1 | 11.8 | 401 | 12.1 |
| Myelomas | 9.4 | 9.7 | 11.8 | 11.5 | 10.4 | 345 | 10.6 |
| Leukemias | 7.4 | 6.8 | 7.4 | 8.1 | 7.8 | 240 | 7.5 |
| Lymphocytic Leukemia | 2.6 | 1.6 | 3.1 | 4.4 | 3.8 | 98 | 3.1 |
| Acute Lymphocytic Leukemia | 0.8 | 0.9 | - | - | 1.0 | 27 | 0.8 |
| Chronic Lymphocytic Leukemia | 1.7 | 0.8 | 2.3 | 3.3 | 2.6 | 66 | 2.2 |
| Myeloid and Monocytic Leukemia | 4.5 | 4.6 | 3.5 | 3.4 | 3.5 | 127 | 3.9 |
| Acute Myeloid Leukemia | 2.8 | 3.6 | 1.4 | 1.9 | 2.0 | 75 | 2.3 |
| Acute Monocytic Leukemia | - | - | - | - | - | - | - |
| Chronic Myeloid Leukemia | 1.5 | 1.0 | 1.6 | 1.3 | 1.6 | 47 | 1.4 |
| Other Leukemia | - | - | 0.8 | - | - | 15 | 0.5 |
| Mesothelioma | - | - | - | - | - | 8 | 0.2 |
| Kaposi Sarcoma | - | - | - | - | - | 13 | 0.4 |
| Ill-Defined & Unspecified Sites* | 18.7 | 16.8 | 15.2 | 18.9 | 15.1 | 529 | 16.9 |

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

*All ICD-O-3 invasive reportable cases are included.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 7. Age-adjusted Incidence Rates, Hispanic Males

| Cancer Site | Rates | | | | | Cases | Rates |
|--|-------|-------|-------|-------|-----------------|-----------|-------|
| | 2007 | 2008 | 2009 | 2010 | 2011 Prelim. | 2007-2011 | |
| All Sites* | 478.4 | 486.1 | 462.1 | 469.8 | 449.3 | 9,556 | 468.3 |
| Oral Cavity and Pharynx | 12.3 | 9.1 | 10.5 | 12.5 | 13.5 | 256 | 11.7 |
| Lip | 1.8 | - | - | - | 1.8 | 15 | 1.0 |
| Tongue | 3.2 | 2.9 | 3.5 | 3.8 | 3.6 | 74 | 3.4 |
| Salivary Gland | 1.7 | 2.5 | - | - | 0.9 | 28 | 1.3 |
| Floor of Mouth | - | - | - | - | - | 11 | 0.5 |
| Gum and Other Mouth | 1.1 | - | - | - | 2.0 | 22 | 0.8 |
| Nasopharynx | 1.2 | - | 1.1 | 1.7 | 1.6 | 25 | 1.2 |
| Tonsil | - | 0.9 | 2.3 | 2.4 | 1.6 | 42 | 1.5 |
| Oropharynx | - | - | - | 1.3 | - | 12 | 0.5 |
| Hypopharynx | - | - | - | 1.7 | 1.2 | 22 | 1.2 |
| Digestive System | 102.4 | 113.3 | 101.6 | 103.6 | 100.8 | 2,098 | 104.2 |
| Esophagus | 4.1 | 6.0 | 4.7 | 8.3 | 4.8 | 107 | 5.6 |
| Stomach | 12.5 | 21.3 | 17.1 | 15.4 | 13.1 | 307 | 15.9 |
| Small Intestine | 2.1 | 1.5 | 1.6 | 1.4 | 1.8 | 39 | 1.7 |
| Colon and Rectum | 50.4 | 51.9 | 46.9 | 44.8 | 42.2 | 945 | 46.9 |
| Colon excluding Rectum | 37.5 | 35.7 | 32.1 | 31.1 | 28.7 | 631 | 32.7 |
| Rectum and Rectosigmoid Junction | 12.9 | 16.3 | 14.8 | 13.7 | 13.5 | 314 | 14.2 |
| Anus, Anal Canal and Anorectum | - | 2.3 | - | 2.0 | 1.6 | 32 | 1.4 |
| Liver and Intrahepatic Bile Duct | 13.0 | 10.9 | 15.2 | 15.6 | 16.7 | 325 | 14.5 |
| Liver | 12.4 | 10.7 | 13.9 | 14.5 | 15.5 | 308 | 13.5 |
| Intrahepatic Bile Duct | - | - | - | 1.1 | - | 17 | 0.9 |
| Gallbladder | - | - | - | - | 2.3 | 20 | 1.2 |
| Other Biliary | 3.4 | 4.0 | 3.6 | 2.6 | 2.8 | 54 | 3.2 |
| Pancreas | 14.2 | 13.3 | 10.7 | 11.1 | 14.2 | 248 | 12.7 |
| Respiratory System | 56.9 | 58.2 | 50.1 | 53.8 | 50.0 | 942 | 53.6 |
| Larynx | 5.5 | 7.0 | 7.1 | 6.7 | 4.9 | 117 | 6.2 |
| Lung and Bronchus | 50.3 | 49.9 | 42.2 | 46.0 | 44.1 | 795 | 46.3 |
| Bones and Joints | 0.6 | 1.3 | 0.7 | 1.1 | 0.9 | 33 | 0.9 |
| Soft Tissue (Including Heart) | 3.4 | 2.5 | 4.9 | 4.3 | 3.2 | 98 | 3.7 |
| Skin (Excluding Basal and Squamous) | 7.0 | 6.9 | 5.8 | 5.4 | 5.3 | 126 | 6.0 |
| Melanoma of the Skin | 6.2 | 6.0 | 3.9 | 4.6 | 3.6 | 103 | 4.8 |

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

Note: Hispanic includes all races.

*All ICD-O-3 invasive reportable cases are included.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 7 (continued). Age-adjusted Incidence Rates, Hispanic Males

| Cancer Site | Rates | | | | | Cases 2007-2011 | Rates |
|---|-------|-------|-------|-------|-----------------|--------------------|-------|
| | 2007 | 2008 | 2009 | 2010 | 2011 Prelim. | | |
| Breast | - | - | - | - | - | 13 | 0.7 |
| Male Genital System | 165.6 | 165.8 | 158.3 | 155.2 | 154.8 | 3,212 | 159.6 |
| Prostate | 159.0 | 158.2 | 153.0 | 149.2 | 148.5 | 2,981 | 153.3 |
| Testis | 4.2 | 4.4 | 4.4 | 4.7 | 4.9 | 193 | 4.5 |
| Penis | 2.4 | 3.2 | - | - | 1.2 | 34 | 1.6 |
| Urinary System | 53.3 | 41.9 | 43.8 | 51.5 | 39.9 | 847 | 45.8 |
| Urinary Bladder (Including <i>in situ</i>) | 34.0 | 24.2 | 26.2 | 26.6 | 23.3 | 420 | 26.6 |
| Kidney and Renal Pelvis | 18.2 | 16.4 | 16.8 | 22.8 | 15.4 | 409 | 17.9 |
| Ureter | - | - | - | - | - | 8 | 0.5 |
| Eye and Orbit | - | - | - | - | - | 11 | 0.4 |
| Brain and Other Nervous System | 7.3 | 8.5 | 7.0 | 6.2 | 6.0 | 203 | 7.0 |
| Brain | 7.3 | 7.9 | 6.4 | 5.8 | 5.6 | 191 | 6.6 |
| Endocrine System | 5.1 | 6.3 | 6.2 | 6.4 | 6.8 | 191 | 6.2 |
| Thyroid | 4.4 | 4.7 | 6.0 | 5.8 | 6.4 | 169 | 5.5 |
| Lymphomas | 23.6 | 28.8 | 25.0 | 27.0 | 26.4 | 646 | 26.3 |
| Hodgkin Lymphoma | 4.6 | 2.8 | 3.1 | 2.8 | 2.5 | 108 | 3.1 |
| Non-Hodgkin Lymphoma | 19.1 | 26.0 | 21.9 | 24.2 | 23.9 | 538 | 23.1 |
| Myelomas | 7.2 | 7.1 | 9.1 | 8.2 | 6.6 | 155 | 7.6 |
| Leukemias | 13.4 | 14.1 | 13.9 | 14.8 | 14.6 | 339 | 14.2 |
| Lymphocytic Leukemia | 5.3 | 4.6 | 5.9 | 6.8 | 7.4 | 154 | 6.1 |
| Acute Lymphocytic Leukemia | 1.9 | 1.3 | 2.8 | 2.0 | 2.2 | 82 | 2.1 |
| Chronic Lymphocytic Leukemia | 3.4 | 2.8 | 2.3 | 4.0 | 4.8 | 58 | 3.5 |
| Myeloid and Monocytic Leukemia | 7.0 | 8.1 | 6.4 | 7.3 | 6.8 | 161 | 7.1 |
| Acute Myeloid Leukemia | 3.5 | 3.9 | 2.5 | 4.9 | 3.9 | 85 | 3.8 |
| Acute Monocytic Leukemia | - | 0.0 | - | - | - | 6 | 0.2 |
| Chronic Myeloid Leukemia | 3.1 | 2.7 | 3.0 | 2.2 | 2.6 | 62 | 2.7 |
| Other Leukemia | 1.1 | 1.4 | 1.7 | 0.7 | - | 24 | 1.0 |
| Mesothelioma | - | - | 1.7 | - | 1.8 | 24 | 1.3 |
| Kaposi Sarcoma | 2.1 | 0.7 | - | 0.7 | 0.9 | 30 | 1.1 |
| Ill-Defined & Unspecified Sites* | 16.7 | 18.7 | 22.1 | 16.9 | 16.5 | 332 | 18.2 |

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

Note: Hispanic includes all races.

*All ICD-O-3 invasive reportable cases are included.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 8. Age-adjusted Incidence Rates, Hispanic Females

| Cancer Site | Rates | | | | | Cases 2007-2011 | Rates |
|--|-------|-------|-------|-------|-----------------|--------------------|-------|
| | 2007 | 2008 | 2009 | 2010 | 2011 Prelim. | | |
| All Sites* | 352.6 | 362.1 | 352.7 | 342.7 | 347.8 | 9,725 | 351.3 |
| Oral Cavity and Pharynx | 4.2 | 5.4 | 5.9 | 2.9 | 5.3 | 131 | 4.7 |
| Lip | - | - | - | - | - | - | - |
| Tongue | 1.0 | 1.1 | 1.3 | 1.1 | 1.9 | 34 | 1.3 |
| Salivary Gland | 1.0 | 1.6 | - | 0.9 | 0.6 | 27 | 1.0 |
| Floor of Mouth | - | - | - | - | - | - | - |
| Gum and Other Mouth | 1.6 | 1.6 | 1.5 | - | 1.1 | 32 | 1.2 |
| Nasopharynx | - | - | - | - | - | 9 | 0.3 |
| Tonsil | - | - | 1.0 | - | - | 13 | 0.5 |
| Oropharynx | - | - | - | - | - | - | - |
| Hypopharynx | - | - | - | - | - | - | - |
| Digestive System | 67.8 | 67.5 | 70.8 | 70.0 | 75.0 | 1,733 | 70.4 |
| Esophagus | 1.8 | 2.7 | 1.1 | - | 1.7 | 36 | 1.5 |
| Stomach | 8.7 | 9.2 | 8.5 | 10.7 | 8.1 | 229 | 9.0 |
| Small Intestine | - | 2.6 | 1.4 | 1.5 | 1.8 | 39 | 1.5 |
| Colon and Rectum | 34.5 | 31.9 | 34.3 | 35.8 | 35.5 | 854 | 34.5 |
| Colon excluding Rectum | 26.7 | 23.0 | 24.1 | 26.4 | 25.5 | 608 | 25.2 |
| Rectum and Rectosigmoid Junction | 7.8 | 9.0 | 10.1 | 9.4 | 9.9 | 246 | 9.3 |
| Anus, Anal Canal and Anorectum | 1.5 | 2.2 | 2.5 | 2.9 | 2.8 | 62 | 2.4 |
| Liver and Intrahepatic Bile Duct | 6.0 | 4.5 | 5.1 | 5.0 | 3.8 | 118 | 4.8 |
| Liver | 4.3 | 4.1 | 3.5 | 3.6 | 2.5 | 89 | 3.6 |
| Intrahepatic Bile Duct | 1.7 | - | 1.6 | 1.3 | 1.3 | 29 | 1.3 |
| Gallbladder | 3.3 | 1.3 | 2.5 | 2.4 | 2.4 | 57 | 2.4 |
| Other Biliary | 1.1 | 1.4 | 2.6 | 1.3 | 2.8 | 46 | 1.9 |
| Pancreas | 8.9 | 9.7 | 11.3 | 9.6 | 14.2 | 252 | 10.9 |
| Respiratory System | 36.4 | 30.7 | 31.6 | 25.1 | 30.5 | 746 | 30.7 |
| Larynx | - | - | - | 1.5 | 1.0 | 20 | 0.8 |
| Lung and Bronchus | 35.4 | 29.6 | 31.0 | 22.7 | 28.3 | 707 | 29.2 |
| Bones and Joints | 0.9 | 1.0 | 1.2 | 1.2 | 1.0 | 41 | 1.1 |
| Soft Tissue (Including Heart) | 1.6 | 3.1 | 2.5 | 1.8 | 1.1 | 63 | 2.0 |
| Skin (Excluding Basal and Squamous) | 7.0 | 5.9 | 4.5 | 4.7 | 3.6 | 147 | 5.1 |
| Melanoma of the Skin | 5.4 | 4.6 | 3.9 | 4.4 | 3.0 | 123 | 4.2 |
| Breast (Invasive) | 95.5 | 96.0 | 97.7 | 89.7 | 91.4 | 2,747 | 93.9 |
| <i>In situ</i> (not included in All Sites) | 26.3 | 28.0 | 25.4 | 30.3 | 25.1 | 825 | 27.0 |

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

Note: Hispanic includes all races.

*All ICD-O-3 invasive reportable cases are included.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 8 (continued). Age-adjusted Incidence Rates, Hispanic Females

| Cancer Site | Rates | | | | | Cases 2007-2011 | Rates |
|---|-------|------|------|------|-----------------|--------------------|-------|
| | 2007 | 2008 | 2009 | 2010 | 2011 Prelim. | | |
| Female Genital System | 47.8 | 51.9 | 44.9 | 51.5 | 47.5 | 1,413 | 48.7 |
| Cervix Uteri | 13.2 | 12.4 | 9.6 | 9.5 | 11.2 | 360 | 11.1 |
| Corpus and Uterus, NOS | 20.0 | 23.9 | 23.1 | 26.7 | 22.9 | 656 | 23.4 |
| Corpus Uteri | 19.5 | 23.2 | 21.8 | 26.2 | 21.6 | 632 | 22.5 |
| Uterus, NOS | - | - | 1.3 | - | 1.3 | 24 | 0.9 |
| Ovary | 10.5 | 12.5 | 9.0 | 10.7 | 9.7 | 302 | 10.4 |
| Vagina | - | - | - | - | - | 14 | 0.6 |
| Vulva | 1.7 | 1.8 | 1.6 | 3.0 | 2.5 | 53 | 2.1 |
| Urinary System | 14.2 | 19.4 | 18.1 | 14.9 | 13.6 | 402 | 16.0 |
| Urinary Bladder (Including <i>in situ</i>) | 5.3 | 8.7 | 6.6 | 8.2 | 4.6 | 154 | 6.6 |
| Kidney and Renal Pelvis | 8.3 | 10.2 | 11.4 | 6.5 | 8.8 | 241 | 9.0 |
| Ureter | - | - | - | - | - | - | - |
| Eye and Orbit | - | - | - | - | - | 13 | 0.4 |
| Brain and Other Nervous System | 6.4 | 4.1 | 5.2 | 4.3 | 4.9 | 157 | 5.0 |
| Brain | 6.2 | 4.1 | 4.5 | 3.9 | 4.6 | 145 | 4.6 |
| Endocrine System | 20.7 | 25.1 | 23.4 | 25.6 | 23.7 | 805 | 23.8 |
| Thyroid | 20.2 | 24.7 | 23.2 | 25.1 | 22.9 | 790 | 23.3 |
| Lymphomas | 19.8 | 20.1 | 20.7 | 21.3 | 18.0 | 557 | 20.0 |
| Hodgkin Lymphoma | 2.7 | 3.1 | 2.3 | 2.8 | 3.0 | 101 | 2.8 |
| Non-Hodgkin Lymphoma | 17.1 | 17.0 | 18.5 | 18.5 | 15.0 | 456 | 17.2 |
| Myelomas | 3.6 | 5.2 | 5.4 | 6.2 | 6.6 | 138 | 5.5 |
| Leukemias | 11.0 | 10.5 | 10.0 | 9.6 | 12.2 | 304 | 10.7 |
| Lymphocytic Leukemia | 4.8 | 4.3 | 4.2 | 4.5 | 5.2 | 134 | 4.6 |
| Acute Lymphocytic Leukemia | 2.6 | 2.4 | 1.8 | 1.6 | 2.1 | 77 | 2.1 |
| Chronic Lymphocytic Leukemia | 1.7 | 1.3 | 2.2 | 2.9 | 2.9 | 51 | 2.3 |
| Myeloid and Monocytic Leukemia | 5.4 | 5.4 | 5.6 | 4.3 | 6.0 | 150 | 5.3 |
| Acute Myeloid Leukemia | 3.2 | 4.1 | 4.2 | 3.2 | 3.3 | 98 | 3.6 |
| Acute Monocytic Leukemia | - | - | - | - | - | 6 | 0.2 |
| Chronic Myeloid Leukemia | 1.7 | 1.1 | 1.1 | 1.1 | 1.7 | 41 | 1.4 |
| Other Leukemia | - | - | - | 0.8 | 1.1 | 20 | 0.7 |
| Mesothelioma | - | - | - | - | - | 11 | 0.4 |
| Kaposi Sarcoma | - | - | - | - | - | 9 | 0.4 |
| Ill-Defined & Unspecified Sites* | 14.1 | 15.3 | 10.2 | 13.3 | 11.4 | 308 | 12.8 |

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

Note: Hispanic includes all races.

*All ICD-O-3 invasive reportable cases are included.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 9. Age-adjusted Incidence Rates, Asian and Pacific Islander Males and Females 2007-2011 Combined

| Cancer Site | Male | | Female | |
|--|-------|-------|--------|-------|
| | Rate | Cases | Rate | Cases |
| All Sites* | 298.3 | 3,868 | 271.1 | 4,554 |
| Oral Cavity and Pharynx | 12.2 | 178 | 3.2 | 55 |
| Lip | - | - | - | - |
| Tongue | 2.9 | 43 | 0.9 | 15 |
| Salivary Gland | 1.1 | 14 | 0.4 | 9 |
| Floor of Mouth | 0.7 | 9 | - | - |
| Gum and Other Mouth | 3.6 | 50 | 0.7 | 11 |
| Nasopharynx | 2.1 | 36 | 0.7 | 14 |
| Tonsil | 0.5 | 9 | - | - |
| Oropharynx | - | - | - | - |
| Hypopharynx | 0.8 | 10 | - | - |
| Digestive System | 80.1 | 1,011 | 52.0 | 752 |
| Esophagus | 3.9 | 49 | 1.3 | 16 |
| Stomach | 13.0 | 158 | 8.1 | 117 |
| Small Intestine | 1.0 | 15 | 0.7 | 12 |
| Colon and Rectum | 34.2 | 439 | 25.6 | 373 |
| Colon excluding Rectum | 21.3 | 256 | 17.4 | 245 |
| Rectum and Rectosigmoid Junction | 12.9 | 183 | 8.1 | 128 |
| Anus, Anal Canal and Anorectum | - | - | 0.5 | 8 |
| Liver and Intrahepatic Bile Duct | 13.2 | 182 | 4.7 | 71 |
| Liver | 12.2 | 171 | 4.1 | 61 |
| Intrahepatic Bile Duct | 1.0 | 11 | 0.6 | 10 |
| Gallbladder | 1.0 | 13 | 1.8 | 25 |
| Other Biliary | 2.5 | 31 | 1.6 | 21 |
| Pancreas | 10.1 | 112 | 6.6 | 90 |
| Respiratory System | 40.2 | 462 | 24.7 | 350 |
| Larynx | 2.6 | 35 | 0.4 | 8 |
| Lung and Bronchus | 36.8 | 415 | 23.9 | 334 |
| Bones and Joints | 0.4 | 8 | 0.7 | 12 |
| Soft Tissue (Including Heart) | 1.8 | 28 | 1.9 | 34 |
| Skin (Excluding Basal and Squamous) | 2.3 | 30 | 1.7 | 28 |
| Melanoma of the Skin | 1.7 | 19 | 1.3 | 18 |
| Breast (Invasive) | 1.2 | 13 | 87.7 | 1,608 |
| <i>In situ</i> (not included in All Sites) | - | - | 32.6 | 624 |

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

*All ICD-O-3 invasive cases are included.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 9 (continued). Age-adjusted Incidence Rates, Asian and Pacific Islander Males and Females 2007-2011 Combined

| Cancer Site | Male | | Female | |
|---|------|-------|--------|-------|
| | Rate | Cases | Rate | Cases |
| Female Genital System | | | 35.5 | 634 |
| Cervix Uteri | ^ | ^ | 5.7 | 106 |
| Corpus and Uterus, NOS | ^ | ^ | 16.9 | 316 |
| Corpus Uteri | ^ | ^ | 16.2 | 305 |
| Uterus, NOS | ^ | ^ | 0.7 | 11 |
| Ovary | ^ | ^ | 10.3 | 177 |
| Vagina | ^ | ^ | 0.9 | 12 |
| Vulva | ^ | ^ | 1.2 | 14 |
| Male Genital System | 79.4 | 1,042 | ^ | ^ |
| Prostate | 76.7 | 999 | ^ | ^ |
| Testis | 1.6 | 33 | ^ | ^ |
| Penis | 0.8 | 8 | ^ | ^ |
| Urinary System | 23.4 | 294 | 8.5 | 123 |
| Urinary Bladder (Including <i>in situ</i>) | 13.1 | 144 | 3.4 | 46 |
| Kidney and Renal Pelvis | 9.6 | 142 | 4.6 | 72 |
| Ureter | 0.6 | 6 | - | - |
| Eye and Orbit | 0.3 | 7 | - | - |
| Brain and Other Nervous System | 4.9 | 85 | 3.3 | 56 |
| Brain | 4.4 | 76 | 3.0 | 49 |
| Endocrine System | 7.9 | 141 | 23.2 | 458 |
| Thyroid | 6.6 | 122 | 22.4 | 445 |
| Lymphomas | 16.1 | 224 | 11.7 | 186 |
| Hodgkin Lymphoma | 2.0 | 36 | 1.0 | 20 |
| Non-Hodgkin Lymphoma | 14.1 | 188 | 10.7 | 166 |
| Myelomas | 4.6 | 60 | 2.7 | 47 |
| Leukemias | 9.3 | 135 | 5.9 | 100 |
| Lymphocytic Leukemia | 4.7 | 67 | 1.8 | 31 |
| Acute Lymphocytic Leukemia | 2.1 | 34 | 1.2 | 23 |
| Chronic Lymphocytic Leukemia | 2.4 | 29 | 0.5 | 7 |
| Myeloid and Monocytic Leukemia | 4.2 | 61 | 3.6 | 61 |
| Acute Myeloid Leukemia | 2.3 | 33 | 2.7 | 44 |
| Acute Monocytic Leukemia | - | - | - | - |
| Chronic Myeloid Leukemia | 1.7 | 25 | 0.7 | 13 |
| Other Leukemia | 0.4 | 7 | 0.5 | 8 |
| Mesothelioma | - | - | - | - |
| Kaposi Sarcoma | - | - | - | - |
| Ill-Defined & Unspecified Sites* | 13.5 | 142 | 8.2 | 107 |

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

*All ICD-O-3 invasive cases are included.

^ Non-applicable gender.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 10. Benign and Borderline Brain Tumor Incidence Rates, New Jersey, 2007-2011

| Population | Site Group | Rates | | | | | Cases 2007-2011 | Rates |
|---------------|------------------------------|-------|------|------|------|-----------------|--------------------|-------|
| | | 2007 | 2008 | 2009 | 2010 | 2011 Prelim. | | |
| Total | Brain | 0.9 | 1.2 | 1.1 | 1.1 | 1.3 | 507 | 1.1 |
| | Intracranial Meninges | 5.8 | 6.5 | 6.6 | 6.5 | 6.4 | 3,089 | 6.3 |
| | Cranial Nerves and other CNS | 1.5 | 1.5 | 1.7 | 1.6 | 1.7 | 760 | 1.6 |
| | Tumors of the Sellar Region | 2.5 | 3.3 | 3.5 | 3.5 | 3.2 | 1,453 | 3.2 |
| | Spinal Cord | 0.4 | 0.6 | 0.5 | 0.7 | 0.5 | 251 | 0.5 |
| | Spinal Meninges | 0.3 | 0.5 | 0.6 | 0.3 | 0.3 | 190 | 0.4 |
| | Total | | 11.5 | 13.5 | 14.0 | 13.5 | 13.4 | 6,250 |
| Male | Brain | 1.2 | 1.6 | 1.2 | 1.1 | 1.3 | 273 | 1.3 |
| | Intracranial Meninges | 3.9 | 4.6 | 4.5 | 4.7 | 4.0 | 901 | 4.3 |
| | Cranial Nerves and other CNS | 1.3 | 1.5 | 1.7 | 1.6 | 1.7 | 353 | 1.6 |
| | Tumors of the Sellar Region | 2.5 | 3.0 | 3.4 | 2.8 | 3.3 | 661 | 3.0 |
| | Spinal Cord | 0.7 | 0.5 | 0.5 | 0.8 | 0.5 | 131 | 0.6 |
| | Spinal Meninges | - | 0.2 | 0.3 | 0.1 | 0.1 | 39 | 0.2 |
| | Total | | 9.7 | 11.4 | 11.7 | 11.1 | 10.9 | 2,358 |
| Female | Brain | 0.7 | 0.9 | 1.1 | 1.1 | 1.3 | 234 | 1.0 |
| | Intracranial Meninges | 7.3 | 8.1 | 8.4 | 8.1 | 8.5 | 2,188 | 8.1 |
| | Cranial Nerves and other CNS | 1.7 | 1.5 | 1.6 | 1.6 | 1.7 | 407 | 1.6 |
| | Tumors of the Sellar Region | 2.5 | 3.6 | 3.7 | 4.1 | 3.3 | 792 | 3.4 |
| | Spinal Cord | 0.2 | 0.6 | 0.5 | 0.6 | 0.5 | 120 | 0.5 |
| | Spinal Meninges | 0.5 | 0.7 | 0.8 | 0.4 | 0.4 | 151 | 0.6 |
| | Total | | 13.0 | 15.4 | 16.1 | 15.8 | 15.7 | 3,892 |
| White | Brain | 1.0 | 1.2 | 1.1 | 1.1 | 1.3 | 402 | 1.2 |
| | Intracranial Meninges | 5.7 | 6.3 | 6.5 | 6.3 | 6.2 | 2,482 | 6.2 |
| | Cranial Nerves and other CNS | 1.7 | 1.7 | 1.8 | 1.7 | 1.8 | 641 | 1.7 |
| | Tumors of the Sellar Region | 2.4 | 2.8 | 3.4 | 3.3 | 3.0 | 1,047 | 3.0 |
| | Spinal Cord | 0.5 | 0.7 | 0.5 | 0.7 | 0.5 | 205 | 0.6 |
| | Spinal Meninges | 0.3 | 0.5 | 0.6 | 0.3 | 0.3 | 158 | 0.4 |
| | Total | | 11.6 | 13.2 | 14.0 | 13.4 | 13.1 | 4,935 |
| Black | Brain | - | 1.4 | 1.2 | 0.8 | 1.0 | 54 | 0.9 |
| | Intracranial Meninges | 5.9 | 7.2 | 7.8 | 8.1 | 7.6 | 412 | 7.3 |
| | Cranial Nerves and other CNS | 0.5 | 0.6 | 0.7 | ^ | 0.8 | 38 | 0.6 |
| | Tumors of the Sellar Region | 3.0 | 5.9 | 5.4 | 4.5 | 4.5 | 289 | 4.7 |
| | Spinal Cord | - | - | 0.5 | 0.4 | 0.4 | 23 | 0.4 |
| | Spinal Meninges | 0.4 | - | - | - | - | 15 | 0.3 |
| | Total | | 10.2 | 15.7 | 15.8 | 14.3 | 14.5 | 831 |

Rates are per 100,000 population and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 11. Myelodysplastic Syndromes and Chronic Myeloproliferative Disorders Incidence Rates, New Jersey, 2007-2011

| Population | | 2007 | 2008 | 2009 | 2010 | 2011* | 2007-2011 | |
|---|------------|-------|------|------|------|-------|-----------|-------|
| | | Rates | | | | | Cases | Rates |
| Total | | 8.4 | 9.1 | 8.4 | 8.6 | 7.8 | 4,070 | 8.5 |
| Male | | 11.0 | 11.9 | 11.0 | 11.2 | 10.1 | 2,204 | 11.1 |
| Female | | 6.8 | 7.2 | 6.7 | 6.7 | 6.1 | 1,866 | 6.7 |
| Myelodysplastic Syndromes (MDS) | | | | | | | | |
| Male | All races | 7.4 | 7.7 | 7.9 | 8.3 | 7.3 | 1,502 | 7.7 |
| Male | White | 7.8 | 8.1 | 8.0 | 8.6 | 7.9 | 1,348 | 8.1 |
| Male | Black | 3.0 | 4.6 | 7.9 | 4.7 | 2.2 | 85 | 4.5 |
| Male | API | 7.2 | 5.4 | 5.4 | 3.2 | 5.6 | 46 | 5.3 |
| Male | Hispanic** | 4.3 | 7.4 | 10.0 | 5.2 | 7.3 | 114 | 6.9 |
| Female | All races | 4.1 | 4.5 | 3.8 | 4.2 | 4.4 | 1,177 | 4.2 |
| Female | White | 4.0 | 4.6 | 3.8 | 4.2 | 4.4 | 1,001 | 4.2 |
| Female | Black | 4.4 | 4.2 | 3.9 | 4.2 | 3.5 | 126 | 4.0 |
| Female | API | 3.1 | 2.5 | - | 3.3 | 2.9 | 36 | 2.7 |
| Female | Hispanic** | 5.3 | 3.2 | 3.9 | 4.2 | 2.6 | 88 | 3.8 |
| Chronic Myeloproliferative Disorders (CMD) | | | | | | | | |
| Male | All races | 3.6 | 4.1 | 3.1 | 3.0 | 2.8 | 702 | 3.3 |
| Male | White | 3.5 | 4.1 | 3.0 | 2.9 | 2.7 | 562 | 3.3 |
| Male | Black | 4.6 | 4.5 | 3.7 | 3.8 | 2.5 | 94 | 3.8 |
| Male | API | 2.1 | 2.3 | - | 1.8 | 1.8 | 29 | 1.7 |
| Male | Hispanic** | 3.1 | 3.9 | 4.6 | 2.4 | 2.9 | 73 | 3.4 |
| Female | All races | 2.7 | 2.7 | 2.9 | 2.6 | 1.8 | 689 | 2.5 |
| Female | White | 2.7 | 2.8 | 2.9 | 2.3 | 1.7 | 559 | 2.5 |
| Female | Black | 3.2 | 2.7 | 2.8 | 4.1 | 1.8 | 95 | 2.9 |
| Female | API | - | - | 1.5 | - | 2.2 | 22 | 1.5 |
| Female | Hispanic** | 3.9 | 3.6 | 1.8 | 2.5 | 1.1 | 64 | 2.5 |

Rates are per 100,000 and age-adjusted to the 2000 US standard population.

MDS includes ICD-O-3 histology codes 9980, 9982, 9983, 9984, 9985, 9986, 9987, 9989.

CMD includes ICD-O-3 histology codes 9950, 9960, 9961, 9962, 9963, 9964.

*2011 data are preliminary.

**Hispanic includes all races.

- Counts and rates are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Table 12. Distribution of Stage at Diagnosis for Selected Cancer Sites, Males, 2007-2011

| | All Races | White | Black | API | Hispanic* |
|-------------------|-----------|--------|-------|-------|-----------|
| Colorectal | | | | | |
| Total Cases | 11,915 | 9,867 | 1,427 | 467 | 1,005 |
| Percent | 100% | 100% | 100% | 100% | 100% |
| <i>In Situ</i> | 6.9% | 6.5% | 9.3% | 6.0% | 6.0% |
| Local | 34.2% | 35.0% | 29.1% | 33.6% | 34.5% |
| Regional | 32.6% | 33.3% | 29.9% | 33.0% | 34.5% |
| Distant | 18.5% | 18.2% | 21.8% | 18.2% | 16.6% |
| Unstaged | 7.8% | 7.0% | 10.0% | 9.2% | 8.4% |
| Lung** | | | | | |
| Total Cases | 14,830 | 12,634 | 1718 | 415 | 795 |
| Percent | 100% | 100% | 100% | 100% | 100% |
| Local | 17.1% | 17.6% | 13.7% | 16.4% | 17.2% |
| Regional | 22.5% | 22.7% | 21.7% | 20.2% | 21.6% |
| Distant | 51.6% | 51.1% | 54.1% | 55.7% | 53.1% |
| Unstaged | 8.8% | 8.6% | 10.5% | 7.7% | 8.1% |
| Melanoma | | | | | |
| Total Cases | 10,815 | 10,272 | 29 | 31 | 162 |
| Percent | 100% | 100% | 100% | 100% | 100% |
| <i>In situ</i> | 44.9% | 43.9% | 34.5% | 38.7% | 36.4% |
| Local | 44.0% | 44.7% | 34.5% | 35.5% | 45.7% |
| Regional | 5.1% | 5.3% | 17.2% | 22.6% | 9.3% |
| Distant | 2.6% | 2.7% | - | - | 3.1% |
| Unstaged | 3.5% | 3.5% | - | - | 5.6% |
| Prostate** | | | | | |
| Total Cases | 37,287 | 29,708 | 5,609 | 999 | 2,981 |
| Percent | 100% | 100% | 100% | 100% | 100% |
| Local | 83.4% | 83.7% | 82.3% | 81.8% | 84.2% |
| Regional | 8.3% | 8.7% | 7.1% | 10.1% | 7.4% |
| Distant | 3.3% | 3.0% | 4.7% | 4.6% | 4.3% |
| Unstaged | 5.1% | 4.6% | 5.9% | 3.5% | 4.2% |

*Hispanic includes all races.

- Data are suppressed for fewer than 5 cases to ensure confidentiality and statistical reliability.

***In situ* cases not presented due to small numbers.

Table 13. Distribution of Stage at Diagnosis for Selected Cancer Sites, Females, 2007-2011

| | All Races | White | Black | API | Hispanic* |
|-------------------|------------------|--------------|--------------|------------|------------------|
| Breast | | | | | |
| Total Cases | 45,032 | 37,249 | 5,131 | 2,232 | 3,572 |
| Percent | 100% | 100% | 100% | 100% | 100% |
| <i>In Situ</i> | 23.6% | 23.5% | 21.0% | 28.0% | 23.1% |
| Local | 46.8% | 48.1% | 40.5% | 41.7% | 43.5% |
| Regional | 22.0% | 21.1% | 28.2% | 23.4% | 25.9% |
| Distant | 4.8% | 4.6% | 6.9% | 3.9% | 4.9% |
| Unstaged | 2.9% | 2.7% | 3.4% | 3.0% | 2.6% |
| Cervical** | | | | | |
| Total Cases | 2,046 | 1,520 | 395 | 106 | 360 |
| Percent | 100% | 100% | 100% | 100% | 100% |
| Local | 43.2% | 45.5% | 34.4% | 41.5% | 49.2% |
| Regional | 37.2% | 35.5% | 44.8% | 37.7% | 33.9% |
| Distant | 11.3% | 11.1% | 13.2% | 10.4% | 9.7% |
| Unstaged | 8.2% | 7.9% | 7.6% | 10.4% | 7.2% |
| Colorectal | | | | | |
| Total Cases | 11,972 | 9,883 | 1,577 | 391 | 921 |
| Percent | 100% | 100% | 100% | 100% | 100% |
| <i>In Situ</i> | 6.0% | 5.5% | 8.9% | 4.6% | 7.3% |
| Local | 34.3% | 34.7% | 32.4% | 30.7% | 34.1% |
| Regional | 32.8% | 33.4% | 30.0% | 35.3% | 32.7% |
| Distant | 17.6% | 17.4% | 18.4% | 21.5% | 15.9% |
| Unstaged | 9.3% | 8.9% | 10.3% | 7.9% | 10.1% |
| Lung** | | | | | |
| Total cases | 15,088 | 13,142 | 1,570 | 334 | 707 |
| Percent | 100% | 100% | 100% | 100% | 100% |
| Local | 20.8% | 21.3% | 17.0% | 19.5% | 20.9% |
| Regional | 22.8% | 23.0% | 23.1% | 16.5% | 22.2% |
| Distant | 46.8% | 46.3% | 50.1% | 51.5% | 47.7% |
| Unstaged | 9.6% | 9.5% | 9.8% | 12.6% | 9.2% |
| Melanoma | | | | | |
| Total Cases | 8,620 | 8,090 | 40 | 22 | 187 |
| Percent | 100% | 100% | 100% | 100% | 100% |
| <i>In situ</i> | 48.6% | 47.6% | 12.5% | - | 34.2% |
| Local | 42.7% | 43.7% | 50.0% | 54.6% | 49.7% |
| Regional | 3.5% | 3.6% | 12.5% | - | 5.9% |
| Distant | 1.8% | 1.8% | 12.5% | - | 4.8% |
| Unstaged | 3.3% | 3.3% | 12.5% | - | 5.4% |

*Hispanic includes all races.

– Data are suppressed for fewer than 5 cases to ensure confidentiality and statistical reliability.

***In situ* cases not presented due to small numbers. *In situ* cervical cancers are not reportable.

Table 14. Comparative Incidence Rates, New Jersey and U.S., Males, 2007-2011

| Cancer Site | New Jersey 2007-2011 | | | | | U.S. 2007-2011 | | | | | |
|----------------------|----------------------|-----------|-------|-------|-------|----------------|-----------|-------|-------|-------|-----------|
| | Population | All Races | White | Black | API* | Hispanic* | All Races | White | Black | API* | Hispanic* |
| All Sites | | 576.6 | 578.8 | 582.1 | 289.7 | 460.5 | 535.8 | 528.9 | 594.8 | 322.3 | 420.9 |
| Prostate | | 166.1 | 155.9 | 222.7 | 72.0 | 149.1 | 142.1 | 131.4 | 216.0 | 72.5 | 120.2 |
| Lung | | 71.4 | 72.4 | 80.0 | 36.7 | 46.0 | 78.6 | 78.2 | 93.3 | 48.0 | 45.0 |
| Colorectal | | 52.6 | 52.4 | 58.1 | 33.8 | 46.6 | 50.0 | 48.9 | 60.6 | 39.9 | 45.9 |
| Bladder | | 42.7 | 46.0 | 22.2 | 13.0 | 26.1 | 36.7 | 38.8 | 19.4 | 15.2 | 20.4 |
| Melanoma | | 27.9 | 31.9 | 0.8 | 1.7 | 4.7 | 25.1 | 28.0 | 1.1 | 1.4 | 4.7 |
| Non-Hodgkin Lymphoma | | 25.1 | 26.2 | 16.6 | 13.8 | 22.8 | 23.2 | 23.8 | 16.9 | 15.3 | 20.0 |
| Thyroid | | 8.8 | 9.7 | 3.7 | 6.6 | 5.5 | 6.6 | 7.0 | 3.4 | 5.9 | 5.0 |

*API=Asians and Pacific Islanders; Hispanic includes all races.

Source: NAACCR Age-adjusted rates per 100,000 (2000 U.S. population standard).

Table 15. Comparative Incidence Rates, New Jersey and U.S., Females, 2007-2011

| Cancer Site | New Jersey 2007-2011 | | | | | U.S. 2007-2011 | | | | | |
|----------------------------|----------------------|-----------|-------|-------|-------|----------------|-----------|-------|-------|-------|-----------|
| | Population | All Races | White | Black | API* | Hispanic* | All Races | White | Black | API* | Hispanic* |
| All Sites | | 450.0 | 465.6 | 399.9 | 266.3 | 345.2 | 419.1 | 424.9 | 399.0 | 283.7 | 330.1 |
| Breast (invasive) | | 129.5 | 133.4 | 118.3 | 86.4 | 92.0 | 122.8 | 124.0 | 120.7 | 86.0 | 91.6 |
| Lung | | 55.1 | 58.1 | 49.2 | 23.7 | 28.6 | 54.6 | 56.3 | 50.7 | 28.0 | 26.3 |
| Colorectal | | 39.9 | 39.4 | 44.7 | 24.7 | 33.5 | 37.8 | 36.9 | 44.8 | 30.0 | 31.5 |
| Endometrial (corpus uteri) | | 29.1 | 30.6 | 24.0 | 16.1 | 22.4 | 24.2 | 24.7 | 22.1 | 16.7 | 19.7 |
| Thyroid | | 25.7 | 28.1 | 12.0 | 22.0 | 22.8 | 19.4 | 20.5 | 12.1 | 19.4 | 18.3 |
| Non-Hodgkin Lymphoma | | 17.9 | 18.8 | 12.1 | 10.5 | 17.0 | 16.1 | 16.6 | 11.7 | 10.6 | 15.2 |
| Melanoma | | 17.2 | 20.5 | 1.0 | 1.3 | 4.0 | 15.8 | 18.1 | 1.0 | 1.2 | 4.1 |

*API=Asians and Pacific Islanders; Hispanic includes all races.

Source: NAACCR Age-adjusted rates per 100,000 (2000 U.S. population standard).

Mortality Tables

Table 16. Age-adjusted Mortality Rates, Males, All Races Combined

| Cancer Site | Rates | | | | | 2007-2011 | |
|--|-------|-------|-------|-------|-------|-----------|-------|
| | 2007 | 2008 | 2009 | 2010 | 2011 | Cases | Rates |
| All Sites | 215.5 | 206.2 | 199.3 | 202.7 | 195.5 | 41,299 | 203.7 |
| Oral Cavity and Pharynx | 3.3 | 2.9 | 2.8 | 3.0 | 3.5 | 674 | 3.1 |
| Lip | - | - | - | - | - | - | - |
| Tongue | 1.0 | 0.9 | 0.8 | 0.8 | 0.9 | 192 | 0.9 |
| Salivary Gland | 0.3 | 0.2 | 0.3 | 0.3 | 0.5 | 67 | 0.3 |
| Floor of Mouth | - | - | - | - | - | 10 | - |
| Gum and Other Mouth | 0.4 | 0.4 | 0.3 | 0.5 | 0.4 | 79 | 0.4 |
| Nasopharynx | 0.3 | 0.3 | 0.3 | 0.4 | - | 58 | 0.3 |
| Tonsil | - | - | - | - | 0.4 | 51 | 0.2 |
| Oropharynx | - | 0.3 | 0.3 | - | 0.3 | 56 | 0.2 |
| Hypopharynx | - | - | - | - | - | 31 | 0.1 |
| Digestive System | 59.2 | 56.9 | 56.2 | 55.5 | 55.8 | 11,747 | 56.7 |
| Esophagus | 6.9 | 6.4 | 6.5 | 7.8 | 7.3 | 1,491 | 7.0 |
| Stomach | 6.1 | 6.4 | 5.8 | 4.8 | 4.4 | 1,115 | 5.5 |
| Small Intestine | 0.3 | 0.5 | 0.5 | 0.4 | 0.4 | 85 | 0.4 |
| Colon and Rectum | 22.5 | 21.1 | 20.2 | 19.0 | 18.6 | 4,109 | 20.2 |
| Colon excluding Rectum | 19.1 | 17.7 | 16.5 | 15.6 | 15.1 | 3,372 | 16.8 |
| Rectum and Rectosigmoid Junction | 3.4 | 3.4 | 3.7 | 3.4 | 3.5 | 737 | 3.5 |
| Anus, Anal Canal and Anorectum | 0.2 | - | - | - | - | 42 | 0.2 |
| Liver and Intrahepatic Bile Duct | 6.9 | 7.4 | 8.3 | 8.3 | 8.9 | 1,733 | 8.0 |
| Liver | 5.8 | 6.2 | 6.2 | 6.6 | 6.7 | 1,380 | 6.3 |
| Intrahepatic Bile Duct | 1.1 | 1.2 | 2.1 | 1.8 | 2.2 | 353 | 1.7 |
| Gallbladder | 0.9 | 0.4 | 0.6 | 0.6 | 0.6 | 125 | 0.6 |
| Pancreas | 14.3 | 13.6 | 12.8 | 13.4 | 14.1 | 2,824 | 13.6 |
| Respiratory System | 61.2 | 58.4 | 54.2 | 55.6 | 52.2 | 11,485 | 56.3 |
| Larynx | 2.1 | 2.2 | 1.8 | 1.9 | 2.2 | 438 | 2.1 |
| Lung and Bronchus | 58.6 | 55.8 | 52.3 | 53.4 | 49.6 | 10,982 | 53.9 |
| Bones and Joints | 0.5 | 0.3 | 0.5 | 0.4 | 0.5 | 96 | 0.5 |
| Soft Tissue (Including Heart) | 1.8 | 1.3 | 1.4 | 2.2 | 1.7 | 349 | 1.7 |
| Skin (Excluding Basal and Squamous) | 5.3 | 4.9 | 4.8 | 4.7 | 4.6 | 985 | 4.9 |
| Melanoma of the Skin | 4.2 | 4.0 | 3.6 | 3.4 | 3.5 | 768 | 3.7 |

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 10 cases to ensure confidentiality and statistical reliability.

Table 16 (continued). Age-adjusted Mortality Rates, Males, All Races Combined

| Cancer Site | Rates | | | | | Cases | Rates |
|--|-------|------|------|------|------|-----------|-------|
| | 2007 | 2008 | 2009 | 2010 | 2011 | 2007-2011 | |
| Breast | 0.3 | 0.4 | 0.3 | 0.6 | 0.2 | 75 | 0.4 |
| Male Genital System | 23.8 | 22.2 | 19.8 | 22.1 | 20.4 | 4,104 | 21.6 |
| Prostate | 23.3 | 21.9 | 19.5 | 21.8 | 19.7 | 4,016 | 21.2 |
| Testis | 0.3 | 0.3 | - | - | 0.4 | 53 | 0.3 |
| Penis | 0.2 | - | - | - | - | 29 | 0.1 |
| Urinary System | 14.5 | 14.3 | 13.8 | 14.7 | 13.6 | 2,801 | 14.2 |
| Urinary Bladder | 9.1 | 8.7 | 7.9 | 8.5 | 8.7 | 1,653 | 8.6 |
| Kidney and Renal Pelvis | 5.1 | 5.2 | 5.6 | 5.6 | 4.6 | 1,084 | 5.2 |
| Ureter | - | - | - | - | - | 17 | 0.1 |
| Eye | - | - | - | - | - | 21 | 0.1 |
| Brain and Other Nervous System | 4.8 | 4.7 | 4.6 | 4.7 | 4.6 | 1,003 | 4.7 |
| Endocrine System | 0.8 | 0.8 | 0.9 | 0.9 | 0.7 | 170 | 0.8 |
| Thyroid | 0.6 | 0.5 | 0.5 | 0.6 | 0.4 | 111 | 0.5 |
| Lymphomas | 8.6 | 7.8 | 8.0 | 8.1 | 7.4 | 1,596 | 8.0 |
| Hodgkin Lymphoma | 0.8 | 0.4 | 0.4 | 0.6 | 0.4 | 105 | 0.5 |
| Non-Hodgkin Lymphoma | 7.8 | 7.4 | 7.6 | 7.5 | 7.1 | 1,491 | 7.5 |
| Multiple Myeloma | 4.3 | 4.0 | 4.6 | 3.7 | 4.0 | 827 | 4.1 |
| Leukemias | 9.5 | 8.7 | 8.7 | 9.1 | 9.4 | 1,803 | 9.1 |
| Lymphocytic Leukemia | 3.0 | 2.3 | 2.3 | 2.6 | 2.8 | 517 | 2.6 |
| Acute Lymphocytic Leukemia | 0.7 | 0.5 | 0.4 | 0.5 | 0.3 | 100 | 0.5 |
| Chronic Lymphocytic Leukemia | 2.1 | 1.7 | 1.8 | 2.0 | 2.4 | 390 | 2.0 |
| Myeloid and Monocytic Leukemia | 4.0 | 3.5 | 3.5 | 4.1 | 4.2 | 781 | 3.9 |
| Acute Myeloid Leukemia | 3.4 | 2.8 | 3.1 | 3.4 | 3.6 | 658 | 3.3 |
| Acute Monocytic Leukemia | - | - | - | - | - | - | - |
| Chronic Myeloid Leukemia | 0.3 | 0.3 | 0.3 | 0.3 | 0.4 | 68 | 0.3 |
| Other Leukemia | 2.5 | 2.8 | 3.0 | 2.4 | 2.3 | 505 | 2.6 |
| Ill-Defined & Unspecified Sites | 17.6 | 18.3 | 18.5 | 17.4 | 16.8 | 3,563 | 17.7 |

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 10 cases to ensure confidentiality and statistical reliability.

Table 17. Age-adjusted Mortality Rates, Females, All Races Combined

| Cancer Site | Rates | | | | | Cases 2007-2011 | Rates |
|--|-------|-------|-------|-------|-------|--------------------|-------|
| | 2007 | 2008 | 2009 | 2010 | 2011 | | |
| All Sites | 157.5 | 155.4 | 149.4 | 146.7 | 146.2 | 42,734 | 151.0 |
| Oral Cavity and Pharynx | 1.1 | 1.5 | 1.4 | 1.4 | 0.9 | 354 | 1.2 |
| Lip | - | - | - | - | - | - | - |
| Tongue | 0.4 | 0.3 | 0.5 | 0.4 | 0.3 | 107 | 0.4 |
| Salivary Gland | - | - | - | 0.3 | - | 46 | 0.2 |
| Floor of Mouth | - | - | - | - | - | - | - |
| Gum and Other Mouth | - | 0.4 | 0.2 | 0.2 | - | 60 | 0.2 |
| Nasopharynx | - | 0.2 | - | 0.3 | - | 46 | 0.2 |
| Tonsil | - | - | - | - | - | 18 | 0.1 |
| Oropharynx | - | - | - | - | - | 28 | 0.1 |
| Hypopharynx | - | - | - | - | - | - | - |
| Digestive System | 35.1 | 36.0 | 34.8 | 35.0 | 32.4 | 10,013 | 34.6 |
| Esophagus | 1.7 | 1.7 | 1.7 | 1.7 | 1.6 | 487 | 1.7 |
| Stomach | 2.7 | 3.1 | 3.0 | 3.0 | 2.4 | 813 | 2.8 |
| Small Intestine | 0.3 | 0.4 | 0.3 | 0.4 | 0.2 | 93 | 0.3 |
| Colon and Rectum | 15.7 | 15.0 | 14.0 | 13.8 | 13.0 | 4,205 | 14.3 |
| Colon excluding Rectum | 13.3 | 12.5 | 11.7 | 11.6 | 11.2 | 3,558 | 12.0 |
| Rectum and Rectosigmoid Junction | 2.4 | 2.5 | 2.3 | 2.2 | 1.8 | 647 | 2.3 |
| Anus, Anal Canal and Anorectum | 0.2 | 0.2 | 0.4 | 0.3 | 0.2 | 72 | 0.3 |
| Liver and Intrahepatic Bile Duct | 3.0 | 3.2 | 3.3 | 3.8 | 2.9 | 911 | 3.2 |
| Liver | 1.7 | 2.1 | 2.1 | 2.3 | 1.6 | 553 | 2.0 |
| Intrahepatic Bile Duct | 1.3 | 1.0 | 1.2 | 1.5 | 1.3 | 358 | 1.3 |
| Gallbladder | 1.0 | 1.0 | 0.7 | 1.1 | 0.6 | 256 | 0.9 |
| Pancreas | 9.4 | 10.3 | 10.5 | 10.1 | 10.1 | 2,891 | 10.1 |
| Respiratory System | 39.5 | 38.2 | 37.1 | 35.3 | 36.3 | 10,366 | 37.3 |
| Larynx | 0.5 | 0.5 | 0.5 | 0.6 | 0.5 | 153 | 0.5 |
| Lung and Bronchus | 38.9 | 37.5 | 36.4 | 34.5 | 35.6 | 10,164 | 36.5 |
| Bones and Joints | 0.4 | 0.4 | 0.3 | 0.3 | 0.5 | 94 | 0.4 |
| Soft Tissue (Including Heart) | 1.2 | 1.2 | 1.3 | 1.7 | 1.1 | 348 | 1.3 |
| Skin (Excluding Basal and Squamous) | 2.1 | 2.6 | 2.3 | 1.9 | 1.7 | 609 | 2.1 |
| Melanoma of the Skin | 1.7 | 2.1 | 1.7 | 1.5 | 1.3 | 471 | 1.7 |
| Breast | 26.0 | 25.6 | 24.0 | 23.2 | 24.3 | 6,893 | 24.6 |

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 10 cases to ensure confidentiality and statistical reliability.

Table 17 (continued). Age-adjusted Mortality Rates, Females, All Races Combined

| Cancer Site | Rates | | | | | Cases | Rates |
|--|-------|------|------|------|------|-----------|-------|
| | 2007 | 2008 | 2009 | 2010 | 2011 | 2007-2011 | |
| Female Genital System | 17.3 | 16.6 | 16.6 | 17.8 | 17.3 | 4,757 | 17.1 |
| Cervix Uteri | 2.1 | 2.1 | 2.5 | 2.4 | 2.6 | 599 | 2.3 |
| Corpus and Uterus, NOS | 5.1 | 5.0 | 5.1 | 6.1 | 5.3 | 1,491 | 5.3 |
| Corpus Uteri | 2.2 | 1.9 | 2.1 | 2.4 | 2.2 | 595 | 2.1 |
| Uterus, NOS | 2.9 | 3.1 | 3.0 | 3.7 | 3.2 | 896 | 3.2 |
| Ovary | 8.9 | 8.7 | 8.0 | 8.5 | 8.4 | 2,384 | 8.5 |
| Vagina | - | 0.3 | - | 0.2 | 0.2 | 52 | 0.2 |
| Vulva | 0.6 | 0.4 | 0.5 | 0.5 | 0.4 | 151 | 0.5 |
| Urinary System | 4.6 | 4.9 | 4.8 | 4.9 | 4.6 | 1,404 | 4.8 |
| Urinary Bladder | 2.4 | 2.7 | 2.5 | 2.7 | 2.5 | 763 | 2.5 |
| Kidney and Renal Pelvis | 2.2 | 2.1 | 2.1 | 2.0 | 2.0 | 598 | 2.1 |
| Ureter | - | - | - | - | - | 21 | 0.1 |
| Eye | - | - | - | - | - | 10 | - |
| Brain and Other Nervous System | 3.1 | 2.6 | 2.9 | 3.0 | 3.3 | 786 | 2.9 |
| Endocrine System | 0.7 | 0.7 | 0.6 | 0.9 | 0.5 | 180 | 0.7 |
| Thyroid | 0.4 | 0.4 | 0.5 | 0.6 | 0.4 | 127 | 0.5 |
| Lymphomas | 6.4 | 5.6 | 4.9 | 4.5 | 5.1 | 1,526 | 5.3 |
| Hodgkin Lymphoma | 0.5 | 0.2 | 0.3 | 0.2 | 0.4 | 83 | 0.3 |
| Non-Hodgkin Lymphoma | 5.9 | 5.4 | 4.6 | 4.3 | 4.7 | 1,443 | 5.0 |
| Multiple Myeloma | 2.8 | 2.8 | 2.3 | 2.2 | 3.0 | 750 | 2.6 |
| Leukemias | 5.2 | 5.8 | 4.6 | 4.7 | 5.0 | 1,423 | 5.0 |
| Lymphocytic Leukemia | 1.1 | 1.3 | 1.1 | 1.4 | 1.0 | 343 | 1.2 |
| Acute Lymphocytic Leukemia | 0.3 | 0.4 | 0.3 | 0.3 | 0.3 | 82 | 0.3 |
| Chronic Lymphocytic Leukemia | 0.7 | 0.8 | 0.8 | 1.0 | 0.6 | 242 | 0.8 |
| Myeloid and Monocytic Leukemia | 2.3 | 2.7 | 2.1 | 2.2 | 2.6 | 652 | 2.4 |
| Acute Myeloid Leukemia | 1.9 | 2.5 | 1.9 | 2.0 | 2.3 | 572 | 2.1 |
| Acute Monocytic Leukemia | - | - | - | - | - | - | - |
| Chronic Myeloid Leukemia | 0.3 | - | - | - | 0.2 | 49 | 0.2 |
| Other Leukemia | 1.8 | 1.7 | 1.4 | 1.1 | 1.4 | 428 | 1.5 |
| Ill-Defined & Unspecified Sites | 11.9 | 11.1 | 11.7 | 10.0 | 10.3 | 3,221 | 11.0 |

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 10 cases to ensure confidentiality and statistical reliability.

Table 18. Age-adjusted Mortality Rates, White Males

| Cancer Site | Rates | | | | | Cases | Rates |
|--|-------|-------|-------|-------|-------|-----------|-------|
| | 2007 | 2008 | 2009 | 2010 | 2011 | 2007-2011 | |
| All Sites | 217.8 | 205.7 | 199.4 | 203.1 | 198.2 | 35,150 | 204.7 |
| Oral Cavity and Pharynx | 2.8 | 2.9 | 2.6 | 2.7 | 3.5 | 521 | 2.9 |
| Lip | - | - | - | - | - | - | - |
| Tongue | 0.9 | 1.0 | 0.8 | 0.8 | 0.9 | 157 | 0.9 |
| Salivary Gland | - | - | 0.4 | 0.3 | 0.5 | 60 | 0.3 |
| Floor of Mouth | - | - | - | - | - | - | - |
| Gum and Other Mouth | - | 0.3 | - | 0.3 | 0.3 | 54 | 0.3 |
| Nasopharynx | 0.3 | - | - | 0.3 | - | 38 | 0.2 |
| Tonsil | - | - | - | - | 0.4 | 40 | 0.2 |
| Oropharynx | - | 0.3 | - | - | 0.3 | 42 | 0.2 |
| Hypopharynx | - | - | - | - | - | 25 | 0.1 |
| Digestive System | 58.8 | 55.3 | 56.1 | 54.1 | 55.9 | 9,761 | 56.0 |
| Esophagus | 7.4 | 6.7 | 6.8 | 7.8 | 8.0 | 1,305 | 7.3 |
| Stomach | 5.3 | 5.9 | 5.4 | 4.7 | 4.3 | 873 | 5.1 |
| Small Intestine | - | 0.5 | 0.6 | 0.4 | 0.4 | 74 | 0.4 |
| Colon and Rectum | 22.7 | 20.4 | 20.4 | 18.4 | 18.3 | 3,438 | 20.0 |
| Colon excluding Rectum | 19.3 | 16.9 | 16.5 | 15.1 | 14.8 | 2,811 | 16.5 |
| Rectum and Rectosigmoid Junction | 3.4 | 3.5 | 3.9 | 3.4 | 3.6 | 627 | 3.5 |
| Anus, Anal Canal and Anorectum | - | - | - | - | - | 34 | 0.2 |
| Liver and Intrahepatic Bile Duct | 6.6 | 6.7 | 8.0 | 7.9 | 8.9 | 1,370 | 7.6 |
| Liver | 5.4 | 5.5 | 5.9 | 5.9 | 6.5 | 1,060 | 5.9 |
| Intrahepatic Bile Duct | 1.2 | 1.2 | 2.2 | 1.9 | 2.3 | 310 | 1.8 |
| Gallbladder | 0.8 | 0.4 | 0.6 | 0.5 | 0.7 | 101 | 0.6 |
| Pancreas | 14.3 | 13.7 | 12.8 | 13.3 | 13.9 | 2,379 | 13.6 |
| Respiratory System | 62.8 | 58.6 | 54.5 | 57.0 | 52.9 | 9,851 | 57.1 |
| Larynx | 2.0 | 2.3 | 1.9 | 1.9 | 2.1 | 359 | 2.0 |
| Lung and Bronchus | 60.4 | 55.9 | 52.4 | 54.9 | 50.5 | 9,436 | 54.8 |
| Bones and Joints | 0.5 | 0.4 | 0.6 | 0.5 | 0.5 | 84 | 0.5 |
| Soft Tissue (Including Heart) | 1.9 | 1.4 | 1.4 | 2.3 | 1.8 | 300 | 1.8 |
| Skin (Excluding Basal and Squamous) | 5.9 | 5.5 | 5.5 | 5.4 | 5.4 | 950 | 5.5 |
| Melanoma of the Skin | 4.7 | 4.6 | 4.2 | 3.9 | 4.1 | 745 | 4.3 |

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 10 cases to ensure confidentiality and statistical reliability.

Table 18 (continued). Age-adjusted Mortality Rates, White Males

| Cancer Site | Rates | | | | | Cases | Rates |
|--|-------|------|------|------|------|-----------|-------|
| | 2007 | 2008 | 2009 | 2010 | 2011 | 2007-2011 | |
| Breast | 0.3 | 0.4 | 0.3 | 0.5 | - | 62 | 0.4 |
| Male Genital System | 21.9 | 20.7 | 17.8 | 19.9 | 18.9 | 3,273 | 19.8 |
| Prostate | 21.3 | 20.4 | 17.5 | 19.5 | 18.2 | 3,192 | 19.3 |
| Testis | 0.4 | 0.3 | - | - | 0.4 | 51 | 0.3 |
| Penis | 0.3 | - | - | - | - | 25 | 0.1 |
| Urinary System | 15.2 | 14.8 | 14.5 | 15.6 | 14.5 | 2,527 | 14.9 |
| Urinary Bladder | 9.8 | 9.2 | 8.4 | 9.1 | 9.2 | 1,526 | 9.1 |
| Kidney and Renal Pelvis | 5.2 | 5.3 | 5.8 | 5.9 | 4.9 | 945 | 5.4 |
| Ureter | - | - | - | - | - | 14 | 0.1 |
| Eye | - | - | - | - | - | 19 | 0.1 |
| Brain and Other Nervous System | 5.2 | 5.1 | 5.1 | 5.2 | 5.0 | 895 | 5.1 |
| Endocrine System | 0.7 | 0.8 | 0.8 | 1.0 | 0.8 | 143 | 0.8 |
| Thyroid | 0.6 | 0.5 | 0.5 | 0.7 | 0.4 | 98 | 0.6 |
| Lymphomas | 9.3 | 8.3 | 8.4 | 8.4 | 8.0 | 1,434 | 8.5 |
| Hodgkin Lymphoma | 0.9 | 0.5 | 0.5 | 0.6 | 0.4 | 96 | 0.6 |
| Non-Hodgkin Lymphoma | 8.4 | 7.8 | 7.9 | 7.8 | 7.6 | 1,338 | 7.9 |
| Multiple Myeloma | 4.3 | 3.7 | 4.0 | 3.6 | 3.7 | 659 | 3.8 |
| Leukemias | 10.3 | 9.1 | 9.3 | 9.6 | 10.2 | 1,639 | 9.7 |
| Lymphocytic Leukemia | 3.2 | 2.5 | 2.4 | 2.8 | 3.1 | 471 | 2.8 |
| Acute Lymphocytic Leukemia | 0.9 | 0.5 | 0.3 | 0.5 | 0.3 | 83 | 0.5 |
| Chronic Lymphocytic Leukemia | 2.2 | 1.8 | 2.0 | 2.1 | 2.6 | 363 | 2.1 |
| Myeloid and Monocytic Leukemia | 4.4 | 3.8 | 3.8 | 4.5 | 4.6 | 718 | 4.2 |
| Acute Myeloid Leukemia | 3.7 | 3.1 | 3.5 | 3.8 | 3.8 | 607 | 3.6 |
| Acute Monocytic Leukemia | - | - | - | - | - | - | - |
| Chronic Myeloid Leukemia | 0.3 | 0.3 | - | 0.4 | 0.5 | 60 | 0.3 |
| Other Leukemia | 2.7 | 2.8 | 3.1 | 2.4 | 2.6 | 450 | 2.7 |
| Ill-Defined & Unspecified Sites | 17.9 | 18.4 | 18.3 | 17.3 | 16.9 | 3,032 | 17.7 |

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 10 cases to ensure confidentiality and statistical reliability.

Table 19. Age-adjusted Mortality Rates, White Females

| Cancer Site | Rates | | | | | Cases | Rates |
|--|-------|-------|-------|-------|-------|-----------|-------|
| | 2007 | 2008 | 2009 | 2010 | 2011 | 2007-2011 | |
| All Sites | 160.3 | 158.7 | 152.9 | 148.6 | 147.7 | 36,437 | 153.6 |
| Oral Cavity and Pharynx | 1.1 | 1.6 | 1.5 | 1.5 | 0.8 | 307 | 1.3 |
| Lip | - | - | - | - | - | - | - |
| Tongue | 0.4 | 0.3 | 0.6 | 0.5 | 0.2 | 95 | 0.4 |
| Salivary Gland | - | - | - | 0.3 | - | 42 | 0.2 |
| Floor of Mouth | - | - | - | - | - | - | - |
| Gum and Other Mouth | - | 0.4 | 0.2 | - | - | 54 | 0.2 |
| Nasopharynx | - | 0.2 | - | 0.3 | - | 36 | 0.2 |
| Tonsil | - | - | - | - | - | 15 | 0.1 |
| Oropharynx | - | - | - | - | - | 25 | 0.1 |
| Hypopharynx | - | - | - | - | - | - | - |
| Digestive System | 34.3 | 35.6 | 34.0 | 34.3 | 32.6 | 8,378 | 34.1 |
| Esophagus | 1.6 | 1.7 | 1.8 | 1.6 | 1.7 | 410 | 1.7 |
| Stomach | 2.3 | 2.8 | 2.7 | 2.6 | 2.5 | 627 | 2.5 |
| Small Intestine | 0.2 | 0.3 | 0.3 | 0.4 | 0.2 | 72 | 0.3 |
| Colon and Rectum | 15.6 | 14.6 | 13.6 | 13.5 | 12.9 | 3,529 | 14.0 |
| Colon excluding Rectum | 13.2 | 12.2 | 11.2 | 11.3 | 11.1 | 2,984 | 11.8 |
| Rectum and Rectosigmoid Junction | 2.4 | 2.5 | 2.4 | 2.3 | 1.8 | 545 | 2.3 |
| Anus, Anal Canal and Anorectum | - | 0.2 | 0.5 | 0.3 | - | 63 | 0.3 |
| Liver and Intrahepatic Bile Duct | 2.9 | 3.2 | 3.3 | 3.8 | 2.9 | 764 | 3.2 |
| Liver | 1.6 | 2.1 | 2.2 | 2.4 | 1.6 | 469 | 2.0 |
| Intrahepatic Bile Duct | 1.3 | 1.1 | 1.1 | 1.4 | 1.3 | 295 | 1.2 |
| Gallbladder | 0.9 | 1.1 | 0.7 | 1.1 | 0.6 | 211 | 0.9 |
| Pancreas | 9.2 | 10.6 | 10.3 | 10.1 | 10.3 | 2,451 | 10.1 |
| Respiratory System | 42.0 | 39.9 | 39.0 | 37.2 | 37.8 | 9,079 | 39.2 |
| Larynx | 0.4 | 0.4 | 0.6 | 0.5 | 0.5 | 118 | 0.5 |
| Lung and Bronchus | 41.4 | 39.3 | 38.2 | 36.4 | 37.1 | 8,914 | 38.5 |
| Bones and Joints | 0.4 | 0.5 | 0.3 | 0.3 | 0.4 | 77 | 0.4 |
| Soft Tissue (Including Heart) | 1.2 | 1.1 | 1.3 | 1.8 | 1.2 | 288 | 1.3 |
| Skin (Excluding Basal and Squamous) | 2.3 | 3.0 | 2.6 | 2.2 | 2.0 | 586 | 2.4 |
| Melanoma of the Skin | 1.9 | 2.4 | 2.0 | 1.8 | 1.6 | 453 | 1.9 |
| Breast | 26.1 | 25.6 | 24.0 | 22.7 | 23.8 | 5,686 | 24.5 |

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 10 cases to ensure confidentiality and statistical reliability.

Table 19 (continued). Age-adjusted Mortality Rates, White Females

| Cancer Site | Rates | | | | | Cases | Rates |
|--|-------|------|------|------|------|-----------|-------|
| | 2007 | 2008 | 2009 | 2010 | 2011 | 2007-2011 | |
| Female Genital System | 17.5 | 16.7 | 16.9 | 17.9 | 17.1 | 3,966 | 17.2 |
| Cervix Uteri | 1.8 | 2.1 | 2.4 | 2.1 | 2.3 | 436 | 2.1 |
| Corpus and Uterus, NOS | 4.8 | 4.6 | 4.6 | 6.0 | 4.9 | 1,168 | 5.0 |
| Corpus Uteri | 2.1 | 1.9 | 1.9 | 2.3 | 2.1 | 479 | 2.1 |
| Uterus, NOS | 2.7 | 2.7 | 2.7 | 3.6 | 2.8 | 689 | 2.9 |
| Ovary | 9.7 | 9.2 | 8.8 | 9.0 | 8.9 | 2,110 | 9.1 |
| Vagina | - | 0.2 | - | 0.2 | - | 43 | 0.2 |
| Vulva | 0.7 | 0.5 | 0.6 | 0.5 | 0.4 | 141 | 0.5 |
| Urinary System | 4.9 | 5.1 | 5.1 | 5.1 | 4.7 | 1,247 | 5.0 |
| Urinary Bladder | 2.4 | 2.8 | 2.7 | 2.8 | 2.7 | 683 | 2.7 |
| Kidney and Renal Pelvis | 2.4 | 2.2 | 2.3 | 2.1 | 1.9 | 528 | 2.2 |
| Ureter | - | - | - | - | - | 20 | 0.1 |
| Eye | - | - | - | - | - | 10 | - |
| Brain and Other Nervous System | 3.4 | 2.9 | 3.3 | 3.1 | 3.6 | 710 | 3.3 |
| Endocrine System | 0.8 | 0.7 | 0.7 | 0.8 | 0.4 | 150 | 0.7 |
| Thyroid | 0.5 | 0.4 | 0.5 | 0.6 | 0.3 | 109 | 0.5 |
| Lymphomas | 6.7 | 5.9 | 5.2 | 4.6 | 5.3 | 1,365 | 5.5 |
| Hodgkin Lymphoma | 0.4 | - | 0.3 | 0.2 | 0.4 | 65 | 0.3 |
| Non-Hodgkin Lymphoma | 6.3 | 5.7 | 4.9 | 4.4 | 4.9 | 1,300 | 5.3 |
| Multiple Myeloma | 2.2 | 2.8 | 2.2 | 1.9 | 2.6 | 575 | 2.3 |
| Leukemias | 5.4 | 6.2 | 5.0 | 4.8 | 5.1 | 1,261 | 5.3 |
| Lymphocytic Leukemia | 1.1 | 1.4 | 1.3 | 1.5 | 1.1 | 313 | 1.3 |
| Acute Lymphocytic Leukemia | 0.3 | 0.4 | 0.4 | 0.4 | 0.3 | 73 | 0.4 |
| Chronic Lymphocytic Leukemia | 0.8 | 0.8 | 0.9 | 1.1 | 0.7 | 223 | 0.8 |
| Myeloid and Monocytic Leukemia | 2.3 | 2.9 | 2.3 | 2.2 | 2.7 | 572 | 2.5 |
| Acute Myeloid Leukemia | 1.9 | 2.7 | 2.1 | 2.0 | 2.4 | 502 | 2.2 |
| Acute Monocytic Leukemia | - | - | - | - | - | - | - |
| Chronic Myeloid Leukemia | 0.3 | - | - | - | - | 43 | 0.2 |
| Other Leukemia | 1.9 | 1.9 | 1.4 | 1.1 | 1.3 | 376 | 1.5 |
| Ill-Defined & Unspecified Sites | 11.9 | 11.2 | 12.0 | 10.2 | 10.3 | 2,752 | 11.1 |

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 10 cases to ensure confidentiality and statistical reliability.

Table 20. Age-adjusted Mortality Rates, Black Males

| Cancer Site | Rates | | | | | Cases | Rates |
|--|-------|-------|-------|-------|-------|-----------|-------|
| | 2007 | 2008 | 2009 | 2010 | 2011 | 2007-2011 | |
| All Sites | 257.0 | 269.3 | 259.8 | 258.2 | 230.1 | 5,078 | 254.5 |
| Oral Cavity and Pharynx | 8.1 | 4.2 | 5.0 | 5.1 | 4.5 | 126 | 5.4 |
| Lip | - | - | - | - | - | - | - |
| Tongue | 2.3 | - | - | - | - | 29 | 1.2 |
| Salivary Gland | - | - | - | - | - | - | - |
| Floor of Mouth | - | - | - | - | - | - | - |
| Gum and Other Mouth | - | - | - | - | - | 16 | 0.8 |
| Nasopharynx | - | - | - | - | - | 13 | 0.5 |
| Tonsil | - | - | - | - | - | 11 | 0.4 |
| Oropharynx | - | - | - | - | - | 14 | 0.6 |
| Hypopharynx | - | - | - | - | - | - | - |
| Digestive System | 73.7 | 81.9 | 70.3 | 79.1 | 67.0 | 1,576 | 74.2 |
| Esophagus | 6.5 | 6.8 | 7.6 | 10.2 | 5.3 | 156 | 7.3 |
| Stomach | 13.2 | 10.4 | 9.1 | 5.9 | 5.7 | 171 | 8.7 |
| Small Intestine | - | - | - | - | - | 10 | 0.5 |
| Colon and Rectum | 26.1 | 32.9 | 24.5 | 28.5 | 28.4 | 563 | 28.0 |
| Colon excluding Rectum | 21.7 | 28.7 | 21.2 | 23.3 | 23.7 | 470 | 23.7 |
| Rectum and Rectosigmoid Junction | 4.4 | 4.2 | 3.3 | 5.2 | 4.6 | 93 | 4.3 |
| Anus, Anal Canal and Anorectum | - | - | - | - | - | - | - |
| Liver and Intrahepatic Bile Duct | 8.7 | 13.4 | 11.0 | 13.8 | 8.6 | 272 | 11.1 |
| Liver | 7.5 | 11.2 | 9.5 | 12.4 | 7.1 | 240 | 9.6 |
| Intrahepatic Bile Duct | - | - | - | - | - | 32 | 1.6 |
| Gallbladder | - | - | - | - | - | 16 | 0.9 |
| Pancreas | 16.0 | 15.8 | 15.4 | 16.7 | 16.6 | 354 | 16.1 |
| Respiratory System | 68.6 | 74.5 | 72.6 | 61.1 | 58.5 | 1,367 | 66.9 |
| Larynx | 4.3 | 3.5 | 2.5 | 2.8 | 3.5 | 70 | 3.3 |
| Lung and Bronchus | 63.5 | 70.5 | 70.1 | 57.8 | 54.6 | 1,289 | 63.1 |
| Bones and Joints | - | - | - | - | - | 11 | 0.4 |
| Soft Tissue (Including Heart) | - | - | - | 1.8 | 1.8 | 40 | 1.5 |
| Skin (Excluding Basal and Squamous) | - | - | - | - | - | 29 | 1.3 |
| Melanoma of the Skin | - | - | - | - | - | 18 | 0.8 |

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 10 cases to ensure confidentiality and statistical reliability.

Table 20 (continued). Age-adjusted Mortality Rates, Black Males

| Cancer Site | Rates | | | | | Cases | Rates |
|--|-------|------|------|------|------|-----------|-------|
| | 2007 | 2008 | 2009 | 2010 | 2011 | 2007-2011 | |
| Breast | - | - | - | - | - | - | - |
| Male Genital System | 52.4 | 45.4 | 47.2 | 53.1 | 42.4 | 781 | 47.9 |
| Prostate | 52.4 | 45.1 | 46.8 | 52.9 | 42.0 | 774 | 47.7 |
| Testis | - | - | - | - | - | - | - |
| Penis | - | - | - | - | - | - | - |
| Urinary System | 12.3 | 12.6 | 10.9 | 9.7 | 9.7 | 213 | 11.0 |
| Urinary Bladder | 6.2 | 6.1 | 4.7 | 4.7 | 5.1 | 95 | 5.3 |
| Kidney and Renal Pelvis | 6.1 | 6.1 | 6.0 | 4.5 | 4.6 | 113 | 5.5 |
| Ureter | - | - | - | - | - | - | - |
| Eye | - | - | - | - | - | - | - |
| Brain and Other Nervous System | 2.6 | 3.4 | 2.9 | 2.6 | 3.5 | 73 | 3.0 |
| Endocrine System | - | - | - | - | - | 16 | 0.7 |
| Thyroid | - | - | - | - | - | - | - |
| Lymphomas | 4.2 | 4.8 | 6.9 | 7.3 | 5.5 | 123 | 5.8 |
| Hodgkin Lymphoma | - | - | - | - | - | - | - |
| Non-Hodgkin Lymphoma | 3.9 | 4.8 | 6.4 | 6.9 | 5.0 | 114 | 5.5 |
| Multiple Myeloma | 6.1 | 8.1 | 10.9 | 4.7 | 7.0 | 142 | 7.3 |
| Leukemias | 5.9 | 7.3 | 6.1 | 7.6 | 6.4 | 134 | 6.7 |
| Lymphocytic Leukemia | - | - | - | - | - | 34 | 1.8 |
| Acute Lymphocytic Leukemia | - | - | - | - | - | - | - |
| Chronic Lymphocytic Leukemia | - | - | - | - | - | 24 | 1.4 |
| Myeloid and Monocytic Leukemia | - | 2.7 | - | 2.9 | 3.3 | 56 | 2.6 |
| Acute Myeloid Leukemia | - | - | - | - | 3.0 | 44 | 2.1 |
| Acute Monocytic Leukemia | - | - | - | - | - | - | - |
| Chronic Myeloid Leukemia | - | - | - | - | - | - | - |
| Other Leukemia | - | 2.5 | 2.7 | 2.9 | - | 44 | 2.2 |
| Ill-Defined & Unspecified Sites | 17.8 | 23.5 | 23.1 | 22.8 | 21.9 | 437 | 21.9 |

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 10 cases to ensure confidentiality and statistical reliability.

Table 21. Age-adjusted Mortality Rates, Black Females

| Cancer Site | Rates | | | | | Cases | Rates |
|--|-------|-------|-------|-------|-------|-----------|-------|
| | 2007 | 2008 | 2009 | 2010 | 2011 | 2007-2011 | |
| All Sites | 169.8 | 166.2 | 159.8 | 164.4 | 167.4 | 5,219 | 165.4 |
| Oral Cavity and Pharynx | - | - | - | - | - | 35 | 1.0 |
| Lip | - | - | - | - | - | - | - |
| Tongue | - | - | - | - | - | - | - |
| Salivary Gland | - | - | - | - | - | - | - |
| Floor of Mouth | - | - | - | - | - | - | - |
| Gum and Other Mouth | - | - | - | - | - | - | - |
| Nasopharynx | - | - | - | - | - | - | - |
| Tonsil | - | - | - | - | - | - | - |
| Oropharynx | - | - | - | - | - | - | - |
| Hypopharynx | - | - | - | - | - | - | - |
| Digestive System | 47.7 | 43.9 | 45.0 | 45.1 | 37.2 | 1,345 | 43.7 |
| Esophagus | 2.6 | 2.3 | 2.0 | 1.9 | - | 65 | 2.0 |
| Stomach | 5.5 | 4.6 | 4.2 | 6.0 | 2.8 | 137 | 4.6 |
| Small Intestine | - | - | - | - | - | 18 | 0.6 |
| Colon and Rectum | 19.8 | 19.7 | 19.6 | 17.0 | 17.3 | 574 | 18.7 |
| Colon excluding Rectum | 17.0 | 16.1 | 16.6 | 14.8 | 15.1 | 490 | 15.9 |
| Rectum and Rectosigmoid Junction | 2.8 | 3.6 | 3.0 | 2.3 | 2.2 | 84 | 2.8 |
| Anus, Anal Canal and Anorectum | - | - | - | - | - | - | - |
| Liver and Intrahepatic Bile Duct | 3.3 | 3.4 | 3.6 | 4.3 | 2.5 | 108 | 3.4 |
| Liver | 1.8 | 2.2 | 1.7 | 2.7 | - | 61 | 2.0 |
| Intrahepatic Bile Duct | - | - | 1.8 | 1.7 | - | 47 | 1.5 |
| Gallbladder | 2.2 | - | - | - | - | 34 | 1.0 |
| Pancreas | 12.9 | 11.1 | 13.4 | 12.8 | 10.9 | 373 | 12.2 |
| Respiratory System | 32.3 | 38.6 | 33.1 | 32.4 | 36.6 | 1,084 | 34.6 |
| Larynx | - | 1.5 | - | 1.5 | - | 34 | 1.0 |
| Lung and Bronchus | 31.5 | 36.9 | 32.7 | 30.9 | 35.7 | 1,049 | 33.5 |
| Bones and Joints | - | - | - | - | - | 12 | 0.4 |
| Soft Tissue (Including Heart) | - | 2.2 | 1.5 | - | - | 48 | 1.4 |
| Skin (Excluding Basal and Squamous) | - | - | - | - | - | 15 | 0.5 |
| Melanoma of the Skin | - | - | - | - | - | 10 | 0.3 |
| Breast | 30.3 | 29.5 | 30.4 | 31.2 | 33.2 | 1,019 | 30.9 |

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 10 cases to ensure confidentiality and statistical reliability.

Table 21 (continued). Age-adjusted Mortality Rates, Black Females

| Cancer Site | Rates | | | | | Cases | Rates |
|--|-------|------|------|------|------|-----------|-------|
| | 2007 | 2008 | 2009 | 2010 | 2011 | 2007-2011 | |
| Female Genital System | 21.0 | 18.6 | 18.9 | 20.0 | 21.2 | 647 | 20.0 |
| Cervix Uteri | 4.2 | 2.0 | 3.3 | 5.0 | 4.8 | 132 | 3.9 |
| Corpus and Uterus, NOS | 9.2 | 7.8 | 9.7 | 8.2 | 9.2 | 281 | 8.8 |
| Corpus Uteri | 3.3 | 1.8 | 3.8 | 3.1 | 3.0 | 96 | 3.0 |
| Uterus, NOS | 5.9 | 6.0 | 5.9 | 5.0 | 6.2 | 185 | 5.8 |
| Ovary | 6.2 | 7.5 | 4.9 | 6.6 | 6.5 | 204 | 6.3 |
| Vagina | - | - | - | - | - | - | - |
| Vulva | - | - | - | - | - | - | - |
| Urinary System | 3.2 | 4.8 | 4.4 | 4.7 | 5.6 | 137 | 4.6 |
| Urinary Bladder | 2.3 | 2.6 | 2.2 | 2.8 | 2.1 | 70 | 2.4 |
| Kidney and Renal Pelvis | - | 2.0 | 1.9 | 1.6 | 3.4 | 61 | 2.0 |
| Ureter | - | - | - | - | - | - | - |
| Eye | - | - | - | - | - | - | - |
| Brain and Other Nervous System | 1.8 | - | - | 2.2 | 2.8 | 56 | 1.7 |
| Endocrine System | - | - | - | - | - | 23 | 0.7 |
| Thyroid | - | - | - | - | - | 12 | 0.4 |
| Lymphomas | 4.5 | 3.9 | 2.8 | 4.1 | 4.2 | 122 | 3.9 |
| Hodgkin Lymphoma | - | - | - | - | - | 17 | 0.5 |
| Non-Hodgkin Lymphoma | 3.7 | 3.4 | 2.6 | 3.9 | 3.4 | 105 | 3.4 |
| Multiple Myeloma | 7.6 | 3.7 | 3.0 | 5.3 | 6.1 | 156 | 5.1 |
| Leukemias | 4.3 | 4.7 | 3.1 | 4.5 | 3.9 | 123 | 4.1 |
| Lymphocytic Leukemia | - | - | - | - | - | 25 | 0.8 |
| Acute Lymphocytic Leukemia | - | - | - | - | - | - | - |
| Chronic Lymphocytic Leukemia | - | - | - | - | - | 17 | 0.6 |
| Myeloid and Monocytic Leukemia | 2.2 | 2.4 | - | 2.0 | 1.8 | 58 | 1.9 |
| Acute Myeloid Leukemia | 2.0 | 2.2 | - | 1.9 | - | 52 | 1.7 |
| Acute Monocytic Leukemia | - | - | - | - | - | - | - |
| Chronic Myeloid Leukemia | - | - | - | - | - | - | - |
| Other Leukemia | - | - | - | - | - | 40 | 1.4 |
| Ill-Defined & Unspecified Sites | 13.3 | 13.2 | 14.2 | 11.0 | 13.0 | 397 | 12.9 |

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 10 cases to ensure confidentiality and statistical reliability.

**Table 22. Age-adjusted Mortality Rates, Hispanic Males and Females
2007-2011 Combined**

| Cancer Site | Male | | Female | |
|--|-------|-------|--------|-------|
| | Rate | Cases | Rate | Cases |
| All Sites | 134.1 | 2,321 | 89.8 | 2,175 |
| Oral Cavity and Pharynx | 1.7 | 35 | 0.8 | 19 |
| Lip | - | - | - | - |
| Tongue | 0.5 | 12 | - | - |
| Salivary Gland | - | - | - | - |
| Floor of Mouth | - | - | - | - |
| Gum and Other Mouth | - | - | - | - |
| Nasopharynx | - | - | - | - |
| Tonsil | - | - | - | - |
| Oropharynx | - | - | - | - |
| Hypopharynx | - | - | - | - |
| Digestive System | 43.4 | 811 | 27.4 | 627 |
| Esophagus | 3.8 | 69 | 1.0 | 23 |
| Stomach | 6.7 | 124 | 3.6 | 85 |
| Small Intestine | - | - | - | - |
| Colon and Rectum | 13.4 | 250 | 9.5 | 225 |
| Colon excluding Rectum | 11.3 | 205 | 8.0 | 186 |
| Rectum and Rectosigmoid Junction | 2.1 | 45 | 1.6 | 39 |
| Anus, Anal Canal and Anorectum | - | - | - | - |
| Liver and Intrahepatic Bile Duct | 8.9 | 179 | 3.5 | 76 |
| Liver | 7.1 | 148 | 2.4 | 52 |
| Intrahepatic Bile Duct | 1.8 | 31 | 1.1 | 24 |
| Gallbladder | 0.7 | 10 | 1.0 | 24 |
| Pancreas | 8.8 | 158 | 7.4 | 160 |
| Respiratory System | 30.8 | 508 | 12.1 | 284 |
| Larynx | 2.3 | 40 | 0.5 | 10 |
| Lung and Bronchus | 28.3 | 464 | 11.6 | 272 |
| Bones and Joints | - | - | - | - |
| Soft Tissue (Including Heart) | 1.1 | 25 | 0.8 | 25 |
| Skin (Excluding Basal and Squamous) | 1.1 | 19 | 0.5 | 13 |
| Melanoma of the Skin | 0.9 | 16 | - | - |
| Breast | - | - | 12.7 | 345 |

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard.

Note: Hispanic includes all races.

- Counts and rates are suppressed when fewer than 10 cases to ensure confidentiality and statistical reliability.

**Table 22 (continued). Age-adjusted Mortality Rates, Hispanic Males and Females
2007-2011 Combined**

| Cancer Site | Male | | Female | |
|--|------|-------|--------|-------|
| | Rate | Cases | Rate | Cases |
| Female Genital System | * | * | 12.0 | 306 |
| Cervix Uteri | * | * | 2.7 | 76 |
| Corpus and Uterus, NOS | * | * | 3.6 | 89 |
| Corpus Uteri | * | * | 1.3 | 33 |
| Uterus, NOS | * | * | 2.4 | 56 |
| Ovary | * | * | 5.2 | 132 |
| Vagina | * | * | - | - |
| Vulva | * | * | - | - |
| Male Genital System | 17.4 | 233 | * | * |
| Prostate | 16.8 | 218 | * | * |
| Testis | - | - | * | * |
| Penis | - | - | * | * |
| Urinary System | 7.8 | 123 | 2.7 | 59 |
| Urinary Bladder | 4.6 | 59 | 1.5 | 30 |
| Kidney and Renal Pelvis | 3.2 | 63 | 1.2 | 28 |
| Ureter | - | - | - | - |
| Eye | - | - | - | - |
| Brain and Other Nervous System | 2.6 | 71 | 2.2 | 60 |
| Endocrine System | 0.6 | 12 | 0.6 | 13 |
| Thyroid | - | - | - | - |
| Lymphomas | 7.1 | 133 | 3.9 | 91 |
| Hodgkin Lymphoma | 0.7 | 16 | - | - |
| Non-Hodgkin Lymphoma | 6.4 | 117 | 3.7 | 86 |
| Multiple Myeloma | 2.8 | 48 | 2.5 | 53 |
| Leukemias | 5.7 | 109 | 4.2 | 106 |
| Lymphocytic Leukemia | 1.4 | 30 | 1.0 | 30 |
| Acute Lymphocytic Leukemia | 0.5 | 16 | 0.6 | 21 |
| Chronic Lymphocytic Leukemia | 0.9 | 13 | - | - |
| Myeloid and Monocytic Leukemia | 2.6 | 49 | 1.9 | 45 |
| Acute Myeloid Leukemia | 1.9 | 38 | 1.6 | 39 |
| Acute Monocytic Leukemia | - | - | - | - |
| Chronic Myeloid Leukemia | - | - | - | - |
| Other Leukemia | 1.7 | 30 | 1.3 | 31 |
| Ill-Defined & Unspecified Sites | 11.4 | 182 | 7.1 | 165 |

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard.

Note: Hispanic includes all races.

* Non-applicable gender

- Counts and rates are suppressed when fewer than 10 cases to ensure confidentiality and statistical reliability.

Table 23. Age-adjusted Mortality Rates, Asian and Pacific Islander Males and Females, 2007-2011 Combined

| Cancer Site | Male | | Female | |
|--|------|-------|--------|-------|
| | Rate | Cases | Rate | Cases |
| All Sites | 97.9 | 1,040 | 75.3 | 1,041 |
| Oral Cavity and Pharynx | 2.2 | 27 | 1.0 | 12 |
| Lip | - | - | - | - |
| Tongue | - | - | - | - |
| Salivary Gland | - | - | - | - |
| Floor of Mouth | - | - | - | - |
| Gum and Other Mouth | - | - | - | - |
| Nasopharynx | - | - | - | - |
| Tonsil | - | - | - | - |
| Oropharynx | - | - | - | - |
| Hypopharynx | - | - | - | - |
| Digestive System | 36.3 | 400 | 21.6 | 281 |
| Esophagus | 2.3 | 28 | 1.0 | 11 |
| Stomach | 7.0 | 70 | 3.6 | 49 |
| Small Intestine | - | - | - | - |
| Colon and Rectum | 9.6 | 105 | 7.5 | 98 |
| Colon excluding Rectum | 8.2 | 88 | 6.5 | 81 |
| Rectum and Rectosigmoid Junction | 1.4 | 17 | 1.0 | 17 |
| Anus, Anal Canal and Anorectum | - | - | - | - |
| Liver and Intrahepatic Bile Duct | 7.2 | 90 | 3.0 | 39 |
| Liver | 6.4 | 79 | 1.9 | 23 |
| Intrahepatic Bile Duct | 0.9 | 11 | 1.1 | 16 |
| Gallbladder | - | - | 0.8 | 11 |
| Pancreas | 8.9 | 88 | 4.8 | 63 |
| Respiratory System | 24.4 | 260 | 14.6 | 191 |
| Larynx | - | - | - | - |
| Lung and Bronchus | 23.6 | 251 | 14.5 | 189 |
| Bones and Joints | - | - | - | - |
| Soft Tissue (Including Heart) | - | - | 0.8 | 12 |
| Skin (Excluding Basal and Squamous) | - | - | - | - |
| Melanoma of the Skin | - | - | - | - |
| Breast | - | - | 11.1 | 181 |

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard.

- Counts and rates are suppressed when fewer than 10 cases to ensure confidentiality and statistical reliability.

Table 23 (continued). Age-adjusted Mortality Rates, Asian and Pacific Islander Males and Females, 2007-2011 Combined

| Cancer Site | Male | | Female | |
|--|------|-------|--------|-------|
| | Rate | Cases | Rate | Cases |
| Female Genital System | * | * | 8.7 | 141 |
| Cervix Uteri | * | * | 1.8 | 30 |
| Corpus and Uterus, NOS | * | * | 2.5 | 41 |
| Corpus Uteri | * | * | 1.2 | 20 |
| Uterus, NOS | * | * | 1.2 | 21 |
| Ovary | * | * | 4.3 | 69 |
| Vagina | * | * | - | - |
| Vulva | * | * | - | - |
| Male Genital System | 6.4 | 48 | * | * |
| Prostate | 6.4 | 48 | * | * |
| Testis | - | - | * | * |
| Penis | - | - | * | * |
| Urinary System | 5.8 | 56 | 1.8 | 20 |
| Urinary Bladder | 3.7 | 27 | 0.9 | 10 |
| Kidney and Renal Pelvis | 1.9 | 26 | - | - |
| Ureter | - | - | - | - |
| Eye | - | - | - | - |
| Brain and Other Nervous System | 2.3 | 35 | 1.4 | 19 |
| Endocrine System | 1.2 | 11 | - | - |
| Thyroid | - | - | - | - |
| Lymphomas | 4.0 | 38 | 3.1 | 39 |
| Hodgkin Lymphoma | - | - | - | - |
| Non-Hodgkin Lymphoma | 4.0 | 38 | 3.0 | 38 |
| Multiple Myeloma | 2.5 | 25 | 1.3 | 18 |
| Leukemias | 2.9 | 30 | 2.9 | 39 |
| Lymphocytic Leukemia | 1.1 | 12 | - | - |
| Acute Lymphocytic Leukemia | - | - | - | - |
| Chronic Lymphocytic Leukemia | - | - | - | - |
| Myeloid and Monocytic Leukemia | - | - | 1.6 | 22 |
| Acute Myeloid Leukemia | - | - | 1.3 | 18 |
| Acute Monocytic Leukemia | - | - | - | - |
| Chronic Myeloid Leukemia | - | - | - | - |
| Other Leukemia | 1.1 | 11 | 0.9 | 12 |
| Ill-Defined & Unspecified Sites | 8.1 | 89 | 5.5 | 68 |

Rates are per 100,000 and age-adjusted to the 2000 U.S. population standard.

* Non-applicable gender

- Counts and rates are suppressed when fewer than 10 cases to ensure confidentiality and statistical reliability.

Table 24. Comparative Mortality Rates, New Jersey and U.S., Males, 2007-2011

| Cancer Site | New Jersey 2007-2011 | | | | | United States 2007-2011 | | | | |
|-------------------|----------------------|-------|-------|------|-----------|-------------------------|-------|-------|-------|-----------|
| | All Races | White | Black | API* | Hispanic* | All Races | White | Black | API* | Hispanic* |
| All Sites | 203.7 | 204.7 | 254.5 | 97.9 | 134.1 | 211.6 | 209.8 | 269.3 | 131.0 | 150.1 |
| Lung | 53.9 | 54.8 | 63.1 | 23.6 | 28.3 | 61.6 | 61.4 | 75.7 | 34.7 | 30.5 |
| Prostate | 21.2 | 19.3 | 47.7 | 6.4 | 16.8 | 22.3 | 20.6 | 48.9 | 10.0 | 18.5 |
| Colorectal | 20.2 | 20.0 | 28.0 | 9.6 | 13.4 | 19.1 | 18.5 | 27.7 | 13.1 | 15.8 |

*API=Asians and Pacific Islanders; Hispanic includes all races.

Source-NAACCR age-adjusted rates per 100,000 (2000 U.S. population standard)

Table 25. Comparative Mortality Rates, New Jersey and U.S., Females, 2007-2011

| Cancer Site | New Jersey 2007-2011 | | | | | United States 2007-2011 | | | | |
|-------------------|----------------------|-------|-------|------|-----------|-------------------------|-------|-------|------|-----------|
| | All Races | White | Black | API* | Hispanic* | All Races | White | Black | API* | Hispanic* |
| All Sites | 151.0 | 153.6 | 165.4 | 75.3 | 89.8 | 147.4 | 147.5 | 169.0 | 91.5 | 99.9 |
| Lung | 36.5 | 38.5 | 33.5 | 14.5 | 11.6 | 38.5 | 39.8 | 36.5 | 18.4 | 14.0 |
| Breast | 24.6 | 24.5 | 30.9 | 11.1 | 12.7 | 22.2 | 21.7 | 30.6 | 11.3 | 14.5 |
| Colorectal | 14.3 | 14.0 | 18.7 | 7.5 | 9.5 | 13.5 | 13.0 | 18.5 | 9.5 | 9.9 |

*API=Asians and Pacific Islanders; Hispanic includes all races.

Source-NAACCR age-adjusted rates per 100,000 (2000 U.S. population standard)

Cancer Incidence and Mortality in New Jersey, 2007-2011

Table 26. Population Denominators by Race, Age Group and Year

All Races

| | Male | | | | | Female | | | | | | |
|-------|------------|-----------|-----------|-----------|-----------|-----------|------------|-----------|-----------|-----------|-----------|-----------|
| | 2007-11 | 2007 | 2008 | 2009 | 2010 | 2011 | 2007-11 | 2007 | 2008 | 2009 | 2010 | 2011 |
| <1 | 271,775 | 55,901 | 55,368 | 54,336 | 53,777 | 52,393 | 259,976 | 53,220 | 53,356 | 51,927 | 51,414 | 50,059 |
| 01-04 | 1,114,430 | 226,092 | 223,884 | 222,005 | 222,229 | 220,220 | 1,067,534 | 216,063 | 213,899 | 212,995 | 213,090 | 211,487 |
| 05-09 | 1,436,428 | 285,570 | 286,772 | 289,149 | 288,223 | 286,714 | 1,372,828 | 272,818 | 273,585 | 276,336 | 275,709 | 274,380 |
| 10-14 | 1,509,932 | 306,679 | 303,325 | 301,139 | 300,121 | 298,668 | 1,441,367 | 292,445 | 289,428 | 287,355 | 286,989 | 285,150 |
| 15-19 | 1,549,294 | 310,809 | 311,834 | 311,238 | 308,376 | 307,037 | 1,449,520 | 291,323 | 292,076 | 290,724 | 287,616 | 287,781 |
| 20-24 | 1,378,177 | 267,569 | 270,734 | 275,079 | 280,620 | 284,175 | 1,290,119 | 251,072 | 253,175 | 257,864 | 263,019 | 264,989 |
| 25-29 | 1,386,455 | 272,156 | 276,022 | 277,812 | 278,273 | 282,192 | 1,367,851 | 268,721 | 272,506 | 274,464 | 275,559 | 276,601 |
| 30-34 | 1,374,922 | 271,929 | 272,457 | 273,201 | 276,688 | 280,647 | 1,397,560 | 275,801 | 275,740 | 278,132 | 282,502 | 285,385 |
| 35-39 | 1,478,907 | 309,986 | 303,556 | 296,477 | 288,088 | 280,800 | 1,527,709 | 321,771 | 313,945 | 306,339 | 297,447 | 288,207 |
| 40-44 | 1,624,345 | 339,350 | 330,080 | 321,560 | 317,852 | 315,503 | 1,696,962 | 353,824 | 345,210 | 336,276 | 332,350 | 329,302 |
| 45-49 | 1,719,386 | 345,538 | 345,942 | 346,353 | 343,553 | 338,000 | 1,792,768 | 359,638 | 360,021 | 361,102 | 358,599 | 353,408 |
| 50-54 | 1,604,526 | 305,374 | 314,557 | 322,289 | 328,839 | 333,467 | 1,693,500 | 322,976 | 331,620 | 340,795 | 347,272 | 350,837 |
| 55-59 | 1,335,164 | 254,864 | 258,174 | 266,203 | 273,890 | 282,033 | 1,446,430 | 278,426 | 281,672 | 287,772 | 295,186 | 303,374 |
| 60-64 | 1,099,538 | 204,229 | 209,679 | 218,585 | 229,233 | 237,812 | 1,228,987 | 228,222 | 234,568 | 244,474 | 256,178 | 265,545 |
| 65-69 | 785,483 | 143,722 | 153,000 | 157,656 | 162,599 | 168,506 | 921,414 | 169,801 | 179,516 | 185,659 | 190,424 | 196,014 |
| 70-74 | 571,905 | 110,606 | 111,972 | 114,310 | 116,325 | 118,692 | 719,228 | 140,680 | 141,791 | 143,195 | 145,428 | 148,134 |
| 75-79 | 458,421 | 94,052 | 92,814 | 91,064 | 90,307 | 90,184 | 637,749 | 132,637 | 129,363 | 126,866 | 125,166 | 123,717 |
| 80-84 | 345,279 | 67,949 | 68,695 | 69,018 | 69,824 | 69,793 | 553,228 | 112,337 | 111,887 | 110,720 | 109,655 | 108,629 |
| 85+ | 273,080 | 50,362 | 52,324 | 54,622 | 56,894 | 58,878 | 600,561 | 113,373 | 116,543 | 120,511 | 124,074 | 126,060 |
| Total | 21,317,447 | 4,222,737 | 4,241,189 | 4,262,096 | 4,285,711 | 4,305,714 | 22,465,291 | 4,455,148 | 4,469,901 | 4,493,506 | 4,517,677 | 4,529,059 |

White

| | Male | | | | | Female | | | | | | |
|-------|------------|-----------|-----------|-----------|-----------|-----------|------------|-----------|-----------|-----------|-----------|-----------|
| | 2007-11 | 2007 | 2008 | 2009 | 2010 | 2011 | 2007-11 | 2007 | 2008 | 2009 | 2010 | 2011 |
| <1 | 190,626 | 39,624 | 39,003 | 37,978 | 37,609 | 36,412 | 181,838 | 37,720 | 37,371 | 36,082 | 35,824 | 34,841 |
| 01-04 | 795,472 | 163,807 | 161,307 | 158,401 | 157,205 | 154,752 | 758,706 | 156,003 | 153,633 | 151,206 | 149,945 | 147,919 |
| 05-09 | 1,040,730 | 208,994 | 208,581 | 209,362 | 207,723 | 206,070 | 987,989 | 197,969 | 197,338 | 198,910 | 197,675 | 196,097 |
| 10-14 | 1,102,385 | 224,736 | 221,889 | 220,090 | 218,797 | 216,873 | 1,046,250 | 213,723 | 210,907 | 208,531 | 207,538 | 205,551 |
| 15-19 | 1,131,134 | 229,009 | 228,506 | 226,641 | 223,678 | 223,300 | 1,048,001 | 212,065 | 211,556 | 209,840 | 206,832 | 207,708 |
| 20-24 | 1,000,571 | 195,112 | 197,120 | 200,272 | 203,437 | 204,630 | 920,584 | 180,344 | 181,511 | 184,459 | 187,110 | 187,160 |
| 25-29 | 1,001,489 | 197,481 | 199,245 | 200,760 | 201,077 | 202,926 | 947,654 | 186,188 | 188,530 | 190,000 | 191,238 | 191,698 |
| 30-34 | 978,824 | 194,940 | 194,542 | 194,186 | 196,326 | 198,830 | 956,725 | 190,619 | 189,475 | 190,071 | 192,466 | 194,094 |
| 35-39 | 1,071,356 | 229,075 | 222,020 | 214,539 | 206,371 | 199,351 | 1,079,255 | 232,370 | 224,084 | 216,206 | 207,698 | 198,897 |
| 40-44 | 1,226,422 | 259,866 | 251,004 | 242,904 | 238,293 | 234,355 | 1,253,396 | 265,452 | 257,069 | 248,410 | 243,402 | 239,063 |
| 45-49 | 1,338,341 | 272,684 | 271,221 | 269,381 | 265,593 | 259,462 | 1,367,577 | 277,999 | 276,767 | 275,130 | 271,803 | 265,878 |
| 50-54 | 1,274,902 | 245,153 | 251,254 | 256,176 | 259,661 | 262,658 | 1,317,310 | 253,753 | 259,025 | 265,037 | 268,591 | 270,904 |
| 55-59 | 1,079,626 | 207,239 | 209,236 | 215,096 | 221,236 | 226,819 | 1,140,472 | 220,620 | 222,533 | 226,878 | 232,415 | 238,026 |
| 60-64 | 901,997 | 169,000 | 172,611 | 179,403 | 187,099 | 193,884 | 983,628 | 184,660 | 188,549 | 195,835 | 203,934 | 210,650 |
| 65-69 | 642,468 | 117,029 | 125,426 | 129,269 | 133,043 | 137,701 | 740,822 | 136,294 | 144,735 | 149,357 | 153,054 | 157,382 |
| 70-74 | 471,112 | 92,225 | 92,666 | 94,076 | 95,308 | 96,837 | 584,824 | 115,671 | 115,982 | 116,435 | 117,514 | 119,222 |
| 75-79 | 394,853 | 82,313 | 80,686 | 78,483 | 77,199 | 76,172 | 541,392 | 114,468 | 110,984 | 107,620 | 105,426 | 102,894 |
| 80-84 | 309,162 | 61,331 | 61,763 | 61,823 | 62,286 | 61,959 | 489,134 | 100,186 | 99,492 | 97,910 | 96,489 | 95,057 |
| 85+ | 249,257 | 46,139 | 47,900 | 49,896 | 51,838 | 53,484 | 544,880 | 103,391 | 106,187 | 109,335 | 112,287 | 113,680 |
| Total | 16,200,727 | 3,235,757 | 3,235,980 | 3,238,736 | 3,243,779 | 3,246,475 | 16,890,437 | 3,379,495 | 3,375,728 | 3,377,252 | 3,381,241 | 3,376,721 |

Black

| | Male | | | | | Female | | | | | | |
|-------|-----------|---------|---------|---------|---------|---------|-----------|---------|---------|---------|---------|---------|
| | 2007-11 | 2007 | 2008 | 2009 | 2010 | 2011 | 2007-11 | 2007 | 2008 | 2009 | 2010 | 2011 |
| <1 | 50,119 | 10,261 | 10,073 | 9,896 | 9,828 | 10,061 | 48,286 | 9,687 | 9,736 | 9,669 | 9,468 | 9,726 |
| 01-04 | 196,182 | 38,921 | 38,915 | 39,131 | 39,644 | 39,571 | 188,717 | 37,282 | 37,212 | 37,690 | 38,306 | 38,227 |
| 05-09 | 247,698 | 49,243 | 49,444 | 49,895 | 49,857 | 49,259 | 238,742 | 47,709 | 47,739 | 47,958 | 47,895 | 47,441 |
| 10-14 | 269,834 | 55,688 | 54,648 | 53,638 | 53,089 | 52,771 | 260,684 | 53,430 | 52,482 | 51,880 | 51,593 | 51,299 |
| 15-19 | 288,558 | 57,505 | 58,077 | 58,408 | 57,976 | 56,592 | 280,508 | 56,571 | 57,071 | 56,687 | 55,990 | 54,189 |
| 20-24 | 250,674 | 48,174 | 48,768 | 49,398 | 51,106 | 53,228 | 248,375 | 47,442 | 48,066 | 49,211 | 51,021 | 52,635 |
| 25-29 | 221,719 | 44,235 | 44,606 | 44,276 | 43,881 | 44,721 | 242,171 | 48,626 | 48,909 | 48,480 | 47,895 | 48,261 |
| 30-34 | 209,157 | 40,570 | 40,791 | 41,658 | 42,652 | 43,486 | 240,232 | 47,048 | 46,863 | 47,861 | 49,030 | 49,430 |
| 35-39 | 219,312 | 45,648 | 44,794 | 43,977 | 43,047 | 41,846 | 254,469 | 52,840 | 51,940 | 51,320 | 49,930 | 48,439 |
| 40-44 | 235,604 | 48,665 | 47,782 | 46,621 | 46,283 | 46,253 | 270,903 | 55,910 | 54,847 | 53,449 | 53,370 | 53,327 |
| 45-49 | 233,088 | 45,243 | 46,187 | 47,102 | 47,342 | 47,214 | 268,728 | 52,340 | 52,990 | 54,415 | 54,539 | 54,444 |
| 50-54 | 201,592 | 36,938 | 38,810 | 40,353 | 42,228 | 43,263 | 237,485 | 44,129 | 45,989 | 47,666 | 49,425 | 50,276 |
| 55-59 | 153,124 | 28,990 | 29,414 | 30,682 | 31,376 | 32,662 | 194,198 | 37,499 | 37,880 | 38,628 | 39,515 | 40,676 |
| 60-64 | 117,352 | 21,409 | 22,203 | 23,186 | 24,741 | 25,813 | 156,100 | 28,373 | 29,376 | 30,901 | 32,897 | 34,553 |
| 65-69 | 85,017 | 16,276 | 16,555 | 16,845 | 17,476 | 17,865 | 118,500 | 22,621 | 23,291 | 23,873 | 24,199 | 24,516 |
| 70-74 | 61,312 | 11,686 | 12,006 | 12,359 | 12,512 | 12,749 | 91,578 | 17,559 | 17,826 | 18,203 | 18,815 | 19,175 |
| 75-79 | 41,474 | 8,083 | 8,072 | 8,203 | 8,399 | 8,717 | 68,605 | 13,233 | 13,250 | 13,767 | 13,910 | 14,445 |
| 80-84 | 24,878 | 4,670 | 4,859 | 4,968 | 5,125 | 5,256 | 46,963 | 9,080 | 9,213 | 9,392 | 9,553 | 9,725 |
| 85+ | 16,373 | 2,962 | 3,060 | 3,249 | 3,461 | 3,641 | 42,761 | 7,788 | 7,952 | 8,637 | 9,036 | 9,348 |
| Total | 3,123,067 | 615,167 | 619,064 | 623,845 | 630,023 | 634,968 | 3,498,005 | 689,167 | 692,632 | 699,687 | 706,387 | 710,132 |

Source: The National Cancer Institute's SEER Program (URL: <http://www.seer.cancer.gov/popdata/index.html>).

Cancer Incidence and Mortality in New Jersey, 2007-2011

Table 26 (continued). Population Denominators by Race, Age Group and Year

Asian and Pacific Islander

| | Male | | | | | | Female | | | | | |
|-------|-----------|---------|---------|---------|---------|---------|-----------|---------|---------|---------|---------|---------|
| | 2007-11 | 2007 | 2008 | 2009 | 2010 | 2011 | 2007-11 | 2007 | 2008 | 2009 | 2010 | 2011 |
| <1 | 28,896 | 5,728 | 6,003 | 5,974 | 5,760 | 5,431 | 27,700 | 5,523 | 5,949 | 5,660 | 5,544 | 5,024 |
| 01-04 | 113,329 | 21,888 | 21,990 | 22,632 | 23,176 | 23,643 | 111,230 | 21,348 | 21,507 | 22,355 | 22,805 | 23,215 |
| 05-09 | 137,134 | 25,389 | 26,705 | 27,695 | 28,355 | 28,990 | 135,549 | 25,334 | 26,520 | 27,337 | 27,875 | 28,483 |
| 10-14 | 126,922 | 24,301 | 24,717 | 25,228 | 25,967 | 26,709 | 123,885 | 23,332 | 23,995 | 24,784 | 25,639 | 26,135 |
| 15-19 | 117,707 | 22,070 | 22,921 | 23,757 | 24,238 | 24,721 | 110,254 | 20,745 | 21,384 | 22,034 | 22,535 | 23,556 |
| 20-24 | 112,820 | 21,699 | 22,104 | 22,537 | 23,097 | 23,383 | 110,496 | 21,366 | 21,573 | 22,029 | 22,619 | 22,909 |
| 25-29 | 149,364 | 27,970 | 29,534 | 29,935 | 30,375 | 31,550 | 166,549 | 31,832 | 32,875 | 33,622 | 33,984 | 34,236 |
| 30-34 | 174,113 | 34,198 | 34,728 | 34,819 | 34,937 | 35,431 | 189,363 | 36,081 | 37,233 | 37,923 | 38,643 | 39,483 |
| 35-39 | 177,377 | 33,375 | 34,728 | 35,736 | 36,318 | 37,220 | 183,581 | 34,617 | 35,882 | 36,716 | 37,676 | 38,690 |
| 40-44 | 151,951 | 28,953 | 29,361 | 29,991 | 31,043 | 32,603 | 162,901 | 30,652 | 31,399 | 32,447 | 33,566 | 34,837 |
| 45-49 | 138,524 | 25,935 | 26,751 | 27,989 | 28,616 | 29,233 | 147,229 | 27,628 | 28,494 | 29,676 | 30,300 | 31,131 |
| 50-54 | 120,203 | 21,900 | 23,029 | 24,180 | 25,273 | 25,821 | 130,810 | 23,751 | 25,129 | 26,479 | 27,543 | 27,908 |
| 55-59 | 96,950 | 17,743 | 18,566 | 19,313 | 20,071 | 21,257 | 105,809 | 19,265 | 20,166 | 21,073 | 21,995 | 23,310 |
| 60-64 | 76,190 | 13,155 | 14,135 | 15,200 | 16,504 | 17,196 | 84,906 | 14,460 | 15,831 | 16,876 | 18,405 | 19,334 |
| 65-69 | 55,347 | 9,971 | 10,549 | 11,007 | 11,514 | 12,306 | 59,222 | 10,399 | 10,955 | 11,842 | 12,559 | 13,467 |
| 70-74 | 37,781 | 6,400 | 6,989 | 7,540 | 8,128 | 8,724 | 40,532 | 7,032 | 7,556 | 8,107 | 8,618 | 9,219 |
| 75-79 | 21,094 | 3,497 | 3,864 | 4,178 | 4,502 | 5,053 | 26,269 | 4,680 | 4,855 | 5,168 | 5,516 | 6,050 |
| 80-84 | 10,616 | 1,820 | 1,952 | 2,119 | 2,284 | 2,441 | 16,025 | 2,860 | 2,982 | 3,196 | 3,380 | 3,607 |
| 85+ | 6,958 | 1,180 | 1,279 | 1,379 | 1,486 | 1,634 | 11,993 | 2,034 | 2,233 | 2,352 | 2,557 | 2,817 |
| Total | 1,853,276 | 347,172 | 359,905 | 371,209 | 381,644 | 393,346 | 1,944,303 | 362,939 | 376,518 | 389,676 | 401,759 | 413,411 |

Hispanic*

| | Male | | | | | | Female | | | | | |
|-------|-----------|---------|---------|---------|---------|---------|-----------|---------|---------|---------|---------|---------|
| | 2007-11 | 2007 | 2008 | 2009 | 2010 | 2011 | 2007-11 | 2007 | 2008 | 2009 | 2010 | 2011 |
| <1 | 72,763 | 14,607 | 14,325 | 14,417 | 14,385 | 15,029 | 69,931 | 13,856 | 13,909 | 13,915 | 13,692 | 14,559 |
| 01-04 | 275,816 | 52,662 | 54,174 | 55,240 | 56,438 | 57,302 | 265,554 | 50,792 | 52,076 | 53,259 | 54,307 | 55,120 |
| 05-09 | 310,766 | 56,453 | 59,291 | 63,001 | 65,063 | 66,958 | 295,659 | 53,189 | 56,002 | 60,023 | 62,249 | 64,196 |
| 10-14 | 300,884 | 57,355 | 58,650 | 59,900 | 61,988 | 62,991 | 285,755 | 54,442 | 55,575 | 57,059 | 58,937 | 59,742 |
| 15-19 | 321,651 | 61,075 | 62,987 | 65,120 | 66,218 | 66,251 | 294,712 | 56,018 | 57,653 | 59,347 | 60,446 | 61,248 |
| 20-24 | 339,632 | 64,367 | 65,791 | 67,848 | 70,307 | 71,319 | 290,202 | 54,183 | 56,030 | 57,911 | 60,561 | 61,517 |
| 25-29 | 356,779 | 70,136 | 71,096 | 71,424 | 71,809 | 72,314 | 315,412 | 61,138 | 62,279 | 63,599 | 64,224 | 64,172 |
| 30-34 | 339,928 | 64,642 | 66,104 | 67,831 | 69,631 | 71,720 | 315,106 | 59,620 | 60,971 | 63,090 | 65,027 | 66,398 |
| 35-39 | 313,060 | 59,598 | 61,012 | 63,061 | 64,166 | 65,223 | 301,516 | 58,175 | 59,070 | 60,682 | 61,556 | 62,033 |
| 40-44 | 290,624 | 55,801 | 56,748 | 57,670 | 59,433 | 60,972 | 290,352 | 56,064 | 57,084 | 57,729 | 59,065 | 60,410 |
| 45-49 | 256,601 | 46,851 | 49,177 | 51,667 | 53,482 | 55,424 | 261,838 | 47,821 | 50,588 | 52,666 | 54,522 | 56,241 |
| 50-54 | 199,149 | 35,178 | 37,560 | 39,750 | 42,252 | 44,409 | 212,934 | 38,283 | 40,140 | 42,626 | 45,065 | 46,820 |
| 55-59 | 145,185 | 26,144 | 27,134 | 28,803 | 30,502 | 32,602 | 163,003 | 29,338 | 30,673 | 32,527 | 34,134 | 36,331 |
| 60-64 | 105,649 | 18,617 | 19,743 | 21,051 | 22,515 | 23,723 | 123,880 | 21,923 | 23,256 | 24,572 | 26,428 | 27,701 |
| 65-69 | 71,606 | 13,100 | 13,611 | 14,053 | 14,853 | 15,989 | 90,060 | 16,384 | 17,054 | 17,960 | 18,762 | 19,900 |
| 70-74 | 50,070 | 8,898 | 9,465 | 10,121 | 10,582 | 11,004 | 67,384 | 12,271 | 12,840 | 13,422 | 14,073 | 14,778 |
| 75-79 | 32,927 | 6,024 | 6,227 | 6,494 | 6,901 | 7,281 | 48,654 | 8,883 | 9,211 | 9,692 | 10,227 | 10,641 |
| 80-84 | 20,011 | 3,506 | 3,724 | 4,014 | 4,259 | 4,508 | 32,650 | 5,747 | 6,110 | 6,617 | 6,909 | 7,267 |
| 85+ | 13,155 | 2,194 | 2,375 | 2,594 | 2,825 | 3,167 | 26,023 | 4,552 | 4,810 | 5,115 | 5,507 | 6,039 |
| Total | 3,816,256 | 717,208 | 739,194 | 764,059 | 787,609 | 808,186 | 3,750,625 | 702,679 | 725,331 | 751,811 | 775,691 | 795,113 |

*Hispanic includes all races.

Source: The National Cancer Institute's SEER Program (URL: <http://www.seer.cancer.gov/popdata/index.html>).

**Table 27. Age Distribution (%) of Incidence Cases in New Jersey, 2007-2011
All Races, Both Sexes**

| Cancer Site | 0-19 | 20-34 | 35-44 | 45-54 | 55-64 | 65-74 | 75-84 | 85+ | All Ages | Total Cases |
|----------------------------------|-------|-------|-------|-------|-------|-------|-------|-------|----------|-------------|
| All Sites | 0.9% | 2.3% | 5.1% | 13.8% | 23.1% | 25.0% | 21.2% | 8.6% | 100% | 245,101 |
| Male | 1.0% | 1.9% | 3.3% | 11.7% | 25.3% | 28.1% | 21.7% | 7.1% | 100% | 124,173 |
| Female | 0.9% | 2.8% | 6.9% | 16.0% | 21.0% | 21.9% | 20.6% | 10.1% | 100% | 120,928 |
| Oral Cavity and Pharynx | 0.5% | 2.1% | 5.6% | 19.4% | 29.0% | 21.4% | 15.6% | 6.5% | 100% | 5,029 |
| Esophagus | 0.0% | 0.4% | 1.9% | 11.6% | 24.9% | 27.5% | 23.2% | 10.4% | 100% | 2,338 |
| Stomach | 0.1% | 1.6% | 3.8% | 10.7% | 19.2% | 24.7% | 25.7% | 14.3% | 100% | 4,001 |
| Colon and Rectum | 0.1% | 1.1% | 3.9% | 12.4% | 18.7% | 22.5% | 26.4% | 15.0% | 100% | 22,344 |
| Male | 0.0% | 1.1% | 4.1% | 13.5% | 21.1% | 24.5% | 25.1% | 10.5% | 100% | 11,090 |
| Female | 0.1% | 1.0% | 3.7% | 11.4% | 16.5% | 20.4% | 27.6% | 19.4% | 100% | 11,254 |
| Colon excluding Rectum | 0.1% | 1.0% | 3.3% | 10.5% | 17.2% | 22.5% | 28.3% | 17.2% | 100% | 15,969 |
| Rectum and Rectosigmoid Junction | 0.0% | 1.4% | 5.3% | 17.3% | 22.7% | 22.3% | 21.6% | 9.4% | 100% | 6,375 |
| Liver and Intrahepatic Bile Duct | 0.8% | 1.0% | 2.1% | 14.4% | 33.1% | 22.7% | 19.5% | 6.6% | 100% | 3,425 |
| Pancreas | 0.1% | 0.3% | 1.7% | 8.8% | 20.7% | 25.1% | 29.1% | 14.3% | 100% | 6,618 |
| Larynx | 0.0% | 0.5% | 2.5% | 14.6% | 28.9% | 28.6% | 19.2% | 5.9% | 100% | 1,709 |
| Lung and Bronchus | 0.0% | 0.2% | 1.3% | 8.1% | 20.5% | 31.1% | 29.4% | 9.5% | 100% | 29,918 |
| Male | 0.0% | 0.2% | 1.1% | 7.8% | 21.4% | 31.7% | 29.0% | 8.7% | 100% | 14,830 |
| Female | 0.0% | 0.3% | 1.4% | 8.3% | 19.5% | 30.5% | 29.7% | 10.3% | 100% | 15,088 |
| Bones and Joints | 26.6% | 16.4% | 10.5% | 13.4% | 12.0% | 7.1% | 9.4% | 4.6% | 100% | 477 |
| Soft Tissue including Heart | 8.7% | 7.5% | 7.8% | 16.0% | 18.2% | 16.9% | 16.3% | 8.7% | 100% | 1,673 |
| Melanoma of the Skin | 0.4% | 4.9% | 8.4% | 17.1% | 21.1% | 21.0% | 19.3% | 7.8% | 100% | 10,393 |
| Breast (female) | 0.0% | 1.6% | 9.7% | 22.9% | 23.8% | 20.5% | 15.3% | 6.2% | 100% | 34,427 |
| Cervix Uteri | 0.2% | 10.9% | 21.9% | 25.2% | 17.8% | 13.7% | 7.0% | 3.3% | 100% | 2,046 |
| Corpus and Uterus, NOS | 0.0% | 1.0% | 3.9% | 16.8% | 33.6% | 25.7% | 14.4% | 4.5% | 100% | 8,166 |
| Ovary | 0.8% | 2.9% | 6.6% | 19.6% | 23.7% | 21.1% | 17.1% | 8.2% | 100% | 3,551 |
| Prostate | 0.0% | 0.0% | 0.7% | 10.4% | 33.0% | 35.5% | 17.2% | 3.2% | 100% | 37,287 |
| Testis | 5.8% | 44.0% | 25.5% | 14.6% | 6.9% | 1.7% | 1.4% | 0.2% | 100% | 1,210 |
| Urinary Bladder | 0.0% | 0.4% | 1.2% | 6.5% | 17.8% | 27.6% | 32.2% | 14.2% | 100% | 11,857 |
| Kidney and Renal Pelvis | 1.1% | 1.6% | 5.9% | 16.0% | 25.2% | 25.2% | 18.9% | 6.0% | 100% | 7,570 |
| Brain and Other Nervous System | 12.2% | 8.0% | 8.3% | 14.6% | 19.4% | 17.6% | 15.0% | 4.9% | 100% | 3,266 |
| Thyroid | 1.6% | 12.7% | 20.8% | 25.4% | 20.5% | 11.6% | 6.0% | 1.4% | 100% | 8,143 |
| Hodgkin Lymphoma | 12.4% | 27.4% | 14.9% | 14.2% | 11.2% | 10.3% | 7.3% | 2.4% | 100% | 1,454 |
| Non-Hodgkin Lymphoma | 1.6% | 3.6% | 6.2% | 13.3% | 19.9% | 22.4% | 23.4% | 9.7% | 100% | 10,180 |
| Myeloma | 0.0% | 0.9% | 3.3% | 11.9% | 23.4% | 26.7% | 24.1% | 9.8% | 100% | 3,281 |
| Leukemia | 7.9% | 4.0% | 4.9% | 11.5% | 17.1% | 20.5% | 22.7% | 11.5% | 100% | 6,719 |
| Lymphocytic Leukemia | 11.2% | 2.1% | 3.3% | 11.0% | 18.1% | 21.2% | 22.3% | 10.8% | 100% | 3,425 |
| Acute Lymphocytic Leukemia | 53.5% | 9.1% | 5.5% | 9.2% | 7.4% | 8.8% | 4.9% | 1.5% | 100% | 714 |
| Chronic Lymphocytic Leukemia | 0.0% | 0.2% | 1.9% | 10.6% | 20.6% | 25.6% | 27.6% | 13.5% | 100% | 2,483 |
| Acute Myeloid Leukemia | 5.2% | 5.2% | 5.9% | 10.6% | 16.3% | 20.6% | 25.2% | 11.0% | 100% | 1,869 |
| Acute Monocytic Leukemia | 6.5% | 5.1% | 8.0% | 10.1% | 18.1% | 19.6% | 21.0% | 11.6% | 100% | 138 |
| Chronic Myeloid Leukemia | 2.6% | 8.9% | 8.1% | 16.1% | 17.4% | 19.8% | 18.1% | 9.0% | 100% | 812 |
| Other Leukemia | 4.1% | 4.4% | 5.2% | 10.1% | 11.1% | 17.4% | 23.6% | 24.2% | 100% | 368 |
| Mesothelioma | 0.0% | 0.7% | 1.8% | 6.5% | 11.9% | 26.6% | 35.7% | 16.7% | 100% | 706 |
| Kaposi Sarcoma | 0.5% | 16.7% | 16.7% | 13.3% | 12.9% | 11.9% | 13.8% | 14.3% | 100% | 210 |

* Include all invasive cancers in ICD-O-3.

**Table 28. Median Age of Cancer Patients at Diagnosis, New Jersey 2007-2011
By Primary Cancer Site, Race and Sex**

| Cancer Site | All | | | White | | | Black | | |
|----------------------------------|-------|------|--------|-------|------|--------|-------|------|--------|
| | Total | Male | Female | Total | Male | Female | Total | Male | Female |
| All Sites | 66 | 67 | 66 | 67 | 68 | 66 | 63 | 64 | 63 |
| Oral Cavity and Pharynx | 62 | 61 | 65 | 63 | 62 | 67 | 59 | 60 | 57 |
| Esophagus | 68 | 67 | 73 | 69 | 67 | 74 | 66 | 65 | 68 |
| Stomach | 71 | 69 | 73 | 72 | 70 | 75 | 68 | 68 | 70 |
| Colon and Rectum | 71 | 69 | 73 | 72 | 70 | 75 | 66 | 65 | 67 |
| Colon excluding Rectum | 73 | 71 | 75 | 74 | 72 | 76 | 67 | 66 | 68 |
| Rectum and Rectosigmoid Junction | 66 | 65 | 67 | 67 | 66 | 68 | 63 | 62 | 65 |
| Liver and Intrahepatic Bile Duct | 64 | 62 | 70 | 65 | 64 | 72 | 60 | 59 | 65 |
| Pancreas | 72 | 69 | 75 | 73 | 70 | 76 | 68 | 64 | 70 |
| Larynx | 66 | 66 | 65 | 66 | 67 | 66 | 63 | 63 | 61 |
| Lung and Bronchus | 71 | 71 | 71 | 72 | 71 | 72 | 68 | 67 | 68 |
| Bones and Joints | 42 | 41 | 44 | 43 | 41 | 46 | 36 | 40 | 28 |
| Soft Tissue including Heart | 60 | 60 | 60 | 62 | 61 | 62 | 52 | 50 | 53 |
| Melanoma of the Skin | 64 | 66 | 60 | 64 | 66 | 61 | 55 | 58 | 54 |
| Breast | 61 | 69 | 61 | 62 | 70 | 62 | 59 | 66 | 59 |
| Cervix Uteri | * | * | 51 | * | * | 51 | * | * | 52 |
| Corpus and Uterus, NOS | * | * | 63 | * | * | 63 | * | * | 64 |
| Ovary | * | * | 63 | * | * | 63 | * | * | 64 |
| Prostate | * | 66 | * | * | 66 | * | * | 64 | * |
| Testis | * | 35 | * | * | 35 | * | * | 37 | * |
| Urinary Bladder | 73 | 73 | 74 | 74 | 74 | 74 | 71 | 70 | 74 |
| Kidney and Renal Pelvis | 65 | 63 | 67 | 65 | 64 | 67 | 63 | 61 | 65 |
| Brain and Other Nervous System | 58 | 57 | 60 | 59 | 58 | 61 | 50 | 53 | 48 |
| Thyroid | 50 | 54 | 49 | 51 | 55 | 50 | 51 | 58 | 50 |
| Hodgkin Lymphoma | 41 | 44 | 38 | 42 | 45 | 39 | 41 | 42 | 37 |
| Non-Hodgkin Lymphoma | 67 | 65 | 69 | 68 | 67 | 70 | 58 | 55 | 62 |
| Myeloma | 69 | 68 | 69 | 70 | 69 | 70 | 66 | 64 | 66 |
| Leukemia | 67 | 66 | 69 | 68 | 67 | 70 | 60 | 58 | 64 |
| Lymphocytic Leukemia | 67 | 65 | 70 | 67 | 66 | 70 | 61 | 56 | 67 |
| Acute Lymphocytic Leukemia | 16 | 15 | 18 | 19 | 17 | 20 | 9 | 7 | 13 |
| Chronic Lymphocytic Leukemia | 71 | 69 | 74 | 72 | 70 | 74 | 70 | 65 | 74 |
| Acute Myeloid Leukemia | 68 | 68 | 68 | 69 | 69 | 69 | 60 | 60 | 61 |
| Acute Monocytic Leukemia | 66 | 68 | 60 | 68 | 68 | 66 | 26 | 30 | 16 |
| Chronic Myeloid Leukemia | 63 | 62 | 64 | 65 | 64 | 68 | 56 | 59 | 53 |
| Other Leukemia | 73 | 69 | 77 | 77 | 74 | 79 | 69 | 60 | 74 |
| Mesothelioma | 75 | 76 | 71 | 76 | 76 | 72 | 68 | 70 | 60 |
| Kaposi Sarcoma | 56 | 50 | 76 | 66 | 60 | 81 | 44 | 43 | 47 |

* Non-applicable gender.